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Summary 
 
Hepatitis C virus (HCV) is a single-stranded RNA virus belonging to the Flaviviridae and 
infects approximately 170 million people worldwide. Unlike other known RNA viruses, 
HCV  causes  a  persistent  infection  in  the  majority  of  infected  people  and  can  lead  to 
cirrhosis  of  the  liver  and  hepatocellular  carcinoma.  For  these  reasons,  HCV  is  rightly 
classified as a major human pathogen. 
 
HCV core protein is believed to form, by analogy with other members of the Flaviviridae 
family, the nucleocapsid of the virus. As well as this, core has been shown to modulate 
many  cellular  processes  via  interactions  with  numerous  host-cell  proteins.  One  such 
protein shown to interact with HCV core is the DEAD-box RNA helicase DDX3. In cells 
expressing either HCV core alone, or as part of the full length HCV polyprotein, DDX3 is 
redistributed from its normal diffuse cytoplasmic localisation to lipid droplets where it 
colocalises with core. The cellular function of DDX3 is still unknown although it has been 
suggested to be involved in processes such as splicing, translation and RNA transport. 
 
The aim of this study was to investigate the role of DDX3 in the life cycle of HCV. This 
was aided by the recent discovery of a fully infectious HCV genotype 2a clone (strain JFH-
1), allowing previously inaccessible aspects of the virus life cycle to be studied such as 
particle assembly and release. A library of HCV core mutants (residues 1-59 only) was 
produced by error-prone PCR and subsequently expressed in bacteria and analysed for 
their ability to bind bacterially expressed DDX3 using a rapid, high throughput ELISA 
screen. Six HCV core residues, conserved throughout all genotypes, were identified as 
being critical for interaction with DDX3. These residues were confirmed as being critical 
for  the  interaction  by  transfection  of  mutant  core  (together  with  E1  and  E2  to  ensure David A Dalrymple    Summary   
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correct processing of core) into Huh7 cells. None of the 6 mutant core proteins were able 
to redistribute cellular DDX3.  
 
In order to study the effects of abolishing the core-DDX3 interaction in terms of a fully 
infectious HCV life cycle, the 6 critical residues were individually mutated to alanine in 
the cell culture infectious strain JFH-1 genome. All 6 mutant JFH-1 RNAs were capable of 
replication and being translated. Further investigation however, suggested that replication 
rate  of  mutant  JFH-1  RNA  was  >50-fold  lower  than  that  of  wild  type  JFH-1  RNA 
replication.  Mutant  core  proteins  colocalised  with  the  lipid  droplet  marker  ADRP, 
indicating  correct  subcellular  localisation  of  the  viral  protein.  Western-immunoblot 
analysis of mutant cores also confirmed that core proteins of same molecular weight to that 
of wild type core were produced, suggesting mutant cores were correctly processed. Of the 
6 mutant JFH-1 clones analysed, 5 of them were capable of secreting infectious HCV 
particles  that  could  subsequently  infect  naïve  Huh7  cells,  as  detected  by 
immunofluorescence and RT-PCR. However, one mutant, in which residue 33 of core had 
been changed from glycine to alanine, was initially unable to produce infectious particles. 
Upon  passaging  of  cells  electroporated  with  this  mutant,  infectious  particles  were 
eventually produced. The production of infectious particles consistently coincided with the 
presence of a second mutation in the surrounding area of the originally mutated residue 33. 
However, JFH-1 RNA containing both the mutation at residue 33 and the second identified 
mutation  nearby,  was  unable  to  produce  infectious  particles  upon  electroporation, 
suggesting another lesion elsewhere in the HCV genome may also be required in order to 
overcome the effect of mutating residue 33.  
 
A recent report has indicated that DDX3 may be a nucleo-cytoplasmic shuttling protein, 
utilising the CRM1 export pathway. To confirm this, DDX3 localisation was analysed in 
the presence of the CRM1 inhibitor leptomycin B (LMB). In the absence of LMB, DDX3 David A Dalrymple    Summary   
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was seen to have a diffuse cytoplasmic localisation while a small proportion was also seen 
in the nucleus. In the presence of LMB however, a build-up of DDX3 was seen in the 
nucleus, confirming that DDX3 uses the CRM1 pathway to shuttle from the nucleus to the 
cytoplasm. 
 
The results of this study indicate that the interaction of the cellular DEAD-box helicase 
DDX3 with core protein is not essential for the life cycle of HCV. It has been shown here 
however, that the replication rates of mutant HCV RNA are lower than that of wild type, 
suggesting that DDX3 may enhance either replication itself, or translation (which in turn 
provides the machinery required for viral RNA replication). Investigating this possibility is 
the subject of our future work. The identification of glycine 33 of core protein as being 
essential for production of infectious virus particles (without abolishing replication) will 
provide the basis for further studies on the production of infectious particles and the role 
that core protein plays in this process. The panel of JFH-1 core mutants will also be useful 
in  studying  the  core-DDX3  interaction  in  a  much  wider  context  involving  the  role  of 
DDX3 in normal cells. 
 
This study has uncovered important details regarding the interaction between core and 
DDX3  and,  together  with  the  reagents  produced  throughout  this  investigation,  should 
enable further successful study into the role of DDX3 in the life cycle of HCV.      4   
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1.1 HCV Background 
1.1.1 Discovery of Hepatitis C Virus 
Hepatitis C virus infects approximately 170 million people worldwide (WHO, 2000). The 
virus was discovered after specific diagnostic tests for both hepatitis A virus (HAV) and 
hepatitis B virus (HBV) revealed that most cases of post-transfusion hepatitis were not 
linked  to  HAV  or  HBV  (Bradley,  1999).  However,  it  was  only  after  many  years  of 
attempting to isolate the agent responsible for this so-called post-transfusion, non-A, non-B 
hepatitis (NANBH) that, in 1989, with the aid of modern techniques of molecular cloning 
and phage display, a new RNA virus, termed hepatitis C virus (HCV), was isolated (Choo 
et al., 1989). HCV causes a persistent infection in the majority of infected people and can 
lead to cirrhosis of the liver and hepatocellular carcinoma (HCC) (Houghton, 1996, Saito 
et al., 1990, Shimotohno, 2000). For this reason, and the high prevalence of infection 
worldwide, HCV is rightly classed as a major human pathogen. 
 
1.1.2 Classification 
HCV, a positive sense, single-stranded RNA virus, has been categorised as a member of 
the Hepacivirus genus within the Flaviviridae by genome analogy with other members of 
this family (Takamizawa et al., 1991, Choo et al., 1991, Choo et al., 1989). This family 
also includes the flaviviruses such as dengue virus and Japanese encephalitis virus (Rice, 
1996), the pestiviruses such as bovine viral diarrhoea virus and classic swine fever virus 
(Rice, 1996), and the recently discovered GBV-A and B viruses (Simons et al., 1995) and 
hepatitis G virus (Linnen et al., 1996). GBV-A and B were discovered after inoculum from 
a  patient  (initials  GB)  with  acute  sporadic  hepatitis  was  used  to  successfully  infect 
tamarins and the viral genomes subsequently cloned from serum of an infected animal. The 
HCV genome encodes a polyprotein of approximately 3011  amino acids (Choo et al., 
1989, Choo et al., 1991), which is comparable in size to other members of the Flaviviridae 
such as the flavivirus yellow fever virus (YFV; ~3460 aa), and the pestivirus bovine viral 
diarrhoea  virus  (BVDV;  ~3960  aa).  The  structural  proteins  of  both  the  flavi-  and 
pestiviruses are located at the N termini of their polyproteins, beginning with a small, basic 
nucleocapsid protein (Collett et al., 1989, Hahn et al., 1988). The N-terminus of the HCV 
polyprotein  is  also  highly  basic  (Choo  et  al.,  1991).  Furthermore,  HCV,  flavi-  and David A Dalrymple    Chapter 1: Introduction 
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pestiviral polyproteins all share similar hydrophobic characteristics. Alignment of the HCV 
genome with other genomes of the Flaviviridae shows regions of sequence homology as 
well as comparable genomic organisation (Miller and Purcell, 1990). For example, one 
region, from amino acids 1230-1500, contains many residues identical to a putative NTP-
binding helicase encoded by human flaviviruses, animal pestiviruses and plant potyviruses 
(Choo et al., 1991). Also, upstream from this lies a region sharing residues conserved 
among  the  putative  trypsin-like  serine  proteases  (Choo  et  al.,  1991),  thought,  by 
comparative sequence analysis with trypsin-like molecules, to be encoded by flaviviruses 
and pestiviruses (Gorbalenya et al., 1989a). The nucleotides of the HCV 5’ non-coding 
region (NCR), show similarity to those of pestiviruses. Several tracts of identical 5’NCR 
sequence have been identified between HCV and two pestiviruses, BVDV and classical 
swine fever virus (CSF) (Han et al., 1991). Unlike the flaviviruses which bind ribosomes 
via 5’-cap structures (Rice, 1996), HCV and the pestiviruses have, within their 5’NCR, an 
internal ribosome entry site (IRES), which directs cap-independent translation of the open 
reading frame (ORF) (Poole et al., 1995, Tsukiyama-Kohara et al., 1992). The 5’NCR of 
HCV has also been shown to share a large, conserved stem-loop structure with the 5’NCR 
of both BVDV and CSF (Brown et al., 1992), suggesting that HCV is more closely related 
to  the  pestiviruses.  Despite  similarities  between  HCV  and  both  flaviviruses  and 
pestiviruses,  significant  differences  also  exist,  leading  to  the  proposal  of  a  third 
Flaviviridae genus, the hepaciviruses (Robertson et al., 1998). 
Within a single patient, a population of variant HCV species (termed quasispecies) can be 
isolated (Gomez et al., 1999). Investigators in Japan were the first to suggest that HCV was 
a genetically diverse virus (Enomoto et al., 1990), with subsequent studies identifying at 
least 6 major genetic groups. To classify these groups, all presently known HCV isolates 
have  been  placed  into  one  of  6  clades  containing  all  11  HCV  subtypes  (Fig.  1.1) 
(Robertson et al., 1998). 
The virus was shown, by filtration, to be between 30 and 60 nm (He et al., 1987) with a 
low buoyant sucrose density between 1.18-1.21 g/ml (Carrick et al., 1992). It is believed to 
be  enveloped  (derived  from  host  cell  membranes)  as  evidenced  by  its  sensitivity  to 
chloroform (Feinstone et al., 1983). Electron microscopy (EM) studies on HCV positive 
plasma samples using specific monoclonal and polyclonal antibodies allowed visualisation 
of spherical particles of diameter 55-70 nm (Prince et al., 1996, Kaito et al., 1994), in 
agreement with the filtration data. 
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Figure  1.1:  Classification  of  HCV  genotypes.  Phylogenetic  analysis  of  whole 
representative genomes, allowing delineation of 6 separate clades for HCV (taken from 
Robertson et al., 1998).  
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1.1.3 Epidemiology and Transmission of HCV 
Despite being endemic worldwide, there is high geographic variability in the distribution 
of HCV. Africa and Asia have the highest reported prevalence rates while the lowest are 
found in industrialised countries such as North America, Australia and those in Northern 
and  Western  Europe  (World  Health  Organisation  guide,  2002)  (Fig.  1.2).  The  highest 
reported seroprevalence rate is in Egypt where approximately 22% of the population are 
HCV seropositive, thought to be due to contaminated glass syringes used in nationwide 
schistosomiasis treatment campaigns from 1960 to 1987 (Frank et al., 2000). 
The  most  common  factors  responsible  for  HCV  transmission  worldwide  are  blood 
(transfusion  from  unscreened  donors),  intravenous  drug  abuse,  unsafe  therapeutic 
injections and other healthcare related procedures (Shepard et al., 2005). Within developed 
countries, the introduction of blood-screening tests for HCV (Kuo et al., 1989, Huber et 
al., 1996) has effectively eradicated transmission by blood transfusion. Instead, injection 
drug use has been the predominant mode of transmission in recent times (Lavanchy, 1999). 
In the developing world however, unsafe therapeutic injections and blood transfusions are 
still  major  modes  of  transmission  (Shepard  et  al.,  2005).    HCV  transmission  via 
occupational, perinatal or sexual exposure is much less common. Perinatal transmission is 
estimated to occur in 2.7–8.4% of infants born to HCV infected mothers, with higher rates 
in those born to HIV/HCV co-infected mothers (Thomas et al., 1998, Yeung et al., 2001). 
Sexual mode of transmission has been reported (Alter et al., 1989), however it is far less 
efficient than for other sexually transmitted viruses. 
 
1.1.4 Clinical Manifestations and Natural History of HCV Infection 
HCV infection is very often clinically silent with most acute infections symptom-free and 
only  a  small  number  showing  signs  of  jaundice  (Houghton,  1996).  Rapid,  fulminant 
hepatitis associated with acute HCV infection has been reported in Japan (Yoshiba et al., 
1994), however this is not common elsewhere. This may reflect differences in genotype 
distribution as genotypes 2 and 3 are most prevalent in Japan while genotype 1 is prevalent 
in North America (Yoshiba et al., 1994). Infection becomes chronic in approximately 75% 
of  patients,  as  confirmed  by  persistence  of  HCV  RNA  in  serum  (Shimotohno,  2000). 
Chronically infected patients may present with vague symptoms such as fatigue and joint 
aching, however it is more common for patients to be unaware until complications of David A Dalrymple    Chapter 1: Introduction 
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Figure 1.2: Estimated prevalence of HCV infection by WHO region (WHO guide 
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chronic liver disease occur, often decades following infection (Di Bisceglie et al., 1991). 
Almost all chronically infected patients develop histological features of chronic hepatitis 
such as portal inflammation, interface hepatitis and lobular injury (Di Bisceglie, 1998). Up 
to 20% of patients develop cirrhosis within the first two decades of HCV infection (Yano 
et al., 1996). A wide range of factors can influence the development of cirrhosis, but it 
seems that being male, aged over 50 at time of infection and high alcohol intake increase 
susceptibility to cirrhosis (Poynard et al., 1997). Complications of chronic liver disease 
include  liver  failure  and  hepatocellular  carcinoma  (HCC).  In  patients  with  established 
cirrhosis, HCC may develop in up to 4% per year and up to 4% of patients infected with 
HCV may go on to develop HCC during their life (Di Bisceglie, 1997).  
 
1.1.5 Immune Response 
Innate and acquired immune responses both play a role in HCV infection. The critical 
period, in terms of determining the outcome of infection appears to be the acute phase 
(Gremion  and  Cerny,  2005).  Natural  killer  (NK)  cells  (part  of  the  innate  immune 
response), may play a vital role as chimpanzees with asymptomatic HCV infection can 
eliminate the virus without any detectable HCV-specific T-cell response (Thomson et al., 
2003).  Within  4  weeks  of  infection,  the  majority  of  patients  show  seroconversion, 
indicated by the presence of antibodies against both structural and non-structural proteins 
(Rubin  et  al.,  1994).  It  is  still  not  completely  understood  whether  or  not  antibodies 
neutralise HCV infectivity. HCV infection of chimpanzees can be neutralised by in vitro 
treatment with antibodies (Farci et al., 1994), however naturally acquired antibodies failed 
to prevent reinfection of immune chimpanzees or humans (Farci et al., 1992, Lai et al., 
1994). Clearance of infection is associated with a strong CD4
+ and CD8
+ T-cell response 
(Thimme et al., 2001, Diepolder et al., 1996). However, the cellular immune response may 
occur at the expense of a long-lasting inflammatory reaction resulting in liver cirrhosis and 
HCC (Gremion and Cerny, 2005). During acute infection, the ability to generate detectable 
CD4
+  and  CD8
+  T-cell responses  seems  to  be  important  in  predicting  the  outcome  of 
infection, with weak T-cell responses resulting in poorly controlled viraemia resulting in 
progression  to  persistence  (Thimme  et  al.,  2001).  While  successful  CD8
+  responses 
generally  target  multiple  major  histocompatibility  complex  (MHC)  class  I-restricted 
epitopes in structural and non-structural HCV proteins (Cooper et al., 1999, Lechner et al., 
2000), infection leading  to chronicity usually correlates with low frequencies of CTLs 
targeting  few  epitopes  (Wedemeyer  et  al.,  2002).  In  those  patients  that  do  proceed to David A Dalrymple    Chapter 1: Introduction 
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chronic  infection,  HCV  specific  CD8+  T-cells  may  partially  control  continuing  viral 
replication as well as contributing to progressive liver disease.   
 
1.1.6 Therapy 
Initially, HCV infection was treated with interferon-α. Beneficial effects of interferon-α 
were noticed before the discovery of HCV itself (Hoofnagle et al., 1986). Interferon-α has 
potent antiviral activity, not by acting directly on the virus or replication cycle, but instead 
by inducing interferon-stimulated genes (ISGs) which in turn promote a non-virus-specific 
antiviral state within the infected cell (Sen, 2001). Interferon-α therapy alone has limited 
success with only 16-20% of patients producing sustained responses after 12 months of 
treatment  (Di  Bisceglie  and  Hoofnagle,  2002).    The  addition  of  the  antiviral  agent 
Ribavirin more than doubled the response rate seen with interferon-α alone (McHutchison 
and Poynard, 1999). The mechanism by which Ribavirin acts is still poorly understood. 
Ribavirin is a guanosine analogue that is intracellularly phosphorylated to the mono-, di- 
and  triphosphate  forms.  Misincorporation  of  the  triphosphate  form  by  the  viral  RNA 
dependent RNA polymerase results in early chain termination and inhibition of replication 
(Maag et al., 2001). However, if ribavirin resulted in inhibition of replication, a reduction 
in viraemia would be expected in the early treatment phase. Ribavirin alone led to only a 
slight  transient  reduction  in  HCV  viraemia  in  early  stages  compared  to  interferon-α, 
suggesting chain termination is not the main mechanism of action (Pawlotsky et al., 2004). 
Other mechanisms have been suggested including inosine-monophosphate-dehydrogenase 
inhibition, immunomodulation and modulation of interferon signalling pathways. Ribavirin 
monophosphate  is  a  competitive  inhibitor  of  inosine-monophosphate-dehydrogenase 
(IMPDH)  leading  to  a  depletion  of  cellular  GTP  (required  for  viral  RNA  synthesis). 
However, the addition of excess guanosine only partly reverses the effects of ribavirin, 
suggesting  this  may  contribute  to,  but  not  be  completely  responsible  for,  the  antiviral 
activity of ribavirin (Lau et al., 2002). Ribavirin has also been shown to alter the TH1/ TH2 
balance towards a TH1 response (Tam et al., 1999), an early response of which has been 
shown to lead to viral clearance (Rehermann and Nascimbeni, 2005). It is also possible that 
ribavirin somehow augments or stabilises the action of interferon-α, thus enhancing its 
effects. Today,  pegylated  interferon,  in which polyethylene glycol (PEG) is  covalently 
attached to recombinant interferon-α, in combination with Ribavirin, is the treatment of 
choice. PEG interferon-α has a longer half-life, better pharmacokinetics and a better rate of 
virological response compared to interferon-α (Zeuzem et al., 2000, Glue et al., 2000). The David A Dalrymple    Chapter 1: Introduction 
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outcome of treatment can be grouped into one of three categories. Sustained virological 
response (SVR) is defined as the loss of detectable HCV RNA during, and continuing for 6 
months after, the end of therapy. End-of-treatment response and relapse is defined as a 
transient response followed by relapse, while non-response, which occurs in approximately 
one-third of chronically infected patients, defines those who never become HCV RNA 
negative. Although benefits can be seen with pegylated interferon-α/ribavirin treatment, 
therapy does result in side effects such as fatigue, influenza-like symptoms, haematological 
abnormalities and neuropsychiatric symptoms (Fried, 2002). 
Recently,  research has focussed  on new targets  for HCV  treatment.  Agents have been 
discovered which inhibit specific processes in the virus life cycle including inhibitors of 
HCV enzymes as well as nucleic acid based molecules that interfere with the viral RNA. 
Small molecule inhibitors have been identified that block essential viral enzymes such as 
the NS3/4A protease and the NS5B  polymerase (De  Francesco and Migliaccio, 2005). 
Nucleic acid based antiviral agents have also been discovered recently including antisense 
oligonucleotides and small interfering RNAs (siRNAs). A major target of these nucleic 
acid based antivirals is the HCV IRES due to the wealth of knowledge on this region and 
its  conservation  throughout  HCV  genotypes.  SiRNAs  have  been  shown  to  completely 
eradicate HCV from more than 98% of HCV replicon-bearing cells (Randall et al., 2003). 
Potential  has  also  been  shown  by  novel  immunomodulatory  agents  as  candidates  for 
treatment of HCV. Synthetic agonists of Toll-like receptors (TLRs) 7 and 9 have shown 
anti-HCV activity by stimulating the production and release of tumour necrosis factor-α 
(TNF-α), interleukin (IL)-12 and interferon-α from plasmacytoid dendritic cells (Lee et al., 
2003, Horsmans, 2004). 
The drawback with many of these proposed therapies is the appearance of mutations within 
the viral genome conferring resistance to the antiviral agent. Resistance is easily acquired 
to NS5B nucleoside analogues (Olsen et al., 2004, Migliaccio et al., 2003) and a single 
mutation is enough to confer resistance to BILN 2061, an NS3/4A protease inhibitor (Lin 
et al., 2004, Lu et al., 2004). Development of BILN 2061 has now been halted due to the 
occurrence of cardiac toxicity in laboratory animals (Reiser et al., 2005). 
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1.2 HCV Genome Structure 
1.2.1 Genome Organisation 
HCV has a single stranded, positive sense genome of approximately 9.6kb. The genome 
contains one long open reading frame (ORF) encoding a polyprotein of approximately 
3011 amino acids, flanked by 5’ and 3’ non-coding regions (NCRs) (Fig 1.3) (Choo et al., 
1991). The highly conserved 5’NCR (Bukh et al., 1992) is 341 nucleotides in length (Han 
et al., 1991) and contains extensive secondary structure (Tsukiyama-Kohara et al., 1992). 
Similarities in structure between the HCV 5’NCR and that of picornaviruses led to the 
conclusion that HCV had an internal ribosome entry site (IRES), required for translation 
initiation (Tsukiyama-Kohara et al., 1992). The ORF encodes a single polyprotein which is 
processed co- and post-translationally by host and viral proteases to produce at least 10 
viral proteins (Lindenbach and Rice, 2001). The structural proteins (core, E1, E2 and p7) 
are located within the amino-terminal third of the polyprotein, while the non-structural 
proteins  (NS2,  NS3,  NS4A,  NS4B,  NS5A  and  NS5B)  are  found  within  the  carboxy-
terminal  two-thirds (Kato et al., 1990, Lindenbach and Rice,  2001). Processing  of the 
polyprotein involves both host and viral proteases, the structural proteins being processed 
by host proteases and the non-structural proteins by viral proteases (Shimotohno et al., 
1995). The 3’ NCR is a tripartite structure consisting of a conventional 3’ end, a poly(U) 
tract and a recently discovered 3’ X-tail (Kolykhalov et al., 1996). This X-tail is highly 
conserved  and  forms  an  elaborate  stem-loop  structure,  suggesting  a  possible  role  in 
replication  (Tanaka  et  al.,  1995a,  Kolykhalov  et  al.,  1996),  a  theory  proven  by  the 
requirement  of  the  3’  X-tail  for  replication  of  the  HCV  replicon  (Friebe  and 
Bartenschlager, 2002). 
 
1.2.1.1 5’ UTR 
Depending on isolate, the HCV 5’UTR consists of approximately 341 nt (Han et al., 1991). 
Sequence analysis of this region shows sections up to 14 nt long that have perfect identity 
to that of the pestiviruses BVDV and CSF (Han et al., 1991). Sequence analysis also shows 
regions of high conservation between HCV isolates (Han et al., 1991, Bukh et al., 1992) as 
well as regions of heterogeneity (Bukh et al., 1992, Smith et al., 1995). The secondary 
structure of the 5’UTR has been predicted, indicating the presence of 4 highly structured 
domains (Fig. 1.4) (Honda et al., 1999b). While members of the flavivirus genus tend to David A Dalrymple    Chapter 1: Introduction 
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Figure 1.3: General features of the HCV genome, polyprotein processing and properties of 
individual  cleavage  products.  5’ and  3’  NCRs are  separated  by  a  single  (ORF)  which 
encodes all HCV proteins. Structural proteins core, E1, E2, and p7 are grouped at the N-
terminus, followed by the non-structural proteins (NS2-5B). Cleavage sites for host cell 
signal peptide peptidase (    ) and signalase (    ), the NS2-3 proteinase (    ) and the NS3-
4A (   ) are highlighted. Approximate molecular weights (in kDa) and properties of each 
protein are indicated (taken from Bartenschlager, 1999). 
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Figure 1.4: Topology of the TMDs of the HCV envelope proteins before and after signal 
sequence cleavage (taken from Op de Beeck et al., 2001). 
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have  smaller  5’UTRs  and  undergo  5’  cap-dependent  translation  (similar  to  that  of 
eukaryotic  mRNAs),  HCV,  similar  to  the  pestiviruses  (Poole  et  al.,  1995),  undergoes 
internal  initiation  of  translation  via  an  internal  ribosome  entry  site  (IRES)  in  a  cap-
independent manner (Wang et al., 1993, Tsukiyama-Kohara et al., 1992). The HCV IRES 
spans domains II, III and IV of the 5’UTR, together with the first 24-40 nucleotides of 
core-coding sequence (Honda et al., 1996, Reynolds et al., 1996). Translation efficiency 
from the IRES has been shown to vary between different genotypes (Collier et al., 1998). 
The IRES therefore, is proposed to provide a structure capable of directing ribosomes to 
the initiation codon at position 342 (Clarke, 1997). The interaction between IRES and 
ribosome is likely to require several protein co-factors. Interestingly, a number of cellular 
proteins have been shown to bind the 5’UTR. Polypyrimidine tract-binding protein (PTB) 
has been shown to bind the 5’UTR at at least 3 sites. Immunodepletion of PTB from 
translation lysates completely inhibits translation from the HCV 5’UTR (Ali and Siddiqui, 
1995). The same group have also shown an interaction between the 5’UTR and the RNA 
binding protein  La  (Ali and  Siddiqui, 1997). Addition of La to  an in vitro translation 
reaction enhanced HCV translation. The open reading frame initiation codon is required 
for binding La, suggesting that La may be involved in initiation of translation. Finally, 
poly(C)-binding proteins (PCBs) 1 and 2 have been shown to bind the 5’UTR (Spangberg 
and Schwartz, 1999). Depletion of PCBs from HeLa S10 extract resulted in abrogation of 
poliovirus  IRES  dependent  translation,  suggesting  PCBs  may  also  be  involved  in 
translation initiation at the HCV IRES. 
 
1.2.1.2 Core 
The  general  properties,  putative  pathogenic  roles  and  interactions  of  core  protein  are 
discussed in detail in section 1.5. 
 
1.2.1.3 E1 and E2 
E1 and E2 are the envelope glycoproteins. These proteins are thought to be involved in 
host-cell entry by binding to cell surface receptors and fusing with host-cell membranes 
(Penin et al., 2004). E1 and E2 are both type I transmembrane (TM) glycoproteins, having 
short C-terminal transmembrane domains (TMDs) and N-terminal ectodomains, and form David A Dalrymple    Chapter 1: Introduction 
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non-covalent heterodimers, the proposed virion components (Deleersnyder et al., 1997). 
Both glycoproteins are modified by N-linked glycosylation with E1 containing up to 6 and 
E2 potentially 11 glycosylation sites (Op De Beeck et al., 2001). The TMDs of E1 and E2, 
composed of 2 short stretches of hydrophobic residues separated by a short polar segment, 
have many important functions including being essential for heterodimerisation (Fig. 1.5) 
(Op De Beeck et al., 2000) as well as being required for glycoprotein retention in the ER 
(due to at least one charged residue within the polar segment) where virion assembly likely 
takes place (Cocquerel et al., 1998, Cocquerel et al., 1999, Cocquerel et al., 2000). Early 
interaction  between  the  TM  domains  (possibly  before  insertion  into  the  endoplasmic 
reticulum) has been shown to improve the stability of E2 insertion into the membrane 
(Cocquerel et al., 1998). Calnexin, an ER chaperone protein involved in disulphide bond 
formation (Bergeron et al., 1994), rapidly associates with both E1 and E2 whereby folding 
and heterodimer formation occur, with assembled glycoprotein complexes being retained 
in a pre-trans-golgi compartment (Dubuisson and Rice, 1996). 
The  development  of  retroviral  particles  bearing  unmodified  HCV  E1E2  (called  HCV 
pseudoparticles or HCVpp) (Bartosch et al., 2003a) has enhanced the understanding of 
both  HCV  entry  and  particle  neutralisation.  HCV  pseudoparticles  have  a  preferential 
tropism for hepatic cells (Bartosch et al., 2003a) and are specifically neutralised by anti-E2 
monoclonal antibodies as well as sera from HCV infected patients, thus confirming the 
correct assembly of the glycoproteins in this system (Bartosch et al., 2003a, Kato et al., 
1990, Weiner et al., 1991). A 27 amino acid region at the N-terminus of E2 (amino acids 
384-410), termed hypervariable region-1 (HVR-1) is a target for anti-HCV neutralising 
antibodies. This region is highly tolerant of  amino acid substitutions and  is subject to 
strong positive selection pressure (Kato et al., 1990, Weiner et al., 1991). The biological 
role of HVR-1 is unknown, however it has been suggested to act as a decoy to the immune 
system  during  acute  infection  (Ray  et  al.,  2000).  Antibodies  against  HVR-1  are 
neutralising in vitro and are capable of protecting chimpanzees after in vitro neutralisation 
(Farci et al., 1996). However, in contradiction to these findings, virus lacking the HVR-1 
( HVR-1) was capable of infecting chimpanzees and causing hepatitis, although this virus 
initially replicated at low levels until the appearance of compensatory mutations, indicating 
that  HVR-1 virus is attenuated but HVR-1 is not essential for HCV viability (Forns et al., 
2000). As both groups used HCV H77 strain in their studies, it is difficult to understand the 
differences  between  their  results.  One  possibility  however,  is  that  their  experimental 
methods may have had different functional effects on E2, with neutralisation of the HVR1 
region having a more detrimental effect on E2 function than the deletion of HVR1. It is 
also possible that there is an alternative, less efficient, method of HCV entry in which David A Dalrymple    Chapter 1: Introduction 
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Figure 1.5: Proposed secondary and tertiary structure of the HCV 5’NCR, including a 
small portion of the core coding sequence, from a genotype 1b infectious clone (HCV-N). 
Major structural domains are labelled with Roman numerals and the initiator codon within 
stem-loop IV is highlighted. Circled nucleotides indicate differences with the genotype 1a 
HCV-H strain (taken from Honda et al,. 1999).  
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HVR1  is  not  required,  thus  explaining  the  attenuated  phenotype  seen  by  Forns  et  al. 
Although the amino acid sequence of HVR1 is highly variable, the conformation is well 
conserved and the sequence made up of basic residues, possibly required for interaction 
with negatively charged molecules such as lipids, proteins and glycosaminoglycans (Penin 
et al., 2001). The HCVpp model has been used to study the neutralising potential of the 
mouse  monoclonal  antibody  AP33,  which  binds  E2  downstream  of  HVR1  between 
residues 412 and 423. Retroviral pseudoparticles incorporating a panel of full-length E1E2 
clones from genotypes 1-6 were assessed for their potential to be neutralised by AP33. The 
monoclonal  antibody  was  able  to  potently  neutralise  HCVpp  entry  no  matter  what 
genotype (Owsianka et al., 2005), a phenomenon that has also been confirmed using the 
recently described JFH-1 HCVcc system (Tarr et al., 2006), suggesting the linear epitope 
recognised by AP33 may be a suitable HCV vaccine target. Four discontinuous residues 
within this epitope have been reported to be required for neutralisation (Tarr et al., 2006), 
however, it still remains to be determined whether or not this antibody will have such 
potent neutralising effects on patient derived virus and if it can also neutralise in animal 
model systems.  
As well as HVR1, two other hypervariable regions have been identified within E2, firstly 
between positions 474 and 482 (HVR2) (Hijikata et al., 1991a), and secondly between 
positions 431 and 466 (HVR3), part of which has been proposed to be exposed at the 
surface  of  E2,  suggesting  it  may  play  a  role  in  immune  recognition  and/or  host-cell 
receptor binding (Troesch et al., 2006). The sequence variations concentrated within these 
regions surely  point  to  some  functional  importance in  receptor binding and cell entry, 
however the exact functional relevance has yet to be elucidated.  
 
1.2.1.4 p7 
The identification of two distinct forms of N-deglycosylated E2 led to the discovery of a 
small hydrophobic protein between E2 and NS2 termed p7 (Lin et al., 1994a). Cleavage of 
p7 from the polyprotein is mediated by a host signal peptidase, which, due to the presence 
of an E2-p7-NS2 precursor and stable E2-p7 form, has been shown to be processed post-
translationally and that cleavage is sub-optimal due to a weak signal peptide cleavage site 
(Isherwood and Patel, 2005, Lin et al., 1994a). Analysis of the amino acid composition of 
p7  shows  that  it  is  made  up  of  mostly  uncharged  polar  or  hydrophobic  residues 
interspersed  by  a  few  conserved  charged  residues,  thus  allowing  a  double  membrane-David A Dalrymple    Chapter 1: Introduction 
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spanning conformation, separated by a few charged residues on the cytoplasmic side and 
with the N- and C-termini facing the luminal side (Lin et al., 1994a).  
The precise role of p7 in the life cycle of HCV is still unknown. It has been shown to be 
dispensable  for  viral  RNA  replication,  as  replicons  lacking  p7  replicate  efficiently 
(Lohmann et al., 1999), while viral RNA with the p7 region deleted was non-infectious in 
chimpanzees (Sakai et al., 2003), suggesting p7 is not required for efficient HCV genome 
replication but is required for the production of infectious virus. A recent report has shown 
that p7 may be involved in assembly and/or release of infectious virus particles as a single 
mutation in p7 increased the yield of infectious virus from an H77S/JFH-1 chimeric clone 
(Yi et al., 2007). Pestiviruses, such as BVDV, also have a p7 protein showing similar 
hydrophobicity and incomplete cleavage pattern (Harada et al., 2000). A large in-frame p7 
deletion within the BVDV genome does not affect replication, however, similar to the 
finding by Sakai et al (2003), no infectious virus is produced (Harada et al., 2000). As p7 
is not thought to be incorporated into the closely related pestivirus particle (Elbers et al., 
1996), p7 may be involved in protecting the infectivity of the newly assembled particles 
before  and/or  during  release  (Yi  et  al.,  2007).  Studies  using  recombinant  expression 
plasmids suggest p7 localises to the ER (due to an ER retention signal) (Carrere-Kremer et 
al.,  2002)  and  mitochondrial  membranes  (Griffin  et  al.,  2005),  while  a  fraction  is 
transported to the cell surface, suggesting it plays multiple roles in the secretory pathway 
(Carrere-Kremer  et  al.,  2002).  A  recent  report  however  suggests  that  HA-tagged  p7, 
expressed from full-length infectious JFH-1 RNA, localises solely to the ER (Haqshenas et 
al., 2007). The fact that p7 has been reported to localise to both the ER and mitochondria 
suggests multiple populations of p7 exist and that p7 may have more than one role in the 
life cycle of the virus. One such role of p7 is that of an ion channel, possibly regulating the 
flow of calcium ions from the ER to the cytoplasm (Griffin et al., 2003, Griffin et al., 
2004). Recently, the same group has revealed the heptameric structure of this channel, 
providing further evidence for its function as an ion channel in the virus life cycle (Clarke 
et al., 2006). As more is known about the properties of p7 it is becoming clear that this is 
an important factor in the virus life cycle, presumably at a post-replication stage. This 
makes p7 an interesting target for future antiviral studies as it may be possible to block the 
proposed ion channel and thus inhibit the production of infectious particles.  
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1.2.1.5 NS2 
The  NS2  region  (in  conjunction  with  the  N-terminal  end  of  NS3)  contains  a  zinc-
dependent metalloproteinase, responsible for cleavage at the NS2/3 junction (Grakoui et 
al., 1993c, Hijikata et al., 1993). This protease overlaps with the serine protease located at 
the N-terminal end of NS3, however the function of the NS2 protease does not rely on its 
NS3 counterpart (Grakoui et al., 1993c, Hijikata et al., 1993). Residues His 952 and Cys 
993 have been shown to be essential for NS2 protease function but have no effect on 
downstream  cleavage  events  (Grakoui  et  al.,  1993c),  presumably  because  downstream 
cleavage is carried out by the NS3 protease. Upon processing, NS2 is inserted into the ER 
membrane  where  it  resides  as  a  transmembrane  protein  (Santolini  et  al.,  1995),  with 
possibly 4 TM domains (Yamaga and Ou, 2002). NS2 is not essential for replication as 
shown by replication of sub-genomic replicons lacking the NS2 gene (Lohmann et al., 
1999),  however  an  interaction  has  been  described  between  processed  NS2  and  NS3 
(Dimitrova  et  al.,  2003,  Kiiver  et  al.,  2006)  and  NS2  plays  an  essential  role  in  the 
phosphorylation of NS5A (Liu et al., 1999), suggesting NS2 has other functions as well as 
NS2/3 cleavage which are not directly involved in replication. The crystal structure of the 
catalytic  domain  of  NS2-3  has  been  solved  (Lorenz  et  al.,  2006),  showing  that  the 
monomeric form has 2 subdomains connected by an extended linker, while the dimeric 
form resembles a “butterfly” in which the C-terminal subdomain of one molecule interacts 
with the N-terminal subdomain of the other and vice versa. The protease activity of NS2 is 
required for its cleavage from the polyprotein, however as it is dispensible for replication, 
its true function remains unknown but is presumably required for some accessory role in 
the virus life cycle as shown by its role in the phosphorylation of NS5A and its association 
with NS3.     
 
1.2.1.6 NS3 
NS3 is a multifunctional protein of 68 kDa, containing a serine protease domain within its 
N-terminal third (Bartenschlager et al., 1993, Grakoui et al., 1993b, Hijikata et al., 1993, 
Tomei et al., 1993) and an NTPase/helicase domain within its C-terminal two-thirds (Kim 
et al., 1995, Suzich et al., 1993). The two functional domains are not cleaved from each 
other (Bartenschlager et al., 1993) yet act independently of each other (Kim et al., 1995). 
The serine protease domain is required for 4 cleavage events, acting in cis to release itself 
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NS5B (Grakoui et al., 1993a, Bartenschlager et al., 1993, Tomei et al., 1993, Lin et al., 
1994b). In addition to the N-terminal third of NS3, a C-terminal domain of NS4A has been 
described  as  an  NS3  co-factor,  required  for  efficient  cleavage  of  the  downstream 
polyprotein, especially at the NS4B/5A cleavage site (Failla et al., 1994, Bartenschlager et 
al., 1994), resembling that seen in flaviviruses and pestiviruses. Cleavage of dengue virus 
(type 4) polyprotein at NS2A/2B and NS2B/NS3 requires NS2B (Falgout et al., 1991), 
while cleavage at NS4B/5 of yellow fever virus by the NS3 protease requires association 
with NS2B (Chambers et al., 1991). The NS3/4A protease has also been shown to control 
host cell antiviral defences by disrupting pathways that lead to activation of interferon 
regulatory factor 3 (IRF3) and subsequent induction of type I interferon. As an antiviral 
defence mechanism, cells possess molecules which are specifically activated by dsRNA. 
One such protein, the DexD/H-box RNA helicase retinoic acid inducible gene I (RIG-I), 
contains a C-terminal helicase domain that binds a pathogen-associated molecular pattern 
(PAMP) embedded within the 5’ or 3’ NCR of HCV. In doing so, the conformation of 
RIG-I is altered, thus allowing recruitment of downstream interacting partners (Sumpter et 
al.,  2005).  One  such  interacting  partner  of  RIG-I  is  mitochondrial  antiviral  signalling 
protein (MAVS; also known as IPS-1, VISA, and CARDIF). Interaction between RIG-I 
and  MAVS  leads  to activation  of  IRF-3  via  phosphorylation  by  the  kinases  TBK  and 
IKKe, which in turn leads to nuclear translocation of IRF-3 and subsequent transcriptional 
activation of promoters of IFN-β, IFN-stimulated genes ISG56 and ISG15, and RANTES 
genes. To overcome this antiviral signalling cascade, HCV possesses a tactic for blocking 
this pathway. In studying the effects of HCV replication and polyprotein expression on 
Sendai virus-induced IRF-3 translocation, it was shown that HCV NS3/4A specifically 
blocks  expression  of  IRF-3-activated  genes  (Foy  et  al.,  2003).  Specifically,  NS3/4A 
cleaves MAVS at cys-508, resulting in dislocation of the N-terminus of MAVS from the 
mitochondria and subsequent inhibition of the signalling pathway (Johnson et al., 2007, Li 
et al., 2005), a catalytic event requiring the protease domain of NS3 and a minimal NS4A 
co-factor but not NS3 helicase activity (Foy et al., 2003, Foy et al., 2005, Johnson et al., 
2007). HCV  has therefore  developed a method for counteracting the antiviral immune 
response  imposed  by  the  host,  possibly  resulting  in  progression  to  chronic  infection. 
Similarly, GBV-B, the phylogenetically closest relation of HCV, has recently been shown 
to disrupt the RIG-I signalling pathway in the same manner (Chen et al., 2007). Inhibitors 
of  the  HCV  NS3  protease  have  been  shown  to  restore  the  normal  mitochondrial 
distribution of MAVS and in doing so reduce viral protein abundance (Johnson et al., 
2007), thus indicating a novel role for HCV protease inhibitors in the battle against HCV 
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NS4A is thought to localise NS3 to the ER membrane in an NS3/4A complex, increasing 
the stability of NS3 (Wolk et al., 2000). NS5B has also been shown to associate with this 
NS3/4A complex, suggesting this complex could function as part of the HCV replication 
machinery (Ishido et al., 1998), while the recent identification of an interaction between 
NS3 and NS2 (section 1.2.1.5) suggests NS2 may function as an anchor to retain NS3 at 
the ER membrane until cleavage of NS4A (Kiiver et al., 2006). 
The C-terminal two-thirds of NS3 possess NTPase and helicase activity. Polynucleotide-
stimulated NTPase activity, capable of hydrolysing all NTPs and dNTPs, has been shown 
(Suzich et al., 1993), while RNA helicase activity, requiring ATP and a divalent ion, has 
also been identified (Kim et al., 1995). Emphasising its role as a functional helicase, the 
NS3 C-terminal domain is capable of unwinding RNA-RNA, RNA-DNA and DNA-DNA 
substrates and does so in a 3’-5’ direction (Tai et al., 1996). According to amino acid 
homology, the helicase domain of NS3 resembles that of the DExH-box NTPase/helicases, 
which includes elongation initiation factor (eIF) 4A , thus classifying NS3 as a member of 
this family (Gorbalenya et al., 1989b). Regarding its function within the viral life cycle, the 
helicase domain of NS3 has been shown to interact with the 3’ terminal sequence of both 
positive and negative HCV RNA (Banerjee and Dasgupta, 2001), similar to that shown for 
poliovirus  NTPase/helicase  2C  (Banerjee  et  al.,  1997),  while  an  active  NS3  helicase 
domain has recently been reported to be required for replication of an HCV subgenomic 
replicon (Lam and Frick, 2006), thus suggesting a role in unwinding viral RNA during 
replication. However, the precise role of the NS3 helicase domain during replication is still 
not fully understood. NS3 has been shown to bind many cellular factors including protein 
kinase A, protein kinase C, tumour suppressor p53 and histones H2B & H4 (reviewed in 
(Tellinghuisen  and  Rice,  2002)  and  has  effects  on  various  processes  such  as  cell 
metabolism, differentiation and tumour promotion (Borowski et al., 1996, Sakamuro et al., 
1995). The multifunctionality of NS3, together with its interactions with numerous cellular 
factors, indicates that this protein plays a pivotal role in the life cycle of HCV, not just in 
terms of replication of the viral RNA but also by interacting with host-cell proteins which 
may result in some of the pathogenic effects associated with HCV infection. Due to its 
enzymatic  activities,  NS3  is  a  possible  antiviral  target.  The  design  of  such  NS3 
protease/helicase inhibitors has been helped by the solving of the structure of NS3 by X-
ray crystallography (Yao et al., 1999).  
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1.2.1.7 NS4A 
Non-structural region NS4 of HCV is a hydrophobic region that is cleaved by the NS3 
protease to produce NS4A and NS4B (Grakoui et al., 1993d). As described in section 
1.2.2.5, NS4A is a co-factor of the NS3 protease, the central hydrophobic domain of which 
(amino acids 21-32) is essential for NS3 protease co-factor function (Lin et al., 1995, 
Tomei et al., 1996). NS4A also helps to stabilise NS3 by anchoring it to the ER membrane 
while also associating with NS4B, NS5A and NS5B to form a complex structure, possibly 
involved in viral replication (Tanji et al., 1995a).  As well as this, NS4A (and NS4B) have 
been  shown  to  inhibit  protein  synthesis  at  the  translation  stage,  with  NS4A  function 
mediated by the first 40 amino acids (Kato et al., 2002, Florese et al., 2002). This effect 
was  negated  when  NS4A  was  co-expressed  with  NS3,  suggesting  conformational 
differences before and after cleavage may be important in  this process  (Florese et al., 
2002). As with bovine viral diarrhea virus protein NS5A (Johnson et al., 2001), HCV 
NS4A has been shown to interact with eukaryotic elongation factor (eIF) 1A (Liu et al., 
2005, Kou et al., 2006), further suggesting an involvement in protein synthesis inhibition. 
It is therefore possible that NS4A is involved in the switch from translation of the HCV 
polyprotein to replication of viral RNA once sufficient protein production/processing has 
occured.  
In conjunction with NS4B, NS4A has been suggested to play a role in abrogating host 
defences  via  inhibition  of  protein traffiking. The precursor  protein NS4A/4B  has been 
shown to slow the rate of ER-Golgi traffiking in a similar manner to that of Poliovirus 3A 
protein (Doedens and Kirkegaard, 1995), however this is only seen when NS4A/4B is 
expressed in isolation and not when NS4A or NS4B are expressed on their own (Konan et 
al.,  2003).  If  ER-Golgi  traffiking  is  slowed  by  NS4A/B,  the  virus  would  require  an 
alternative route of exit. Rotaviruses exit the cell via a non-classical secretory route that 
bypasses the Golgi apparatus (Jourdan et al., 1997). It is possible that HCV exits via a 
similar non-Golgi route, thus inhibition of the secretory pathway downstream of the ER 
would not affect virus maturation but would affect host defences, such as traffiking of 
MHC antigen presentation molecules to the cell surface (Konan et al., 2003), therefore 
providing  a  possible  role  for  NS4A/B  in  inhibition  of  host-cell  defenses.  Finally, 
phosphorylation of NS5A by cellular kinases has also been shown to be enhanced in the 
presence of NS4A (Kaneko et al., 1994, Reed et al., 1997, Tanji et al., 1995b).       
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1.2.1.8 NS4B 
The relatively hydrophobic NS4B protein is the least well-understood HCV protein. The 
27 kDa protein is exclusively present as a fine membraneous network in the cytoplasm 
(Park  et  al., 2000), localising to  the  ER where it  colocalises  with other non-structural 
proteins (Hugle et al., 2001). Localisation to the ER is independent of other HCV proteins, 
indicating the presence of endogenous signals for ER targeting and membrane anchorage 
(Hugle et al., 2001). NS4B is thought to have at least 4 TM domains, with a fifth occurring 
upon predicted translocation of the N-terminus to the lumenal side of the ER (Lundin et 
al., 2006, Lundin et al., 2003). This translocation is impaired by NS5A, suggesting NS4B 
has  different functions during  the  viral  life cycle  (Lundin  et  al.,  2006).  Alterations  to 
membrane structure (termed the membranous web) have been described in cells expressing 
NS4B and also in cells expressing full length HCV polyprotein (Egger et al., 2002). The 
membranous web may comprise the HCV replication complex and has been shown to 
harbour all HCV structural and non-structural proteins in UHCVcon-57.3 cells (Egger et 
al., 2002). Within the ER membrane, NS4B is mobile but becomes less mobile at small 
foci within this membranous web (termed membrane associated foci, (MAFs)) (Gretton et 
al., 2005).  If these MAFs are the site of HCV replication complexes then it could be 
suggested that the formation of oligomeric complexes incorporating NS4B increase the 
bulk of TM domains and thus retard movement (Gretton et al., 2005). Palmitoylation of 
NS4B,  the  attachment  of  fatty  acids  to  cysteine  residues  of  membrane  proteins,  has 
recently  been  described.  Cysteine  residues  257  and  261  have  been  shown  to  be 
palmitoylated, with mutation of these residues affecting interaction between NS4B and 
NS5A  (Yu  et  al.,  2006).  Abolishing  palmitoylation  at  cys261  was  also  shown  to 
completely inhibit replication of a sub-genomic replicon (Yu et al., 2006). A nucleotide-
binding motif has also been identified in NS4B, genetic disruption of which impairs GTP 
binding/hydrolysis and inhibits RNA replication in a replicon system (Einav et al., 2004). 
The importance of this nucleotide-binding motif for replication would suggest that NS4B 
has other roles in replication as well as simply providing structural scaffolding for the 
replication complex.  
Expression profiles of HeLa genes in the presence of NS4B showed that 34 genes were up-
regulated and 56 genes down-regulated, including genes involved in oncogenesis, tumour 
suppression,  cell  receptors,  adhesion,  transcription  and  translation,  and  cellular  stress 
(Zheng et al., 2005). Similarly, Park et al. showed that NS4B, co-expressed with HA-ras, 
led  to  loss  of  contact  inhibition,  morphological  alterations  and  anchorage-independent David A Dalrymple    Chapter 1: Introduction 
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colony  formation  in  NIH3T3  cells  (Park  et  al.,  2000),  indicating  NS4B  may  also  be 
involved in HCV pathogenesis. 
 
1.2.1.9 NS5A 
NS5A is a predominantly hydrophilic protein containing no transmembrane helices and is 
associated with the ER membrane via an amphipathic alpha helix within its N-terminal 30 
amino acids (Brass et al., 2002). There are two phosphorylated forms of NS5A, a basally 
phosphorylated 56 kDa form and a hyperphosphorylated 58 kDa form (Tanji et al., 1995b, 
Kaneko  et  al.,  1994).  As  described  previously  (section  1.2.1.7),  NS4A  is  required  for 
hyperphosphorylation  of  the  56  kDa  NS5A  protein  (Kaneko  et  al.,  1994)  and  the  N-
terminal portion of NS5A has been shown to be required for both NS4A binding and 
resultant  NS5A  phosphorylation  (Asabe  et  al.,  1997).  The  kinases  responsible  for 
phosphorylation  of  NS5A  are  thought  to  be  serine/threonine  kinases  from  the  CMGC 
(CDK, MAPK, GSK and Cdc-like) kinase family although specific kinases have not yet 
been identified (Reed et al., 1997). NS5A/NS5 serine/threonine phosphorylation has been 
shown  for  flavivirus  (yellow  fever  virus),  pestivirus  (bovine  viral  diarrhea  virus)  and 
hepacicvirus  (HCV)  genera  of  the  Flaviviridae,  suggesting  NS5A/NS5  may  play  an 
important role in the Flaviviridae life cycle (Reed et al., 1998). Mutation resulting in the 
disruption  of  the  amphipathic  alpha  helix  of  NS5A  completely  inhibited  replicon 
replication,  suggesting  that  NS5A  membrane  association  is  essential  for  HCV  RNA 
replication (Elazar et al., 2003). Human vesicle-associated membrane protein-associated 
protein-A (hVAP-A) is thought to function as a docking site for assembly or localisation of 
the HCV replication complex (Tu et al., 1999). The same group showed that hVAP-A 
binds NS5A, leading to the postulation (Evans et al., 2004) that the hyperphosphorylated 
form of NS5A represents a “closed” conformation within the replication complex, unable 
to bind hVAP-A and thus inhibiting replication whereas the hypophosphorylated form of 
NS5A represents an “open” conformation, allowing interaction with hVAP-A and viral 
replication, thus regulating the HCV life cycle.  
A  40  amino  acid  region  of  NS5A  has  been  reported  to  contain  residues  that  confers 
resistance to interferon-α treatment (Enomoto et al., 1995, Enomoto et al., 1996). This 
region has been termed the interferon sensitivity determining region (ISDR) (Enomoto et 
al., 1995). Interferon induces cellular antiviral responses, mediated in part by the dsRNA-
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expression  upon  cellular  exposure  to  interferon.  Upon  activation  by  dsRNA,  PKR 
phosphorylates the α-subunit of eukaryotic translation initiation factor 2 (eIF-2α), resulting 
in  cessation  of  protein  synthesis  and  therefore viral  replication  (Merrick  and  Hershey, 
1996). NS5A, via its ISDR, has been shown to interact and inhibit interferon-induced PKR 
(Gale et al., 1997, Gale et al., 1998), although in a separate study, no interaction between 
NS5A and PKR could be detected (Podevin et al., 2001). The discrepancy between these 
two reports may be accounted for by the different cell lines used by the two groups. Gale et 
al. used the fibroblast Cos-1 cell line while Podivin et al. used the more relevant hepatoma 
Huh7 cell line. Podevin et al. did however see an impact of NS5A on the regulation of 
interferon-α antiviral efficacy, suggesting a PKR-independent mechanism (Podevin et al., 
2001).  One  such  mechanism  suggested  involves  the  cytokine  interleukin  (IL)-8,  the 
expression of which has been reported to be induced by NS5A (Girard et al., 2002, Polyak 
et al., 2001).  IL-8  can attenuate the antiviral properties  of interferon-α  (Khabar et al., 
1997), thus suggesting  a  theory  of PKR-independent inhibition of interferon-α. Recent 
reports have however suggested that NS5A does not contain an ISDR (Aus dem Siepen et 
al., 2005, Brillet et al., 2007). NS5A genes, isolated from interferon-α responders and non-
responders (infected with the same HCV strain), were inserted into the backbone of the 
Con1  replicon.  No  significant  differences  in  sensitivity  of  HCV  RNA  replication  to 
interferon-α treatment were seen (Aus dem Siepen et al., 2005). Similarly, no significant 
changes were seen in NS5A amino acid sequence between interferon-α responders and 
non-responders  24  hrs  post-administration,  suggesting  interferon-α  does  not  select 
interferon-resistant  variants  with  specific  NS5A  sequences  (Brillet  et  al.,  2007).  The 
argument over whether or not NS5A has an ISDR is difficult to assess, possibly due to 
genetic differences within human hosts, thus resulting in some patients being susceptible to 
interferon resistant variants while others are not. 
NS5A has also been suggested to modulate mitogenic signalling via mitogen-activated 
protein kinase (MAPK) pathways, inhibit apoptosis and induce HCC via perturbation of 
phosphatidylinositol  3-kinase-mediated  signalling  pathways  (Macdonald  and  Harris, 
2004), indicating it too may be involved in HCV pathogenesis. 
 
1.2.1.10 NS5B 
Replication of HCV RNA involves synthesis of a complementary negative-strand RNA 
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positive-strand  RNA  copies  from  the  negative-strand  intermediate  RNA  template.  The 
protein  responsible  for  this  in  HCV  is  NS5B. Containing  motifs  common  amongst  all 
RNA-dependent RNA polymerases, NS5B was confirmed as the HCV RdRp by presence 
of enzymatic activity capable of copying HCV RNA (Behrens et al., 1996, Lohmann et al., 
1997). Since then the crystal structure has been resolved and classical “fingers”, “palm” 
and “thumb” sub-domains identified (Ago et al., 1999, Bressanelli et al., 1999, Lesburg et 
al., 1999). NS5B has been shown to be an integral membrane protein with a cytosolic 
orientation, associating with membranes via a highly hydrophobic 21 aa C-terminus, thus 
being  a  member  of  the  tail-anchored  protein  family  (Schmidt-Mende  et  al.,  2001).  In 
functional assays, bacterially expressed, purified NS5B can copy full-length HCV RNA in 
the absence of a primer, presumably using the 3’ ends of both positive and negative strand 
HCV RNA as templates (Oh et al., 1999). Indeed, a specific interaction between NS5B and 
the  3’  end  of  viral  RNA  has  been  reported  (Cheng  et  al.,  1999).  Having  no  cellular 
equivalent, HCV RdRp, like NS3, is an attractive target for antiviral therapy (Huang et al., 
2006). 
 
1.2.1.11 3’ UTR 
The 3’ UTR is a tripartite structure consisting of a short (28-42 nt), poorly conserved 
sequence (variable region), followed by a poly(U)/polypyrimidine tract of variable length 
and a highly conserved 98 nt sequence termed the X-tail (Fig 1.6) (Tanaka et al., 1996, 
Kolykhalov et al., 1996, Blight and Rice, 1997). Despite the significant heterogeneity in 
the poly(U)/polypyrimidine tract between isolates, all isolates carry this tract, suggesting 
some importance in replication (Friebe and Bartenschlager, 2002). The X-tail is highly 
conserved even between the most divergent HCV isolates (Tanaka et al., 1996), suggesting 
some functional importance. The secondary structure of the 3’UTR has been determined 
(Blight and Rice, 1997, Kolykhalov et al., 1996) and includes two stem-loops upstream of 
the poly(U)/polypyrimidine tract and another 3 within the X-tail. Structural determination 
indicated  one  stable  stem-loop  within  the  terminal  46  nts  of  the  X-tail  (3’SL1),  and 
possibly two other unstable stem-loops within the remaining 52 nts of the X-tail (3’SL2 
and  3’SL3)  (Blight  and  Rice,  1997,  Kolykhalov  et  al.,  1996).  Several  studies  have 
indicated regions of the 3’UTR that are required for both replication and translation. Two 
in vivo studies showed that deletion of the X-tail destroyed the ability of infectious RNA to 
replicate in chimpanzees (Kolykhalov et al., 2000, Yanagi et al., 1999) while Yanagi et al. 
took this study further and showed that deletion of any large segment of the 3’UTR (except  David A Dalrymple    Chapter 1: Introduction 
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Figure 1.6: Proposed secondary and tertiary structure of the HCV 3’NCR.  The 3’UTR is a 
tripartite  structure  consisting  of  a  variable  region,  a  poly(U)/polypyrimidine  tract  of 
variable length and a highly conserved X-tail which forms 3 stem loops (taken from Ito & 
Lai, 1997). 
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for the variable region) abolished the replicative ability of the HCV RNA (Yanagi et al., 
1999). These in vivo studies were confirmed by studies using HCV replicons showing that 
the  X-tail  and  poly(U)/polypyrimidine  tract  are  indispensable  for  replication,  while 
deletion  of  the  complete  variable  sequence  reduces  replication  efficiency  (Friebe  and 
Bartenschlager, 2002). Replication was also shown to be abolished when any of the 3 
putative  X-tail  stem-loops  were  deleted,  and  similarly,  replication  was  abolished  on 
deletion of the complete poly(U)/polypyrimidine tract (Yi and Lemon, 2003). In this study, 
replication  was  only  sustainable  in  the  presence  of  at  least  50  nts  of 
poly(U)/polypyrimidine tract. Translation of the HCV polyprotein is also thought to be 
influenced  by  the  3’UTR  in  that  the  X-tail  specifically  enhances  IRES-dependent 
translation from the 5’-end of HCV viral RNA (Ito et al., 1998a), while more recently it 
was shown that all regions of the 3’UTR contribute to translation stimulation and that this 
stimulation was stronger in hepatoma cell lines (Huh-7 and HepG2) compared to non-
hepatoma lines (BHK and HeLa) (Song et al., 2006).  
A number of studies have shown an interaction between the 3’UTR and host-cell proteins, 
for example polypyrimidine tract-binding protein (PTB). PTB has been reported to bind 
the poly(U)/polypyrimidine tract and the 5’-end of the X-tail of the 3’UTR (Tsuchihara et 
al.,  1997,  Gontarek  et  al.,  1999,  Luo,  1999).  This  interaction  is  of  interest  as  it  has 
previously been shown that PTB can also bind the 5’UTR (Ali and Siddiqui, 1995) and 
since PTB is capable of dimerisation, it is conceivable that PTB is required to bring the 5’ 
and 3’UTRs together, possibly during replication. Other cellular proteins shown to bind the 
3’UTR include La, heterogeneous nuclear ribonucleoprotein C (hnRNPC), glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) and ribosomal proteins L22, L3 and S3, as well as 
the mitochondrial homologue of  L3 (mL3) (Wood et al., 2001, Gontarek et al., 1999, 
Petrik et al., 1999, Spangberg et al., 1999). Finally, in agreement with the theory of the 
3’UTR being involved in replication, both NS5B and the helicase domain of NS3 have 
been shown to specifically interact with the 3’UTR (Cheng et al., 1999, Banerjee and 
Dasgupta, 2001). The array of host cell proteins shown to bind the 3’UTR, along with the 
enzymatic NS5B and NS3 suggest that a major complex of proteins may form around the 
3’UTR thus contributing to the viral RNA replication process. 
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1.3 HCV Replication 
Until the recent discovery of an HCV clone fully infectious in cell culture (Wakita et al., 
2005), the study of HCV replication was severely hampered. Using comparative analysis 
and characterisation of recombinant HCV proteins however, a hypothetical model of HCV 
replication  has  been  proposed  (Fig.  1.7)  (Bartenschlager  and  Lohmann,  2000).  The 
detection of hepatitis C-specific antigens in liver biopsies of chronic HCV carriers (Blight 
et al., 1994) has led to the identification of the liver as the primary site of virus replication 
(Bartenschlager  and  Lohmann,  2000).  Extrahepatic  sites  of  replication  have  also  been 
suggested however. Peripheral blood mononuclear cells (PBMC) are permissive for HCV 
replication although replication levels are low (Cribier et al., 1995), while viral particles 
have  also  been  identified  within  an  HCV  infected  human  B  lymphoblastoid  cell  line 
(Serafino et al., 1997). Human T-cells have also been suggested to be capable of sustaining 
HCV replication  (Shimizu et al., 1992)  and more recently negative strand  HCV RNA 
(indicative of replication) has been detected in the central nervous systems of patients with 
recurrent  HCV  infection  after  liver  transplantation,  suggesting  HCV  is  neuroinvasive 
(Vargas et al., 2002). While the liver is clearly the primary site of HCV replication, it is 
possible that extrahepatic sites of replication do exist, however the role these infections 
play in the pathogenesis of HCV has yet to be ascertained.  
 
1.3.1 Attachment and Entry 
To initiate its life cycle, a virus must bind to the host cell. Binding occurs via a specific 
interaction between a host cell receptor and an attachment protein on the surface of the 
virus. Glycoproteins E1 and E2 are present on the surface of the HCV particle and are 
believed to be responsible for virus attachment and entry. Antibodies against E2 and the 
HVR1 of E2 have been shown to block virus attachment in vitro (Zibert et al., 1995) and 
neutralise infectious virus both in vivo (Farci et al., 1996) and in infectious cell culture 
system (Lindenbach et al., 2005). Initially, due to the lack of reproducible cell culture 
model, virus-like particles (VLPs) were used for the study of HCV binding. VLPs were 
produced in insect cells by recombinant baculovirus containing cDNA of HCV structural 
proteins  (Baumert  et  al.,  1998),  however  these  particles  were  non-infectious  and  were 
retained within intracellular compartments making it difficult to evaluate how closely they 
resembled real virus particles. A better model for studying HCV binding is the David A Dalrymple    Chapter 1: Introduction 
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Figure 1.7: Putative model for the HCV replication cycle. Upon attachment and entry into 
the host cell, positive-sense, single-stranded genomic RNA is released into the cytoplasm 
and translated. A single polypeptide is produced which is subsequently processed by both 
host  and  viral  proteases.  Formation  of  a  membrane-bound  replication  complex  occurs, 
consisting  of  viral  proteins  NS3-5B  which  generates  negative-sense  replication 
intermediate HCV RNA that is then used to as a template for production of more genomic 
HCV RNA. Progeny RNA is encapsidated by core protein and resultant nucleocapsids are 
enveloped by budding into the ER lumen, prior to egress via the secretory pathway (taken 
from Bartenschlager & Lohmann, 2000). 
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pseudoparticle (HCVpp) model. Pseudoparticles are retroviral or lentiviral core particles 
displaying  unmodified HCV envelope  glycoproteins (Hsu et al.,  2003, Bartosch et al., 
2003a). These particles mimic the early stages of infection, have a preferential tropism for 
the liver and are neutralised by anti-E2 monoclonal antibodies and HCV positive patient 
sera (Hsu et al., 2003, Bartosch et al., 2003a, Lavillette et al., 2005, Owsianka et al., 
2005). While these model systems have helped elucidate some of the mechanisms behind 
cell tropism and entry, it is only with the production of infectious HCV particles from a 
cloned  viral  genome  (Wakita  et  al.,  2005),  that  these  mechanisms  can  be  clearly 
understood in terms of  infectious virus particles.  
The first molecule to be suggested as a putative HCV receptor was CD81 (Pileri et al., 
1998). CD81 is a 25 kDa cell-surface molecule involved in many processes including cell 
adhesion  and  signal  transduction  and  has  4  transmembrane  domains,  giving  rise  to  2 
extracellular  loops  (termed  large  and  small)  and  categorising  it  as  a  member  of  the 
tetraspanin superfamily. Evidence for  CD81  being  a receptor  for HCV  came from the 
competitive inhibition of binding of anti-CD81 to CD81-expressing cells by recombinant 
E2,  with  E2  specifically  binding  to  the  large  extracellular  loop  of  CD81  in  protein 
immunoblots (Pileri et al., 1998). Recombinant GST-fusion polypeptides encompassing 
the  large  extracellular  loop  of  human  CD81,  pre-incubated  with  HCVpp,  specifically 
precipitated E1-E2 complexes and was shown to neutralise HCVpp infection of Huh-7 
cells (Bartosch et al., 2003a), while HCVpp infection was also inhibited by monoclonal 
antibodies against CD81 as well as by knockdown of CD81 expression by siRNA (Zhang 
et  al.,  2004).  Finally,  evidence  from  infectious  cell  culture  systems  suggests  an 
involvement  of  CD81  since  infectivity  was  blocked  by  pre-incubation  with  soluble 
recombinant CD81 large extracellular loop molecules (Lindenbach et al., 2005) while anti-
CD81 monoclonal antibodies were able to neutralise infectious virus (Wakita et al., 2005). 
Koutsoudakis et al. recently added to this by showing that anti-CD81 inhibits HCV JFH-1 
infection at a post-binding stage, suggesting CD81 is required after an initial binding step 
(Koutsoudakis et al., 2006) while susceptibility to HCV infection depends on a critical 
quantity of cell surface CD81 molecules (Koutsoudakis et al., 2007). A study comparing 
the large extracellular loop of human CD81 with that of African Green Monkey (AGM) 
(having no affinity for E2), showed only 4 differences in amino acid sequence (Flint et al., 
1999) while mutagenesis of these 4 residues indicated that residues 163 and 186 were 
important for  E2  binding  (Higginbottom  et  al.,  2000).  CD81  mutant  T163A  increased 
binding affinity for E2 while mutant F186L completely abolished interaction with E2. In a 
similar study, residues 162, 182, 184 and 186 were identified by random mutagenesis as 
being critical for E2 binding (Drummer et al., 2002). The region of E2 involved in binding David A Dalrymple    Chapter 1: Introduction 
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CD81 has been studied by site-directed mutagenesis and subsequent functional analysis of 
CD81 binding and infectivity in the context of HCVpp. From this, it has been suggested 
that E2 residues 420, 527, 529, 530 and 535 are important in binding since mutation led to 
>90%  reduction  in  binding  to  recombinant  CD81.  Interestingly,  while  those  mutants 
showing  >90% reduction in CD81 binding showed concomitant poor infectivity, some 
mutants that were able to bind CD81 also showed poor infectivity, indicating that CD81 
binding is necessary but not sufficient for HCVpp infectivity (Owsianka et al., 2006). In a 
similar study, residues 436-438 and 441-443 were also shown to be important for both 
CD81  binding  and  HCVpp  infectivity  (Drummer  et  al.,  2006).  In  agreement  with  the 
theory that CD81 binding is not sufficient for infectivity, a study of which cell types were 
permissive for HCVpp infection showed that while all human cell lines studied (with the 
exception of HepG2 and HH29) expressed CD81, only 4 (Huh-7, Huh-7.5, PLC/PR5 and 
Hep3B) were permissive to HCVpp infection, suggesting CD81 alone is not sufficient to 
confer susceptibility to infection (Zhang et al., 2004). 
The low-density lipoprotein (LDL) receptor has also been suggested as a putative HCV 
receptor (Agnello et al., 1999). Analysis of HCV particles with heterogenous densities led 
to  the  identification  of  an  association  between  HCV  and  low  density  β-lipoproteins 
(Thomssen et al., 1992), suggesting β-lipoprotein associated particles may enter host cells 
via the LDL receptor. While anti-LDL receptor antibody could inhibit HCV infection in a 
dose-dependent  manner,  increasing  cell  surface  LDL  receptor  levels  increased  the 
percentage  of  cells  positive  for  HCV  infection  (Agnello  et  al.,  1999).  Biochemical 
inhibitors  of  LDL  endocytosis  (heparin  sulphate  and  EGTA)  inhibited  LDL  receptor 
mediated endocytosis of HCV particles, suggesting LDL receptor mediates endocytosis of 
HCV (Agnello et al., 1999). Further evidence for the requirement of the LDL receptor for 
HCV entry came from the inhibition of particle-binding to human fibroblasts by purified 
LDL and  the  reporting  that HCV  only binds  COS-7 cells when  transfected  with LDL 
receptor cDNA (Monazahian et al., 1999). LDL and HCV particles have been shown to co-
localise on the surface of Molt-4 cells, however, LDL was unable to completely block 
HCV binding (Wunschmann et al., 2000), suggesting other receptors may be involved. 
Recently, Wunschmann et al. reported an increase in E2 binding to Molt-4 and Huh-7 cells 
when LDL was incubated with E2 prior to contact with cells. A dose-dependent reduction 
in binding was also seen when cells were pre-incubated with anti-LDL receptor antibody 
(Wunschmann et al., 2006). Interestingly, binding of E2 to 3T3 cells was only seen when 
cells expressed human CD81, with no increase in binding seen in the presence of LDL 
suggesting  a  requirement  for  human  LDL  receptor  for  this  increase  in  binding 
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A  third  putative  HCV  receptor  is  human  scavenger  receptor  class  B  type  I  (SR-BI) 
(Scarselli et al., 2002). SR-BI, which selectively uptakes cholesterol from the hydrophobic 
cores  of  lipoproteins,  belongs  to  the  CD36  superfamily  that  includes  cell-surface 
membrane proteins that bind chemically modified lipoproteins (Acton et al., 1996). SR-BI 
is a high-density lipoprotein (HDL) receptor which has 2 transmembrane domains with 
short N- and C-termini located in the cytoplasm and a large extracellular loop (Acton et al., 
1994) and is expressed primarily in the liver and steroidogenic tissue (Acton et al., 1994, 
Landschulz et al., 1996). HepG2 cells, which do not express CD81, efficiently recognise 
recombinant  E2,  suggesting  the  presence  of  an  alternative  attachment  molecule.  By 
reversible  cross-linking  with  E2  and  subsequent  cell  lysis,  an  82  kDa,  glycosylated 
molecule was isolated and identified as SR-BI (Scarselli et al., 2002). HVR1 of E2 is 
required for recognition of SR-BI as mutant E2 lacking HVR1 is unable to bind SR-BI 
(although still able to recognise CD81) (Scarselli et al., 2002). Using HCVpp, Bartosch et 
al. confirmed the requirement of SR-BI for HCV infection, however both CD81 and LDLr 
were also required (Bartosch et al., 2003b). Alternative HCV models have also confirmed 
a role for SR-BI in HCV infection. The tree shrew, Tupaia belangeri, is closely related to 
primates and can be infected with HCV (Xie et al., 1998). Anti-tupaia SR-BI antibodies 
inhibited the binding of HCV VLPs and soluble E2 to primary tupaia hepatocytes in a 
concentration dependent manner, providing more evidence for an involvement of SR-BI in 
HCV binding (Barth et al., 2005). However, inhibition of E2/SR-BI interaction during 
infection studies using HCV RNA positive serum did not prevent infection, suggesting 
other  receptors  may  also  play  a  role  in  HCV  entry  (Barth  et  al.,  2005).  High-density 
lipoproteins (HDLs) have been suggested to enhance SR-BI mediated HCV cell entry. 
Increased entry of HCVpp in the presence of HDLs has been reported (Voisset et al., 2005, 
Bartosch et al., 2005) and this enhancement shown, by RNAi knockdown of SR-BI, to be 
dependent on SR-BI, while drugs inhibiting the transfer of HDL cholesteryl ester have also 
been  shown  to  reduce  HCVpp  entry  (Voisset  et  al.,  2005).  SR-BI  binds  HDLs  and 
lipopolysacharrides (LPS), allowing entry to the cell via intracellular compartments such as 
the  golgi  complex  or  endocytotic  compartment  (Vishnyakova  et  al.,  2003).  HCV  may 
therefore utilise this entry pathway in order to avoid the classical degradation pathway. 
Also, fusion-activation of HCV glycoproteins is pH-dependent, suggesting HCV may use 
SR-BI to traffic itself to endosomal compartments in which low pH could activate the 
fusion properties of the glycoproteins (Bartosch et al., 2003b). 
Other molecules thought to bind HCV particles include the asialoglycoprotein receptor 
(ASGP-R)  (Saunier  et  al.,  2003)  and  the  liver  (L)-  and  dendritic  cell  (DC)-specific 
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SIGN) (Gardner et al., 2003, Pohlmann et al., 2003, Lozach et al., 2003). Anti-ASGP-R 
antibody was shown to inhibit binding of virus-like particles to Molt-4 and HepG2 cells, 
while  binding  to  3T3  cells  was  only  possible  in  the  presence  of  transfected  ASGP-R 
(Saunier et al., 2003). L-SIGN and DC-SIGN are type II integral membrane proteins with 
short N-terminal cytoplasmic domains and a C-terminal calcium dependent lectin domain 
(Gardner et al., 2003). L-SIGN is expressed in the liver (although not on hepatocytes) 
(Pohlmann et al., 2003) while DC-SIGN is found on dendritic cells. L-SIGN and DC-
SIGN  are  known  to bind HIV  gp120  with high affinity  and transfer virus particles to 
adjoining CD4-positive cells (Geijtenbeek et al., 2000). These molecules have also been 
shown to bind E2, VLPs and infectious HCV from human serum (Gardner et al., 2003, 
Lozach  et  al.,  2003,  Pohlmann  et  al.,  2003),  while  co-culture  of  DC-SIGN/L-SIGN 
expressing cells (pre-incubated with HCVpp) with Huh-7 cells permits transmission of 
infectious HCVpp to Huh-7 cells (Cormier et al., 2004a, Lozach et al., 2004). L-SIGN is 
expressed on liver sinusoidal endothelial cells which form vessels that separate hepatic 
blood from hepatocytes, leading to the suggestion that these cells could be involved in 
trans-infection, transferring virus from the blood to hepatocytes in the liver (Lozach et al., 
2004, Lozach et al., 2003).   
Several  putative  receptors  have  now  been  suggested for  HCV  binding and  entry.  It  is 
possible  that  the  virus  requires  more  than  one  receptor,  possibly  using  one  for  initial 
binding followed by binding to a second co-receptor with or without some conformational 
change (Cormier et al., 2004b, Bartosch et al., 2003b). However, until the recent discovery 
of the infectious cell culture system, the exact function, if any, of these receptors in the 
HCV life cycle has been difficult to confirm. Initial analysis of potential HCV receptors 
relied  on  soluble,  truncated  E2,  however  it  is  not  certain  whether  this  model  fully 
represents the corresponding E2 structures on the HCV virion. Owsianka et al. showed 
ligand-dependent  differences  in  monoclonal  antibody  inhibition  of  E2-CD81  when 
comparing soluble, truncated E2, full-length E1E2 and virus-like particles (Owsianka et 
al., 2001), indicating care is required when interpreting results from these experimental 
systems.   
Upon initial binding to the cell surface, enveloped viruses enter the host either by fusion at 
the  plasma  membrane  or  by  receptor-mediated  endocytosis.  Receptor-mediated 
endocytosis results in fusion of the viral envelope with the endosomal membrane, triggered 
by low pH within the endosome. Flaviviruses, such as West Nile virus and tick-borne 
encephalitis virus, undergo pH-dependent fusion with membranes, indicating they enter 
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1986). Hsu et al. has shown that HCVpp infectivity is reduced by >90% in the presence of 
inhibitors of vacuolar acidification (ammonium chloride or concanamycin A) (Hsu et al., 
2003), while Blanchard et al. showed similar results using the inhibitors bafilomycin and 
chloroquine  in  the  HCVcc  system  (Blanchard  et  al.,  2006),  thus  indicating  that  HCV 
requires a pH-sensitive route of entry. A dose-dependent inhibition of infectivity using the 
HCVcc system was seen even if the inhibitor concanamycin was added up to 3 hrs post-
binding (Koutsoudakis et al., 2006). HCV pH-dependent entry is thought to be clathrin-
mediated, a theory that was confirmed by siRNA knockdown of clathrin as well as by 
chlorpromazine inhibition of clathrin-coated pit assembly, both of which reduced HCVcc 
entry (Blanchard et al., 2006). Fusion has also been shown to be dependent on E1 and E2, 
occurs optimally at pH 5.5 and is enhanced by cholesterol (Lavillette et al., 2006). pH-
dependent viruses usually synthesise their glycoproteins in an inactive form, preventing 
premature fusion with internal cellular membranes (Hsu et al., 2003). Interestingly, Op de 
Beek et al. reported conformational changes in E1E2 of HCVpp at low pH (Op De Beeck 
et al., 2004) and pre-exposure to low pH decreased fusion ability (Lavillette et al., 2006), 
indicating that some conformational change takes place within E1E2 which is required at 
the point of fusion. Some viruses encode an ion channel (viroporin) thought to facilitate a 
pH change within the virion to allow uncoating (Fischer and Sansom, 2002). Recently, 
HCV p7 was identified as a putative member of the viroporin family (Pavlovic et al., 2003, 
Griffin et al., 2003), suggesting that this may be a mechanism for pH-induced fusion and 
uncoating of the HCV virion. 
 
1.3.2 Viral RNA Transcription, Replication and Translation 
In  common  with  all  other  positive-sense,  single  stranded  RNA  viruses,  HCV  RNA 
translation and replication is thought to take place in the cytoplasm of infected cells. Being 
a  positive  sense  RNA  virus,  the  viral  RNA  acts  as  mRNA  and  is  therefore  directly 
translated. Unlike cellular mRNAs which are capped, allowing translation by the scanning 
ribosome mechanism, HCV RNA translation is cap-independent and instead requires an 
IRES located in the 5’UTR for translation initiation (Tsukiyama-Kohara et al., 1992), (See 
section 1.2.2.10). Translation by the scanning ribosome mechanism involves binding of the 
ribosomes to the 5’ end of the mRNA and scanning until the authentic AUG codon is 
found. However, the HCV IRES directs the ribosome to a site in close proximity to the 
initiator AUG. No cellular factors are required for HCV RNA translation (Pestova et al., 
1998), although cellular factors such as PTB and La have been shown to bind to the IRES David A Dalrymple    Chapter 1: Introduction 
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and influence translation (Ali and Siddiqui, 1995, Ali and Siddiqui, 1997). Translation of 
HCV RNA occurs at the rough ER and produces a single polyprotein which is cleaved co- 
and post-translationally by both viral and cellular proteases, to produce the structural and 
non-structural proteins (Grakoui et al., 1993d, Hijikata et al., 1993), (See section 1.2). 
Many positive-sense, single stranded RNA viruses induce distinct membrane alterations 
within their host and the same has been shown for HCV. Changes in membrane structure, 
termed the membraneous web, have been seen in HCV infected cells and is thought to be 
induced by NS4B (Gosert et al., 2003, Shi et al., 2003, Egger et al., 2002, El-Hage and 
Luo, 2003). All HCV proteins interact with cellular membranes directly or indirectly and 
all have been shown to associate with the membraneous web, as has replicating HCV 
RNA, indicating the membraneous web may harbour the HCV replication complex (Egger 
et al., 2002, El-Hage and Luo, 2003, Gosert et al., 2003, Shi et al., 2003). These membrane 
structures are resistant to detergent treatment and can be co-fractionated with the lipid-raft 
associated caveolin-2, suggesting that the replication complexes are situated within lipid-
raft type membrane structures (Shi et al., 2003). 
HCV replicates via negative strand replication intermediates as shown by the presence of 
negative strand HCV RNA in serum and the liver of infected patients (Fong et al., 1991). 
As  with  all  positive-sense  RNA  viruses,  once  sufficient  translation  of  HCV  RNA  has 
occurred, the virus must switch the template role of genomic RNA from translation to 
replication  (Ahlquist  et  al.,  2003).  A  “copy-back”  replication  mechanism  has  been 
suggested  for  HCV  (Behrens  et  al.,  1996,  Lohmann  et  al.,  2000),  in  which  the  high 
complimentarity  of  the  3’UTR  sequence  allows  the  3’-terminal  nucleotides  to 
intramolecularly base-pair, thus generating a primer/template molecule which can then be 
used by the NS5B RNA-dependent RNA polymerase. NS5B is able to copy long templates 
without additional viral or cellular factors and has no apparent template specificity, being 
capable  of  copying  homologous  and  heterologous  templates  (Lohmann  et  al.,  1997, 
Lohmann et al., 2000), thus confirming its capability to replicate molecules such as the 
HCV genome. 
 
1.3.3 Assembly, Maturation and Release 
Nucleocapsid  formation  of  virus  particles  probably  involves  multimerisation  of  core 
protein  and  an  interaction  with  viral  RNA.  With  this  in  mind,  several  studies  have 
indicated  an  interaction  between  core  and  the  HCV  5’UTR.  Residues  1-75  of  core, David A Dalrymple    Chapter 1: Introduction 
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containing 4 clusters of basic amino acids, have been shown to have RNA binding capacity 
(Santolini et al., 1994), while a number of groups have identified HCV RNA sequences 
capable of binding core. HCV RNA from nucleotide 1-2327 was detected by northern blot 
after  immunoprecipitation  by  anti-core  antibody  (Shimoike  et  al.,  1999),  with  further 
delineation of this region mapping specific sequences within the 5’UTR (Tanaka et al., 
2000). Surface plasmon resonance (SPR) was used to confirm a stable interaction between 
core and the HCV 5’UTR. Core was found to preferentially bind sequences with high G 
content. Loop IIId domain of the 5’UTR (Fig. 1.4), having a high G content, was identified 
as the main core-binding region. Interestingly, loops IIIe and IIIf also have high G content 
yet do not bind core, suggesting that the hairpin loop and internal bulge loop of domain 
IIId are essential secondary structures required for core interaction (Tanaka et al., 2000). 
The secondary structure of loop IIId is highly conserved across all genotypes and also in 
the  related  pestiviruses,  suggesting  this  may  be  an  essential  structure  in  nucleocapsid 
formation  (Brown  et  al.,  1992).  Residues  1-20  of  core  have  been  shown  to  inhibit 
translation  from  the  HCV  IRES  with  this  inhibition  depending  on  both  a  minimum 
concentration of core and a high core:RNA ratio (Li et al., 2003). This suggests that core 
may  be  involved  in  the  switch  from  translation  of  RNA  to  replication  and  resultant 
packaging of viral RNA.  
Multimerisation  of  core,  requiring  homotypic  interaction,  would  be  expected  if  core 
protein is to form capsid structures. Yeast-2-hybrid studies have led to various regions of 
core  being  suggested  as  homotypic  interaction  sites,  with  the  hydrophilic  region 
encompassing amino acids 1-115 of core shown to be sufficient for core-core interaction, 
although no interaction was detected using full-length core protein, possibily due to the 
hydrophobic domain of core affecting the nuclear transport of the fusion proteins in yeast 
(Matsumoto et al., 1996). Residues 1-115 of core are rich in basic residues and are highly 
conserved, indicating essential properties (Bukh et al., 1994). The binding domain was 
tentatively mapped to residues 36-91 by yeast-2-hybrid analysis, overlapping the predicted 
ribosome and RNA binding domains (Santolini et al., 1994). However, residues 36-91 
were  insufficient  for  efficient  core-core  binding  suggesting  surrounding  areas  may  be 
required (Matsumoto et al., 1996). In agreement, the interaction domain was reported to be 
within residues 82-102 of core (Nolandt et al., 1997). Again, this was only seen using C-
terminal truncated core protein and no interaction was seen using full-length core protein. 
These results also bring up the possibility that the homotypic interacting domain may be 
masked in full-length core and some conformational change is required to allow core-core 
interaction.  Interestingly,  a  conformational  change  in  core  has  been  identified  upon 
interaction  with  tRNA  (Kunkel  and  Watowich,  2002).  The  N-terminus  of  core  is David A Dalrymple    Chapter 1: Introduction 
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proteinase-sensitive  and  the  C-terminal  end  is  required  to  stabilise  free  core  protein. 
However,  core  complexed  with  RNA  or  assembled  into  nucleocapsid  particles  was 
proteinase-resistant, suggesting conformational changes in core occur upon binding RNA 
and  assembling  into  nucleocapsids,  possibly  in  order  to  protect  core  from  cellular 
degradation  (Kunkel  and  Watowich,  2002).  Other  domains  of  core  have  also  been 
suggested to be involved in homotypic interaction including residues 122-172 (Nolandt et 
al., 1997) and both the N- and C-termini (Yan et al., 1998). In agreement with the N- and 
C-termini being involved in multimerisation, truncated core protein (residues 1-124) was 
shown  to  assemble  into  virus-like  particles  only  in  the  presence  of  highly  structured 
positive-strand 5’UTR RNA while full-length core underwent de novo assembly in the 
absence of RNA (Kim et al., 2006), thus suggesting the N-terminus may be involved in 
multimerisation upon interaction with RNA while the C-terminus may initiate spontaneous 
multimerisation early in capsid formation. Other studies on HCV assembly have shown 
that  the  HCV structural proteins core, E1 and E2, encoded in baculovirus vectors and 
expressed in insect cells, assemble into VLPs with a lipid bilayer (Baumert et al., 1998). 
These virus-like particles were shown to have E1 and E2 on their lipid bilayer surface and 
could be specifically labelled with anti-E1 and anti-E2 antibodies, as well as with anti-
HCV human serum (Clayton et al., 2002, Baumert et al., 1998), while also preferentially 
encapsidating HCV RNA (Baumert et al., 1998). Cell-free systems have also been used to 
show  that  core  can  multimerise  into  capsid  structures.  Capsid  assembly  in  a  cell-free 
system  is  independent  of  E1  and  E2  (Klein  et  al.,  2004)  and,  similar  to  the  results 
generated by yeast-2-hybrid studies (Matsumoto et al., 1996), clusters of basic residues at 
the N-terminus are critical for assembly (Klein et al., 2005).   
Upon formation of the nucleocapsid, envelopment by cellular membranes containing viral 
glycoproteins is likely. Although the mechanism of budding for HCV is not understood, by 
comparison with the related flaviviruses, HCV is thought to acquire its envelope at the ER 
as the HCV glycoproteins localise predominantly to the ER (Deleersnyder et al., 1997, 
Dubuisson et al., 1994). HCV glycoproteins do not migrate further than the cis Golgi, 
suggesting that HCV budding may indeed occur in the ER (Dubuisson et al., 1994). As 
flaviviruses and alphaviruses share similar structural features (Helenius, 1995), expression 
of HCV structural proteins within a semliki forest virus vector has been studied (Blanchard 
et al., 2002). Major differences in ER structure were observed, with areas of convoluted 
membranes  present  in  transfected  cells.  Self-assembly  of  HCV  structural  proteins  was 
observed at these convoluted  membranes by  EM. At  higher  magnification, budding  of 
virus-like particles of approximately 50 nm towards the dilated ER lumen was observed 
and  these  particles  could  be  strongly  labelled  with  anti-core  and  anti-E1  antibodies, David A Dalrymple    Chapter 1: Introduction 
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suggesting the HCV capsid acquires its envelope by budding through the ER membrane. 
Enforced expression of E1 and E2 (in trans) in replicon harbouring cells increases the 
formation frequency of replication complexes (Brazzoli et al., 2006). In these cells, co-
localisation of HCV structural proteins with all non-structural proteins and HCV RNA was 
observed,  indicating  this  may  be  a  hypothetical  site  for  virus  budding.  No  infectious 
particles were found in the supernatant however, and no data on structured particles within 
the  cell  has  been  reported  (Brazzoli  et  al.,  2006).  Envelopment  and  budding  of  the 
nucleocapsid is likely to require an interaction between core and the HCV glycoproteins. 
Indeed, an interaction between core and E1 has been reported (Ma et al., 2002, Lo et al., 
1996). Since little, if any, of E1 is situated on the cytosolic side of the ER, the interaction is 
likely to occur within the ER (Ma et al., 2002, Lo et al., 1996).    
Following particle formation at intracellular membranes as seems most likely with HCV, 
viral  egress  to  the  cell  surface  is  expected.  Flaviviruses  commonly  egress  through 
utilisation  of the host cell constitutive secretory  pathway  (Fields,  2001).  The  secretory 
pathway is a highly conserved route for proteins destined for the outer membrane of the 
cell.  The  pathway  involves  a  complex  series  of  membrane-bound  subcellular 
compartments  including  the  ER,  intermediate  compartment  and  Golgi.  Most  proteins 
traversing the secretory pathway are modified by addition of oligosaccharide side-chains. 
Interestingly,  HCV  glycoproteins  are  modified  by  N-linked  glycosylation,  with  E1 
containing up to 6 and E2 potentially 11 glycosylation sites (Op De Beeck et al., 2001). 
Addition of these side-chains takes place in the lumen of the ER, which is also where the 
HCV  glycoproteins  are  located.  During  transport  through  the  secretory  pathway,  it  is 
essential that the integrity and fusogenic form of the glycoproteins are maintained, so as to 
allow  future  host-cell  attachment  and  entry.  To  prevent  premature  acid-induced 
inactivation  of  the  glycoproteins,  several  viruses  employ  a  viroporin  to  prevent 
acidification of vesicles. Influenza M2 protein is a viroporin which is suggested to play a 
role in regulating the pH of vesicles in the trans-golgi network, thus ensuring the correct 
maturation of the hemagglutinin glycoprotein during egress (Sugrue and Hay, 1991). HCV 
also encodes a viroporin in its p7 gene (Griffin et al., 2003) and therefore may have a 
similar role to the M2 viroporin of influenza, ensuring premature acid-induced activation 
of the HCV glycoproteins is avoided. Members of the flavivirus genus adopt a mechanism 
of  delayed  cleavage,  preventing  irreversible  conformational  changes  in  the  acidic 
compartment of the secretory pathway. Tick-borne encephalitis (TBE) virus employs its 
prM protein to form a stable heterodimeric complex with the envelope protein (E). Low pH 
in the acidic compartment of the secretory pathway induces a conformational change in 
prM,  providing  access  to  a  furin-specific  cleavage  site.  Furin  is  a  membrane-bound, David A Dalrymple    Chapter 1: Introduction 
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calcium-dependent protease of the trans-golgi network (Bosshart et al., 1994). Cleavage of 
prM by furin shortly before release from the cell results in formation of the mature virion 
(Stadler et al., 1997), thus preventing premature exposure of the mature virion to low pH. 
It is possible that HCV employs a similar mechanism in order to retain the fusogenic 
properties of its glycoproteins. Interestingly, a recent report has described differences in 
buoyant  densities  between  infectious  intracellular  virus  particles  and  infectious 
extracellular  particles,  suggesting  the  biological  composition  of  these  two  forms  of 
infectious particles may differ (Gastaminza et al., 2006). It is possible that this difference 
in buoyant density may be due to factors involved in avoiding premature fusion during 
viral egress. 
 
1.4 Model Systems to Study HCV 
Before  the  discovery  of  a  fully  infectious  HCV  clone  capable  of  producing  infectious 
particles in cell culture (Wakita et al., 2005), it was difficult to study the virus’s structure 
and assembly process. The following paragraphs describe the various model systems used 
to study HCV in the absence of a robust cell culture model, culminating in the description 
of the infectious JFH-1 cell culture system which has opened up new avenues in HCV 
research. 
 
1.4.1 Comparative Studies with HCV-related Viruses 
Much of the current knowledge of HCV has been derived from comparative studies. HCV 
has been shown to share similarity at the level of genomic organisation and amino acid 
sequence  with  the  flaviviruses  and,  in  particular,  the  pestiviruses  (Miller  and  Purcell, 
1990).  The  pestivirus  BVDV  generally  provides  the  best  model  for  HCV  comparative 
studies  due  to  the  availability  of  infectious  clones  and  efficient  cell  culture  systems 
(Moormann et al., 1996, Meyers et al., 1996) and is also used as a surrogate model of HCV 
for the evaluation of antiviral agents (Buckwold et al., 2003). GB virus-B, a hepatotropic 
virus  of  unknown  natural  host  that  causes  acute  and  sometimes  chronic  hepatitis  in 
tamarins and marmosets, has also been used as a surrogate model for HCV as it is the virus 
most closely related to HCV, with infection resulting in similar pathological features to 
those of HCV infection (Beames et al., 2001, Muerhoff et al., 1995). Domain 2 of GB David A Dalrymple    Chapter 1: Introduction 
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virus-B core protein shows ~41% sequence identity with that of domain 2 of HCV core 
protein (Hope et al., 2002), suggesting these two domains may perform similar functions. 
Also, the putative envelope proteins of GB virus-B and HCV share common structural 
features while significant homology was observed among the NS3 serine protease, the NS3 
RNA  helicase  and  the  NS5B  RNA-dependent  RNA  polymerase  regions  as  well  as  at 
predicted cleavage sites in the non-structural regions (Muerhoff et al., 1995). The function 
and  substrate  specificities  of  the  GB  virus-B  and  HCV  NS3  serine  proteases  are  also 
similar (Scarselli et al., 1997).   
 
1.4.2 Animal Models 
The only animal capable of being infected with HCV is the chimpanzee. HCV was shown 
to be transmissible to chimpanzees many years before the discovery of the virus in 1989. 
The chimpanzee model was used to characterise the physicochemical properties of the then 
unknown agent (Farci and Purcell, 1998) and later, HCV was cloned from plasma collected 
from a persistently infected chimpanzee (Choo et al., 1989). RNA transcripts produced 
from full-length cDNA clones have been shown to be infectious upon injection into the 
liver of chimpanzees (Yanagi et al., 1997). The chimpanzee is an ideal model for HCV 
infection, being more than 98.5% genetically identical to humans (Grakoui et al., 2001). 
However,  chimpanzees  are  limited  in  availability  and  are  expensive  to  acquire  and 
maintain, not to mention the ethical issues which arise from their use. To overcome the 
lack of suitable animal model, transgenic mice with humanised livers have been produced 
(Turrini et al., 2006, Mercer et al., 2001). These mice can be infected with HCV-positive 
human serum and support HCV replication within the human portion of their livers at 
clinically  relevant  titres.  HCV  is  capable  of  long-term  persistence  and  can  be  serially 
passaged from infected mouse to naïve transgenic mouse (Mercer et al., 2001). Transgenic 
mice carrying HCV proteins have been used in many studies to investigate the pathogenic 
properties of these proteins (Honda et al., 1999a, Moriya et al., 1998, Moriya et al., 1997). 
Tree shrews (Tupaia) have been shown to be capable of infection with HCV and produce 
anti-HCV  antibodies.  Efficiency  of  infection  was  increased  by  whole-body  irradiation, 
suggesting immunosuppression may facilitate infection (Xie et al., 1998). The feasibility of 
using this model to study HCV has yet to be investigated however.     
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1.4.3 Infection of cultured cells 
HCV-positive patient sera has been used to infect certain monolayer cell lines and primary 
cell cultures of liver origin (Ito et al., 1996), as well as blood mononuclear cells (although 
replication in vitro was at low levels) (Cribier et al., 1995). A human T-lymphotropic virus 
(HTLV) type I infected cell line (MT-2) was reasonably sensitive to HCV infection and 
HCV replication was detected 10 days post-infection, however no infectious particles were 
produced (Kato et al., 1995). As HCV can infect Tupaia (Xie et al., 1998), Zhao et al. 
(2002)  investigated the possibility of infecting  primary Tupaia hepatocytes with HCV. 
Negative strand HCV RNA was detected in these cells and nuclease resistant RNA found 
in  the  culture  medium.  This  culture  medium  was  infectious  for  naïve  primary  Tupaia 
hepatocytes,  indicating these cells were capable of HCV replication  and production  of 
progeny particles (Zhao et al., 2002). More recently, a 3-D radial flow bioreactor (RFB) 
has been used to study HCV infection in vitro. This system allowed human liver cells to 
retain their differentiated hepatocyte functions and morphological appearance for longer 
periods of time (Matsuura et al., 1998). FLC4 cells, grown in a 3-D RFB were susceptible 
to  propagation  of  HCV  RNA  or  infected  serum  and  allowed  production  of  infectious 
particles that could be immunogold labelled with anti-E1 antibody (Aizaki et al., 2003). At 
present this system is relatively complex and expensive, providing an obstacle to its use as 
a research tool for HCV particle production. 
 
1.4.4 HCV Pseudo-particles 
In an attempt to study the process of HCV cell entry, infectious, genetically tagged HCV 
pseudo-particles  harbouring  unmodified  E1  and  E2  glycoproteins  were  developed 
(Bartosch et al., 2003a). HCV glycoproteins E1 and E2 were assembled onto retroviral 
core proteins derived from murine leukaemia virus (MLV) by transfection of human 293T 
cells with expression vectors encoding E1E2 polyprotein (including the carboxyl terminus 
of core), MLV Gag-Pol core proteins and a packaging-competent MLV-derived genome 
encoding GFP as a marker. Expression in human 293T cells results in the packaging of the 
GFP marker-gene into MLV-core pseudo-particles, displaying unmodified E1 and E2 HCV 
glycoproteins. These pseudo-particles were released into the culture medium and shown to 
infect naïve hepatocytes, thus confirming that HCV pseudo-particles show a preferential 
tropism  for  hepatic  cells  while  also leading  to the  discovery  that  they are  specifically 
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pseudo-particle  system  allows  detailed  study  of  the  interactions  between  HCV 
glycoproteins and cell surface receptors. A similar system using lentivirus transfer and 
packaging constructs has also been described (Hsu et al., 2003). 
   
1.4.5 HCV Replicon System 
A major breakthrough in HCV research came with the development of the HCV replicon 
system.  The  replicon  system  was  based  on  the  stable  autonomous  replication  of 
subgenomic, selectable, HCV RNAs (Lohmann et al., 1999). Deletion of the core-NS2 
region,  and  insertion  of  a  gene  encoding  the  selectable  marker  neomycin 
phosphotransferase  (neo)  and  the  EMCV  IRES,  resulted  in  a  bicistronic  replicon  with 
translation of neo driven by the HCV IRES and translation of the second cistron (NS3-5B) 
driven  by  the  EMCV  IRES.  Upon  transfection  into  Huh-7  cells  and  selection  with 
neomycin  sulphate  (G418),  colonies  grew  containing  autonomously  replicating  HCV 
RNAs. HCV RNA replication levels in these cells were ~100,000 fold higher than in other 
in vitro systems (Bartenschlager and Lohmann, 2001), however limited numbers of G418-
resistant colonies grew and cell culture adaptive mutations were required for enhancement 
(Blight  et  al.,  2000,  Lohmann  et  al.,  2001,  Krieger,  2001).  Several  mutations  were 
identified and, in particular, mutation of aa 2884 in NS5B led to ~500 fold increase in 
replication (Lohmann et al., 2001), while a cluster of mutations were found in the central 
region of NS5A (Blight et al., 2000) and two others identified in NS3 (Krieger, 2001). The 
replicon system was further modified in 2002 when Pietschmann et al. generated selectable 
full-length HCV genomes in which the HCV structural proteins were efficiently expressed. 
Intruigingly however, no viral particles were produced from this system, suggesting that 
Huh-7 cells  may  lack some essential factors required for  production of HCV particles 
(Pietschmann et al., 2002) (a theory which has now been dispelled due to the production of 
JFH-1 infectious particles from these cells (Wakita et al., 2005)). The replicon system has 
been an invaluable discovery in studying HCV replication and also in antiviral drug design 
given that all viral enzymes are present and replicating RNA can be propagated for years.   
1.4.6 JFH-1 Infectious Clone 
Recently, a major breakthrough occurred when an HCV genotype 2a clone (isolated from a 
Japanese  patient  suffering  from  fulminant  hepatitis  (Kato  et  al.,  2001))  that  was  fully 
infectious in cell culture was discovered (Wakita et al., 2005). Since then, a number of David A Dalrymple    Chapter 1: Introduction 
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reports have confirmed these results (Lindenbach et al., 2005, Zhong et al., 2005). Initially, 
the aim was to construct a genotype 2a replicon construct as no 2a replicon had previously 
been made. Upon analysis of this replicon it was noted that efficient replication occurred 
without the need for cell culture-adaptive mutations (Kato et al., 2003). In vitro-transcribed 
full-length JFH-1 RNA was transfected into Huh-7 cells and resulted in HCV replication 
and  secretion  of  infectious  particles  (Wakita  et  al.,  2005).  HCV  RNA  was  shown  to 
replicate to high levels by Northern hybridisation and virus could be serially passaged. 
Sucrose-density  gradients  showed  that  core  protein  and  nuclease-resistant  HCV  RNA 
sedimented to the same density of 1.17 g/ml indicating the presence of cell culture-derived 
virus particles, while particles were also visualised by immuno-electron microscopy, being 
labelled  with  an  anti-E2  antibody.  Most  importantly,  the  particles  visualised  were 
infectious for naïve Huh-7 cells. CD81-specific antibodies and HCV positive human sera 
were  both  capable  of  neutralising  infectivity  in  a  dose-dependent  manner  and  culture 
medium was infectious for chimpanzees when injected intravenously (Wakita et al., 2005). 
Shortly after this discovery, these results were confirmed and it was shown that virus titres 
could consistently reach 10
4-10
5 infectious units/ml (Zhong et al., 2005). Using the non-
structural  genes  of  JFH-1,  infectious  particles  were  produced  by  a  chimeric  construct 
containing the structural proteins of genotype 2a J6 isolate, but not by a similar construct 
using genotype 1a H77 structural proteins, while both chimeras were replication competent 
(Lindenbach et al., 2005). This suggests that interactions between the structural and non-
structural proteins may be essential for production of infectious particles. Interestingly, 
although by equilibrium centrifugation in 10-40 % iodixanol, the peak fraction of HCV 
RNA  was  found  to  correspond  to  a  density  of  1.13-1.14  g/ml,  this  fraction  had  little 
infectivity. Instead the most infectious fraction was found to correspond to a density of 
1.09-1.11  g/ml, suggesting most  of the particles are  non-infectious (Lindenbach et al., 
2005). The discovery of this new system should enable the study of previously inaccessible 
stages of the HCV life cycle.  
 
1.5 HCV Core Protein 
1.5.1 Maturation 
Core is the N-terminal most product of the HCV polyprotein and is cleaved by host cell 
proteases  (Grakoui  et  al.,  1993d,  Hijikata  et  al.,  1991b),  with  three  products  being David A Dalrymple    Chapter 1: Introduction 
57 
described as a result of this processing. As the amino terminus of E1 has been mapped to 
residue 192 (Hijikata et al., 1991b), it is believed that core is cleaved from the polyprotein 
at  residue  191.  A  second  cleavage  event  around  residue  173  produces  a  smaller  core 
protein, thought to be the mature form (Santolini et al., 1994), however, other reports 
suggest this cleavage event occurs between residues 179 and 181 (Hussy et al., 1996). 
There has been some confusion over the names of these two core molecules with some 
groups naming them P21 and P19 (Hussy et al., 1996, Lo et al., 1994, Lo et al., 1995), 
however, in the remaining sections they will be termed P23 and P21 in accordance with 
more recent publications (McLauchlan, 2000). Isolate HCV-1 has a third cleavage site, 
producing a P16 form of core which is only found in genotype 1a isolates, resulting from a 
lysine residue at amino acid 9 of core. Mutation of this residue to arginine abolishes the 
P16 form (Lo et al., 1994, Lo et al., 1995). Generation of both P23 and P21 requires 
microsomal  membranes,  suggesting  membrane  associated  proteases  are  responsible  for 
cleavage of core (Santolini et al., 1994, Hussy et al., 1996). Cleavage at residue 191 is 
predicted to occur on the luminal side of the ER by the cellular signal peptidase complex 
(Santolini  et  al.,  1994,  McLauchlan,  2000),  while  a  membrane-bound  signal  peptide 
peptidase is responsible for the second cleavage event resulting in the mature P21 form of 
core,  with  residues  180,  183  and  184  of core being  necessary  for  efficient  processing 
(McLauchlan et al., 2002, Hussy et al., 1996). Amino acid sequence analysis shows that 
core is highly conserved among all genotypes (Bukh et al., 1994), with 3 domains being 
identified from its hydropathicity pattern (Fig. 1.8). Residues 1- ~122 (domain 1) contain a 
high proportion of basic residues (23.4%) as well as 2 short hydrophobic domains. Domain 
2 (amino acids 123-174) has a lower proportion of basic residues and is more hydrophobic 
than domain 1 while domain 3 (residues 175-191) is highly hydrophobic. Domain 3, acting 
as a signal sequence, is required to direct E1 to the ER (Santolini et al., 1994), while 
removal of the C-terminus results in translocation of core to the nucleus (Suzuki et al., 
1995, Moradpour et al., 1996).  
 
1.5.2 Intracellular Distribution 
Difficulty in detecting core in biopsy samples of HCV-infected patients has hampered the 
study of the subcellular localisation of core. However, core has been shown to have a 
cytoplasmic, granular localisation in some liver biopsies (Gonzalez-Peralta et al., 1994, 
Yap  et  al.,  1994).  Subcellular  fractionations  indicate  that  core  is  associated  with 
membranes while immunofluorescence data from tissue culture systems has also shown David A Dalrymple    Chapter 1: Introduction 
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Figure  1.8:  Hydropathicity  pattern  of  HCV  core  protein.  Domain  1  (residues  1-~122) 
contains  a  high  proportion  of  basic  residues  (23.4%)  as  well  as  2  short  hydrophobic 
regions. Domain 2 (residues 123-174) has a lower proportion of basic residues and is more 
hydrophobic  than  domain  1,  while  domain  3  is  highly  hydrophobic  (taken  from 
McLauchlan 2000). 
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core to be cytoplasmic, and to  associate with granular structures or reticular  networks 
(Selby et al., 1993, Santolini et al., 1994, Barba et al., 1997). These granular structures 
have been shown to be lipid droplets by EM and an accumulation of gold particles has 
been seen around lipid droplets and ER in liver biopsies of HCV-infected chimpanzees 
(Barba et al.,  1997).  Domain  D2 of  core, consisting of two  amphipathic alpha-helices 
separated by a hydrophobic loop, is responsible for targeting core to lipid droplets (Hope 
and McLauchlan, 2000a, Boulant et al., 2006). No single structural motif within domain 
D2 is responsible for lipid droplet association. Instead, a combination of both amphipathic 
alpha-helices and the hydrophobic loop are required (Boulant et al., 2006). While core has 
mostly  been  reported  to  be  cytoplasmic,  several  reports  have  also  suggested  that  a 
proportion may localise to the nucleus. C-terminally truncated core protein localised to the 
nucleus (Suzuki et al., 1995), as does HCV-1 P16 core in the absence of E1 sequence (Lo 
et al., 1995). A nuclear species of core was also reported to be conformationally distinct 
from the cytoplasmic species since antibodies could discriminate between core species in 
either  compartment  (Yasui  et  al.,  1998).  However,  the  presence  and  relevance  of  this 
nuclear species of core has yet to be confirmed in vivo. 
  
1.5.3 The Structural Role of Core 
By analogy with other members of the Flaviviridae, core is thought to form the capsid of 
the HCV particle. However, due to the lack of robust cell culture (prior to the report of the 
JFH-1 infectious cell culture system), or small animal model and low detection levels in 
infected human or chimpanzee livers, little is known about core in this regard. Core protein 
has been detected in patient sera by fluorescent enzyme immunoassay (FEIA) (Tanaka et 
al., 1995b, Kashiwakuma et al., 1996), suggesting core is associated with the virus particle, 
while core protein of similar size to that of recombinant core (produced in mammalian 
cells) was found in virus-like particles produced from recombinant baculovirus (Baumert 
et al., 1998). Residues 1-75 of core can bind RNA (Santolini et al., 1994), as would be 
expected of a capsid protein, while the same region has been shown to be involved in core 
multimerisation (Matsumoto et al., 1996) (section 1.3.3). A cell-free system has recently 
been described in which cellular events are reproduced in eukaryotic cell extracts (Klein et 
al., 2004). In this system, the production of either P23 or P21 forms of core results in 
capsid assembly, with velocity sedimentation and buoyant density peaks similar to those of 
de-enveloped particles from patient sera. Transmission electron microscopy showed that 
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and morphological appearance to those from patient sera (Klein et al., 2004). Essential 
residues required for assembly in this system were shown to be within the first 68 residues 
of core (Klein et al., 2004) and were further identified as being basic residues within this 
region (Klein et al., 2005). Decreasing the density of basic residues in this region was 
shown to reduce the ability of core to assemble into capsids, while deletion of a region 
containing no basic residues (amino acids 27-38) has no effect on capsid assembly. By 
yeast-2-hybrid  screen,  residues  82-102  of  core  were  shown  to  be  required  for  core 
multimerisation (Nolandt et al., 1997), while using a Semliki Forest virus replicon system, 
the aspartic acid at residue 111 of core was identified as being important for assembly 
(Blanchard et al., 2003). In the cell-free system however, deletion of residues 82-102 nor 
mutation of residue 111 had any effect on capsid assembly (Klein et al., 2005), suggesting 
that  these  model  systems  may  not  accurately  reproduce  in  vivo  capsid  assembly.  As 
described in section 1.4.6, the discovery of the JFH-1 infectious cell culture system has 
improved the study of infectious HCV particles and should lead to a better understanding 
of core protein and its role as capsid protein for HCV.   
 
1.5.4 Core (+1) ORF/ARF/F Protein 
The HCV genome contains a number of synonymous codons with highly conserved 3
rd 
position nucleotides (Fig. 1.9) (Walewski et al., 2001). In a study of 8 highly divergent 
HCV sequences, residues 33, 39 and 41 of core contained the same glycine codon (GCA). 
The  probability  that  all  8  sequences  contained  the  same  glycine  codon  is  1:16,384, 
indicating that more genetic information may be contained than in a single ORF. A second 
coding region could therefore contribute to the excessive 3
rd position conservation in the 
main HCV ORF (Walewski et al., 2001). The HCV genome has been shown to contain an 
alternative  reading  frame,  overlapping  the  core  protein  gene  and  encoding  a  recently 
described core+1 ORF/alternate reading frame (ARF)/frameshift (F) protein (Varaklioti et 
al., 2002, Walewski et al., 2001, Xu et al., 2001).  Synthesis of this alternative protein is 
thought to be due to ribosomal frameshift around codon 11 of core protein, within a region 
of 10 adenine nucleotides (Xu et al., 2001). A similar overlapping ORF has been identified 
in GBV-B (Bukh et al., 1999), and sera from HCV infected patients reacted with in vitro 
synthesised protein (Xu et al., 2001, Walewski et al., 2001), suggesting that this protein is 
produced during natural HCV infection. No function has yet been assigned to this protein, 
however it is not required for replication of the HCV genome as subgenomic replicons 
(lacking the structural genes) replicate efficiently (Lohmann et al., 1999). Functional David A Dalrymple    Chapter 1: Introduction 
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Figure  1.9:  Clusters  of  synonymous  codons  in  the  main  ORF  of  HCV.  Codons  with 
conserved third position nucleotides conserved in 8 highly divergent HCV sequences show 
a prominent cluster in the core-coding region, providing a rational basis for an alternative 
reading frame in this region (taken from Walewski et al., 2001). 
  
 
 
 
 
 David A Dalrymple    Chapter 1: Introduction 
62 
properties assigned to core protein have also been studied using the F protein including 
modulation of c-myc and p53 promoters, as well as effects on TNF-α-mediated apoptosis, 
however as yet none seem to be conclusively due to this alternative protein (Basu et al., 
2004).    
 
1.5.5 Possible Pathogenic Roles of Core Protein 
1.5.5.1 Effects on Apoptosis 
Expression of HCV core has been shown to affect apoptosis. Apoptosis, or programmed 
cell death, is an orderly cellular process resulting in dell death via several morphological 
phases including cell shrinkage, nuclear condensation, blebbing of the plasma membrane 
and  “laddering”  of  genomic  DNA  by  digestion  (McLauchlan,  2000).  Induction  of 
apoptosis can be caused by a number of stimuli including oxidative stress, heat shock, 
ionizing radiation, cytokines and virus infection. Induction of apoptosis by these stimuli 
normally occurs via cell surface molecules such as Fas or TNF receptors, resulting in a 
cascade  of  intracellular  events  including  death  domain  clustering  and  activation  of 
caspases, which are responsible for many of the morphological changes during apoptosis. 
Apoptosis is modulated by core protein via 3 receptor pathways, Fas receptor-mediated, 
TNFα receptor-mediated and lymphotoxin β receptor-mediated apoptosis.  
Conflicting reports on the effect core protein has on Fas-mediated apoptosis have been 
published. The first report on the effect of core on this apoptotic pathway suggested that 
the interaction between anti-Fas antibody with the Fas receptor induced marked apoptosis 
in the presence of core expressed in HepG2 cells (Ruggieri et al., 1997). In contrast, core 
protein was also shown to protect HepG2 cells from Fas-mediated apoptosis induced by 
the  same  anti-Fas  antibody  (Marusawa  et  al.,  1999).  The  methodologies  used  in  both 
experiments  were  similar,  however  the  use  of  clonal  cell  lines  stably  expressing  core 
(Ruggieri et al., 1997) as opposed to transient transfection of the full HCV open reading 
frame (Marusawa et al., 1999), may explain the contradictory results.  
As with the effect of core protein on Fas-mediated apoptosis, contradictory results have 
been reported on the effect core has on TNFα-mediated apoptosis. Transiently transfected 
core protein was initially shown to inhibit TNFα-induced apoptosis in MCF7 cells (Ray et 
al.,  1998a).  In  agreement  with  this,  core  protected  HepG2  cells  from  TNFα-mediated David A Dalrymple    Chapter 1: Introduction 
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apoptosis, with suppression of apoptosis thought to be upstream of caspase-8 (Marusawa et 
al., 1999). Core was also shown to activate NF-κB and activation was enhanced upon 
stimulation  by  either  anti-Fas  or  anti-TNFα  antibody,  thus  preventing  apoptosis 
(Marusawa et al., 1999). However, core protein was also shown to sensitise HepG2 and 
HeLa cells to TNFα-induced apoptosis (Zhu et al., 1998). Residues 1-115 of core were 
identified as the binding region for TNFR1, while the death domain within the cytoplasmic 
tail of TNFR1 was shown to be required for interaction with core. TNFR1 has no catalytic 
activity therefore the death domain is thought to act as a signal transducer in the apoptopic 
pathway. Further to this, the effects core had on downstream protein interactions were 
analysed.  Upon  oligomerisation  of  TNFR1,  TRADD  is  recruited  which  subsequently 
recruits FADD. In turn, FADD then interacts directly with downstream apoptotic proteases 
leading to apoptosis. Core was shown to bind FADD but not TRADD in core expressing 
293 cells, while a dominant negative form of FADD blocked the core-induced sensitisation 
to TNFR1-mediated apoptosis. It is therefore suggested that core enhances TNFα-mediated 
apoptosis by recruiting FADD to TNFR1. Core, binding  the death domain of TNFR1, 
blocks TRADD from binding TNFR1 (Zhu et al., 2001). A recent report (Saito et al., 
2006) has contradicted this work by Zhu et al., claiming that TNFα-induced apoptosis is 
inhibited by core protein and that core does not interact with TNFR1 or TRADD. This 
report suggests that core sustains levels of c-FLIP, which in turn inhibits the cleavage and 
activation  of  caspase-8,  resulting  in  inhibition  of  apoptosis.  As  with  Fas-mediated 
apoptosis, the contradictory reports may be due to different cell lines or mode of core 
expression. 
Core protein can also enhance LT-βR-mediated apoptosis in a cell-type dependent manner. 
Enhancement was seen in HeLa cells expressing core, although this was not observed in 
HepG2 or Huh-7 cells also expressing core (Chen et al., 1997). 
Finally, a recent report suggests that core may induce ER stress, thus leading to apoptosis. 
Transient  transfection  of  core  in  HepG2  or  Huh-7  cells  resulted  in  an  increase  in 
expression of glucose-regulated protein 78 (Grp78), an ER-resident chaperone, indicating 
ER stress. Similar results were also seen in replicon-harbouring cells and transgenic mice. 
Increase in Grp78 expression was not seen in cells transfected with HBV core. Levels of 
CHOP, an ER stress-induced cell death modulator (Rao et al., 2004), are increased in the 
presence of core protein in cell culture and transgenic mice, suggesting that ER stress, 
induced by HCV core protein, may lead to apoptosis (Benali-Furet et al., 2005). 
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1.5.5.2 Effects on Cell Transformation 
Studies  using  primary  rat  embryo  fibroblasts  (REFs)  have  shown  that  HCV  core,  in 
combination with the oncogene H-ras, can convert cells to a transformed phenotype. Cells 
showed rapid proliferation, anchor-independent growth and tumour formation in athymic 
mice (Ray et al., 1996). Although core, in combination with the oncogene could produce 
this effect, core alone was unable to do so. However, core alone was shown to transform 
established  NIH3T3  cells,  resulting  in  anchor-independent  growth  and  tumourigenicity 
when injected into nude mice (Smirnova et al., 2006, Ray et al., 1996). Transformation of 
NIH3T3  cells  by  core  was  the  result  of  core  interacting  with  and  activating  (through 
phosphorylation), signal transducer and activator of transcription 3 (STAT3) (Yoshida et 
al., 2002). Core, in combination with H-ras, can also prevent contact inhibition of growth 
and promote anchorage-independent growth of BALB/3T3 A31-1-1 cells by stimulating 
the  activation  of  the  Erk1/2-serum  response  element  pathway,  involved  in  signal 
transduction of growth stimuli (Tsuchihara et al., 1999).  In contrast, it has been reported 
that core is unable to transform REFs in the presence of H-ras (Chang et al., 1998). This 
discrepancy may be due to the HCV isolates used in the two studies as Chang et al. used 
HCV-RH core while Ray et al. used HCV-1 core (although both are genotype 1a). HCV-1 
core gene has been shown to produce a 16 kDa core species which shows predominant 
nuclear localisation (Lo et al., 1995), therefore this species of core may be responsible for 
the differences reported by the two groups. In agreement with Ray et al. however, Chang et 
al.  showed  that  the  established  REF  line  Rat-1  was  readily  transformed  by  core  and 
showed anchorage-independent growth. Abnormal cellular proliferation is also seen due to 
the effects of core protein on the transcription factor LZIP. In the context of core protein, 
LZIP presents activities consistent with that of a tumour suppressor. LZIP is a nuclear 
CRE-activating  factor  whose  transcriptional  activity  is  repressed  by  core.  Subcellular 
sequestration of LZIP by core results in inactivation of LZIP and subsequent abnormal 
cellular proliferation (Jin et al., 2000).    
1.5.5.3 Effects on Transcription and Regulatory Factors 
A number of reports have indicated that core protein can modulate expression from cellular 
and viral promoters (McLauchlan, 2000). The first report of this kind showed that HCV 
core protein could suppress expression and replication of hepatitis B virus (HBV) in Huh-7 
cells (Shih et al., 1993). Suppression was evident between 6 and 9 days post-transfection 
and coincided with  intracellular relocalisation of HCV core from  the cytoplasm to the 
nucleus (Shih et al., 1993). Other viruses may also be transcriptionally regulated by HCV David A Dalrymple    Chapter 1: Introduction 
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core. Core transactivates expression from the HIV-1 long terminal repeat (LTR) and also 
from the SV40 promoter, while suppressing expression from the rous sarcoma virus (RSV) 
LTR  (Ray  et  al.,  1995).  In  terms  of  cellular  promoters,  core  has  been  shown  to 
transactivate the c-myc promoter while suppressing the c-fos and p53 tumour suppressor 
promoters  (Ray  et  al.,  1995,  Ray  et  al.,  1997).  Contradictory  effects  of  core  on  the 
promoter of a negative regulator of cell cycle progression (p21) have also been reported. 
Core was reported to suppress p21 promoter activity indicating that p21 regulation of cell 
growth  was  affected  in  the  presence  of  core  during  liver  regeneration,  resulting  in 
enhanced cell growth (Ray et al., 1998b). On the other hand, enhancement of activity from 
the p21 promoter by core protein has also been shown (Lu et al., 1999). An attempt was 
made to resolve this inconsistency by showing that core affected p21 promoter activity in 
different  ways,  depending  on  the  cell  line  used  (Kwun  and  Jang,  2003).  While  core 
transactivated p21 promoter activity in HepG2 and Hep3B cells, suppression of expression 
from the promoter was seen in NIH3T3 cells and primary hepatocytes from transgenic 
mice. Different cell lines were also used in the studies by Ray et al. (1998b) and Lu et al. 
(1999). While Ray et al. (1998b) used COS7 cells, Lu et al. (1999) used both HepG2 and 
Hep3B cells, results which were consistent with those of Kwun & Jang (2003). Finally it 
has been reported that core may counteract the antiviral effects of IFN by suppressing 
activity  from  the  promoters  of  the  IFN  effector  proteins  MxA,  PKR  and  2’-5’ 
oligoadenylate synthetase (2’-5’ OAS) (de Lucas et al., 2005). 
 
1.5.5.4 Effects on Immune Presentation 
As HCV establishes chronicity in the majority of cases, the virus must be able to avoid 
clearance by the immune system. Core protein may play a role in HCV immune evasion by 
inhibiting the immune response to infection. Cytotoxic T cells are primed against HCV as 
a result of interaction between antigen-presenting cells (APC), HCV antigen and the T 
cells themselves. APCs are a site of HCV replication (Lerat et al., 1998) and have therefore 
been  studied  in  the  context  of  HCV  proteins  and  stimulation  of  cytotoxic  T  cells. 
Expression of HCV proteins core, E1 and E2, or core protein alone using adenoviral vector 
systems  have  shown  that  dendritic  cells  expressing  HCV  proteins  possess  reduced 
stimulatory capacity for cytotoxic T cells and produced and released lower levels of T cell 
stimulatory  cytokine  IL-12  (Hiasa  et  al.,  1998,  Sarobe  et  al.,  2002).  Addition  of 
exongenous  IL-12  to  dendritic  cell/T  cell  cultures  did  not  restore  T-cell  proliferation, 
indicating that lack of IL-12 is not the main cause of abnormal T cell priming (Sarobe et David A Dalrymple    Chapter 1: Introduction 
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al., 2002). Studies in mice using recombinant vaccinia virus showed that those expressing 
core protein had elevated virus titre 5 days post-infection compared to those expressing 
HCV non-structural proteins and, while those expressing non-structural proteins overcame 
infection, mice expressing core protein succumbed to lethal infection (Large et al., 1999). 
Failure to clear vaccinia virus infection in the presence of HCV core protein led to the 
theory that core protein plays a role in inhibition of the cytotoxic T cell response. Analysis 
of cytotoxic T cell precursor indicated a 10-fold lower frequency in core expressing mice 5 
days  post-infection  compared  to  mice  expressing  non-structural  proteins.  Interferon-γ 
production by immune splenocytes was also profoundly suppressed in the presence of core 
protein, with a reduction in antigen-stimulated IL-2 production also seen (Large et al., 
1999). Core protein has also been shown to modulate the immune response by interfering 
in the complement pathway (Kittlesen et al., 2000). Binding of complement protein C1q to 
its receptor, gC1qR, blocks proliferation of cytotoxic T cells (Ghebrehiwet et al., 1990). 
HCV core protein has been shown to bind gC1qR in both yeast-2-hybrid and GST pull-
down assays and is believed to mimic C1q in blocking proliferation of cytotoxic T cells 
(Kittlesen et al., 2000). Core protein is secreted from transfected cell lines expressing core 
(Sabile  et  al.,  1999)  and  circulating  core  protein  is  detectable  in  the  plasma  of  HCV 
infected  patients  (Masalova  et  al.,  1998).  Exposure  to  core  protein  inhibited  T  cell 
proliferation in a dose-dependent manner (Kittlesen et al., 2000) and this was suggested to 
be due to inhibition of the ERK/MEK MAP kinase signalling pathway (Yao et al., 2001). 
Inhibition of activation of the ERK/MER MAP kinase by C1q/gC1qR interaction inhibits 
transcription  of  early  genes  involved  in  T  cell  activation  (such  as  IL-2)  and  leads  to 
suppression of proliferation. Production of IL-2 is also inhibited in the presence of core 
protein, suggesting core may inhibit T cell proliferation by inhibiting the ERK/MEK MAP 
kinase signalling pathway (Yao et al., 2001).  
 
1.5.5.5 Effects on Lipid Metabolism 
HCV infection has been suggested to have effects on lipid metabolism as shown by studies 
on steatosis in the liver of HCV infected patients (Bach et al., 1992, Moriya et al., 2001) 
and in transgenic mice harbouring HCV core protein or the entire HCV genome (Lerat et 
al.,  2002,  Moriya  et  al.,  1997),  as  well  as  through  an  association  between  HCV  core 
protein  and  apolipoprotein  AII  (Barba  et  al.,  1997).  In  comparison  with  patients  with 
autoimmune chronic hepatitis, those with chronic hepatitis C presented more commonly 
with steatosis (72% vs. 19%) (Bach et al., 1992). HCV core protein localises to the surface David A Dalrymple    Chapter 1: Introduction 
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of lipid droplets as shown in both chimpanzees and HepG2 cells stably expressing core 
protein (Barba et al., 1997), as well as in transgenic mice (Moriya et al., 1997), suggesting 
that core may regulate expression of cellular genes involved in lipid metabolism (Barba et 
al., 1997). Transgenic mice, expressing HCV core from birth, presented with steatosis at 2 
months and although mild at first, progressed in severity, coinciding with an increased 
frequency of large (in comparison to small) lipid droplets, suggesting a role for core in 
steatosis, possibly by binding enzymatic molecules or apolipoproteins involved in lipid 
metabolism  (Moriya  et  al.,  1997).  Interestingly,  core  was  shown  to  colocalise  with 
apolipoprotein II on lipid droplets within HepG2 cells (Barba et al., 1997). Comparison of 
lipid levels and fatty acid composition of lipids in core-expressing transgenic mice, non-
transgenic mice and non-transgenic obese mice indicated that triglyceride levels in the 
livers of transgenic mice and non-transgenic obese mice were significantly higher than in 
non-transgenic mice while the concentration of carbon 18 mono-unsaturated fatty acids 
(oleic and vaccenic acids) was increased only in transgenic mice, suggesting HCV core 
may affect a specific pathway in lipid metabolism, different to that affected by other causes 
of steatosis. Similar results on lipid composition were found in human livers (Moriya et al., 
2001).  Core  protein  has  also  been  shown  to impair  hepatic  assembly and  secretion  of 
triglyceride-rich, very low-density lipoproteins (VLDL) (Perlemuter et al., 2002) and a 
marked  reduction  in  number  of  normal  sized  lipoprotein  particles  was  seen  in  core 
expressing  transgenic  mice.  Microsomal  triglyceride  transfer  protein  (MTP)  and 
apolipoprotein  B  (apo  B)  are  major  regulators  of  VLDL  assembly.  Transgenic  mice 
expressing core show significantly lower MTP activity compared to non-transgenic mice, 
suggesting that core protein may impair secretion of VLDL by decreasing MTP activity 
and thus VLDL assembly (Perlemuter et al., 2002). Transgenic mice have also recently 
been  used  to  show  that  the  proteasome  activator  PA28γ  is  involved  in  core-induced 
steatosis. PA28γ specifically binds core protein in the nucleus, resulting in degradation of 
the viral protein in a PA28γ-dependent manner (Moriishi et al., 2003). Vacuolation of 
mouse liver cells was seen in the presence of core and PA28γ but not in the absence of 
either core or PA28γ, suggesting that PA28γ is required for the induction of liver steatosis 
by HCV core (Moriishi et al., 2007).       
 
1.5.6 Host Cell Proteins Interacting with Core 
A number of host cell proteins have been identified which interact with HCV core protein. 
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libraries using core sequences as bait. Once identified, the interactions were confirmed by 
biochemical  analyses  including  GST-pull  down  assay  and  in  vivo  colocalisation  by 
immunofluorescence.  More  recently,  proteomic  profiling  using  2-dimensional 
electrophoresis and mass spectrometry has been used to identify proteins interacting with 
core (Kang et al., 2005), and to analyse lipid droplet composition in core expressing cells 
(Sato et al., 2006). 
 
1.5.6.1 Lymphotoxin-β Receptor (LT-βR) 
Core protein binds the cytoplasmic tail of LT-βR (Matsumoto et al., 1997, Chen et al., 
1997), which is a member of the tumour necrosis factor receptor family. The exact function 
of  LT-βR  is  unknown  however  it  is  thought  to  be  involved  in  cytolytic  and  NF-κB 
activation in certain cell types. The region of core required for interaction with LT-βR 
includes residues 1-91  of domain I (Matsumoto et al., 1997, Chen et al., 1997). Core 
protein,  expressed  in  HeLa  cells,  enhances  the  cytolytic  effects  of  LT-βR  ligand 
(lymphotoxin-α1-β2) while having no such effects in either Huh7 or HepG2 cells (Chen et 
al., 1997).  
 
1.5.6.2 Tumour Necrosis Factor Receptor 1 (TNFR1) 
Core protein has also been shown to bind the prototype tumour necrosis factor receptor, 
TNFR1 (Zhu et al., 1998). TNFR1 is the primary receptor mediating TNF induction and is 
involved  in  cell  death  signalling  and  NF-κB  activation.  GST-fusion  protein  pull-down 
assays were used to identify an interaction between core and TNFR1. This interaction 
requires residues 1-115 of core protein and the cytoplasmic tail region of TNFR1 (residues 
345-407). In the presence of core, HepG2 and HeLa cells were more sensitive to TNF- or 
anti-TNFR1 antibody-induced cell death (Section 1.5.5.1) (Zhu et al., 1998). 
 
1.5.6.3 Heterogeneous Nuclear Ribonucleoprotein K (hnRNP K) 
hnRNP K, a component of the hnRNP complex, is a transcriptional regulator with both 
RNA- and DNA-binding properties. Although predominantly found in the nucleus, hnRNP David A Dalrymple    Chapter 1: Introduction 
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K also shuttles to the cytoplasm and has been suggested to play a role in processing and 
transport of pre-mRNA. Core protein specifically interacts with hnRNP K as shown by 
yeast-2-hybrid, GST-fusion protein binding and colocalisation studies (Hsieh et al., 1998). 
By yeast-2-hybrid analysis, residues 1-115 of HCV core domain I were required for the 
interaction. Core  protein  was  also  shown  to  partially  reverse  the  suppressive  effect  of 
hnRNP K on the human thymidine kinase gene, possibly by binding proline-rich regions of 
hnRNP K which blocks the interaction of hnRNP K with other cellular factors (Hsieh et 
al., 1998). 
 
1.5.6.4 Apolipoprotein AII (apoAII) 
In a study describing the cytoplasmic localisation of core protein, it was reported that core 
and apoAII colocalise on the surface of lipid droplets in HepG2 cells (Barba et al., 1997). 
The region involved in the interaction was later identified as residues 160-173 of core. 
Truncation of this region leads to loss of interaction with apoAII and localisation of core to 
the  nucleus  (Sabile  et  al.,  1999).  Association  between  apoAII  and  HCV  core  may  be 
involved in the modulation of lipid metabolism by core protein, thus playing a role in HCV 
pathogenicity. 
 
1.5.6.5 p53 
Activation of the tumour suppressor p53 has been shown to be enhanced by HCV core 
protein (Lu et al., 1999). Core was able to enhance the gene transactivation activity of 
exogenous p53 in p53-negative Hep3B cells as well as endogenous p53 in HepG2 cells. 
Enhancement  of  transactivation  by  p53  in  the  presence  of  core  resulted  in  enhanced 
expression  of  the  downstream  p53  effector  gene,  the  cdk  inhibitor  p21
waf1/Cip1/Sdi1. 
Increased expression of p21
Waf1/Cip1/Sdi1 can suppress the cell cycle and, in the presence of 
core protein, Hep3B cell growth was suppressed in a p53-dependent manner. Suppression 
of hepatocellular growth by core protein in a p53-dependent manner may have important 
implications in HCV pathogenesis. Direct interaction between core and p53 was identified 
by  co-immunoprecipitation  experiments.  Binding  p53  does  not  require  residues 
downstream of amino acid 151 of core, while residues 366-380 of p53 are required for 
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1.5.6.6 14-3-3ε protein 
An interaction between core protein and the epsilon isoform of 14-3-3 protein (14-3-3ε) 
has been shown by yeast-2-hybrid analysis (Aoki et al., 2000a). The 14-3-3 protein family 
associate  with  components  of  several  signal  transduction  pathways  such  as  the  Raf-1 
kinase cascade. Residues 49-97 of core protein are required for interaction, as are residues 
165-234 of 14-3-3 protein. Interaction may occur in a phospho-serine dependent manner, 
as phosphorylation of serine-53 of core is essential for interaction with the cellular protein 
in HepG2 cells stably expressing core. Activation of Raf-1 kinase, a central component of 
the mitogen-activated protein (MAP) kinase pathway, requires binding of core protein to 
14-3-3 protein. Interestingly, Ito et al. reported enhanced MAP kinase activation in HCC 
(Ito et al., 1998b), suggesting core may play a role in the progression of HCV to HCC 
(Aoki et al., 2000a). 
 
1.5.6.7 p21
Waf1/Cip1/Sdi1 (p21) 
Core protein may be involved in de-regulation of the cell cycle via interaction with the cell 
cycle regulator p21 (Wang et al., 2000). In vitro pull-down studies identified an interaction 
between core and p21 with the binding site mapped to residues 24-52 of core protein and 
residues 139-164 of p21. As p21 is a regulator of the cell cycle, interaction with core 
protein  may  inhibit  nuclear  transport  of  newly  synthesised  p21  and  its  subsequent 
involvement in cell cycle regulation (Wang et al., 2000).   
1.5.6.8 Leucine Zipper Protein (LZIP) 
The transcription factor LZIP has been shown to bind HCV core protein by yeast-2-hybrid 
analysis  and  co-immunoprecipitation  studies  (Jin  et  al.,  2000).  Endogenous  LZIP  was 
shown to localise to the nucleus in HepG2 and HeLa cells, as was exogenously expressed 
LZIP. However, upon co-expression with HCV core protein, exogenously expressed LZIP 
was  relocalised  from  the  nucleus  to  the  cytoplasm.  Loss  of  LZIP  function  (by  over-
expression  of  a  transcriptionally  incompetent  LZIP  mutant)  resulted  in  loss  of  contact 
inhibition in  NIH3T3  cells,  resulting  in  dense foci  of  cells.  This  dysregulation  of cell 
growth was enhanced in the presence of core protein, suggesting that by sequestration of 
LZIP, core protein can prevent LZIP function and act as a co-factor in cell transformation 
(Jin et al., 2000).     David A Dalrymple    Chapter 1: Introduction 
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1.5.6.9 Complement Receptor gC1qR 
Screening of a human lymphocyte-expression library identified the complement receptor 
gC1qR  as  a  core-binding  protein  (Kittlesen  et  al.,  2000).  The  residues  required  for 
interaction include amino acids 26-124 of core and 188-259 of gC1qR. Binding of gC1qR 
to its natural ligand, complement protein C1q, specifically inhibits T-cell proliferation in a 
dose-dependent manner (Ghebrehiwet et al., 1990). Naked core protein has been shown to 
circulate in the plasma of HCV-infected patients (Kanto et al., 1994) and be secreted from 
transfected cell lines (Sabile et al., 1999). Kittlesen et al. showed that core protein could 
specifically  inhibit  T-cell  proliferation  in  a  dose-dependent  manner  and  that  inhibition 
could  be  blocked  by  either  anti-gC1qR  or  anti-core  antibody  (Kittlesen  et  al.,  2000). 
Inhibition of T-cell proliferation by circulating, naked core protein may be a mechanism by 
which the virus evades the immune system and establishes persistence. 
 
1.5.6.10 p73 
As well as interacting with p53 (section 1.5.6.5) (Lu et al., 1999), core protein has also 
been shown to bind p73, another member of the p53 superfamily (Alisi et al., 2003). p73 
has been reported to transactivate endogenous targets of p53 such as the p21
Waf1/Cip1/Sdi1 
promoter (Jost et al., 1997) and core protein can modulate the transcriptional activity of 
p73 on the p21 promoter (Alisi et al., 2003). An interaction between core and p73 was 
identified  by  co-immunoprecipitation  studies  in  HepG2  cells  while  deletion  studies 
identified residues 321-353 of p73 as being required for the interaction (Alisi et al., 2003). 
Core protein is able to inhibit p73 dependent cell growth arrest in HepG2 cells, suggesting 
an involvement of the core-p73 interaction in the pathogenesis of HCV (Alisi et al., 2003). 
 
1.5.6.11 Sp110b 
During a study on the molecular mechanisms behind core modulation of all-trans-retinoic 
acid  (ATRA)-induced  cell  death,  Sp110b  was  identified  as  a  core-interacting  protein 
(Watashi et al., 2003). Residues 21-80 of core and 389-453 of Sp110b are required for this 
interaction. Within the nucleus, Sp110b acts as a transcriptional corepressor of the retinoic 
acid response element (RARE), preventing the enhancement of downstream proapoptotic David A Dalrymple    Chapter 1: Introduction 
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gene expression (Watashi et al., 2003). Core protein sequesters Sp110b from the nucleus to 
the cytoplasmic surface of the ER, thus releasing the suppressive function of Sp110b and 
activating RARα-mediated transcription, leading to ATRA-induced cell death (Watashi et 
al., 2003).    
 
1.5.6.12 DEAD-box RNA Helicase (DDX3/CAP-Rf/DBX) 
Finally,  core  protein  has  been  shown  to  bind  a  DEAD-box  RNA  helicase  termed 
DBX/DDX3/CAP-Rf (Mamiya and Worman, 1999, Owsianka and Patel, 1999, You et al., 
1999). The name DDX3 has been approved by the HUGO/GDB Nomenclature Committee 
and will therefore be used in the remainder of this thesis. The interaction between core and 
DDX3 will be discussed in detail in section 1.6.4.  
The following section describes the properties and functions of DEAD-box RNA helicases 
as a family, before reviewing the current literature on DDX3. 
 
1.6 DEAD-box RNA Helicases 
1.6.1 General Features 
Proteins capable of catalysing the separation of RNA-RNA, RNA-DNA or RNA-protein 
complexes in an energy-dependent manner are termed RNA helicases. They are ubiquitous 
proteins, found in all cellular organisms and in many viral genomes (Linder and Daugeron, 
2000), and play vital roles in all processes involving RNA such as transcription, splicing, 
translation, ribosomal biogenesis, RNA transport and RNA turnover (de la Cruz et al., 
1999). Despite being termed helicases, in vitro helicase activity has only been shown for a 
few proteins including cellular proteins eIF4A (Rozen et al., 1990), p68 (Hirling et al., 
1989), X. laevis An3 (Gururajan and Weeks, 1997) and Drosophila Vasa (Liang et al., 
1994), and viral proteins NPH-II of vaccinia virus (Shuman, 1992) and NS3 of HCV and 
BVDV  (Kim  et  al.,  1995,  Jin  and  Peterson,  1995,  Warrener  and  Collett,  1995).  The 
requirement of co-factors by some helicases for activity (e.g. eIF4A, (Rozen et al., 1990)) 
may explain why many putative helicases lack demonstrable activity. RNA helicases are 
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conserved motifs in their amino acid sequence (Gorbalenya and Koonin, 1993). DEAD-
box RNA helicases belong to SF2 (Caruthers and McKay, 2002) and contain 9 conserved 
motifs required for ATPase and helicase function (Tanner et al., 2003). 
 
1.6.2 DEAD-box Helicase Motifs 
All DEAD-box helicases contain a cluster of 9 conserved motifs spanning a central ~400-
residue domain (Fig. 1.10) (Caruthers and McKay, 2002, Tanner et al., 2003). The N- and 
C-termini however, are highly variable in both sequence and length and are thought to be 
involved in substrate interaction as well as subcellular localisation (Cordin et al., 2006). 
The N-terminal most motif of the central domain is termed the Q motif and consists of a 9 
amino acid sequence containing an invariant glutamine as well as a conserved aromatic 
group (usually phenylalanine) 17 residues further upstream (Tanner et al., 2003). Site-
directed mutagenesis of either the conserved phenylalanine or conserved glutamine in the 
essential  yeast  proteins  eIF4A  or  Ded1  is  lethal.  Mutants  show  significantly  reduced 
ATPase  activity  and  RNA  binding  activity,  indicating  that  the  Q  motif  is  involved  in 
control of ATP binding and hydrolysis as well as RNA substrate affinity (Cordin et al., 
2004, Tanner et al., 2003). Although highly conserved throughout other RNA and DNA 
helicase  families,  the  glutamine  residue  is  not  essential  outwith  the  DEAD/DEAH 
subfamilies (Tanner et al., 2003). Motif I, also known as the Walker A motif (Walker et 
al., 1982), is essential for ATPase and helicase activities. Mutation of a conserved lysine to 
asparagine within this motif in eIF4A results in vastly reduced ATP binding (Rozen et al., 
1989), while mutation of a conserved alanine to valine inhibits ATP hydrolysis and RNA 
helicase activity, without adverse effects on ATP binding (Blum et al., 1992). Motif II, 
also known as the Walker B motif (Walker et al., 1982), gives rise to the name DEAD-box 
and is involved in ATP-binding and/or ATP hydrolysis (Walker et al., 1982, Pause and 
Sonenberg, 1992). Motif III is thought to link ATPase and helicase activities and mutations 
in this motif inhibit the helicase activity of eIF4A while not significantly interfering with 
ATP binding/hydrolysis (Pause and Sonenberg, 1992). Motif IV is the least-well studied 
DEAD-box  protein  motif,  encompassing  between  3  and  8  residues,  with  no  definite 
function assigned as yet (Cordin et al., 2006). Motif V is proposed to be an RNA binding 
motif (Caruthers et al., 2000) and motif VI required for RNA binding and ATP hydrolysis 
(Pause et al., 1993). 
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Figure 1.10: Conserved motifs of the DEAD-box family of RNA helicases. The conserved 
central region contains 9 motifs flanked by diverse N- and C-termini of varying length, 
thought to be  involved in  substrate specificity, subcellular localisation and  interactions 
with cellular co-factors (adapted from de la Cruz et al., 1999). 
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1.6.3 Functional Classification of RNA Helicases 
RNA helicases are ubiquitous cellular proteins involved in all aspects of RNA metabolism, 
including transcription, pre-mRNA splicing, ribosome biogenesis, RNA export, translation 
and RNA decay (de la Cruz et al., 1999). Below, examples are given of RNA helicases 
involved in each of these processes. 
 
1.6.3.1 Transcription 
Saccaromyces cerevisiae protein POP2, a component of the multi-subunit transcriptional 
regulator complex Ccr4p, has been shown to physically interact with the putative RNA 
helicase  DHH1  (Hata  et  al.,  1998).  Overexpression  of  DHH1  suppressed  phenotypes 
associated with POP2 mutants, suggesting DHH1 may be part of the Ccr4p transcription 
complex, while the DEAD-box RNA helicase RHII/Gu has been suggested to be involved 
in  c-jun  mediated  transcription  activation  (Westermarck  et  al.,  2002).  The  N-terminal 
transcription activation region of c-jun interacts with RHII/Gu and a dominant negative 
form of RHII/Gu interferes with c-jun mediated transcription (Westermarck et al., 2002).  
 
1.6.3.2 Pre-mRNA Splicing 
Before transcribed molecules leave the nucleus, pre-mRNA undergoes a series of processes 
including 5’ capping, 3’ modification and intron excision. Intron excision, or splicing, is 
carried out by the spliceosome, a ribonucleoprotein (RNP) composing of a large number of 
proteins and small nuclear RNAs. The spliceosome is an energy-dependent machine and 
RNA  helicases  are  thought  to  be  the  driving  force  behind  the  extensive  structural 
rearrangements that take place during splicing (Staley and Guthrie, 1998). At least 8 RNA 
helicases are believed to be involved in yeast pre-mRNA splicing including the DEAD-box 
RNA helicases Prp5p and Prp28p as well as the DexH-box RNA helicase Brr2p (Staley 
and Guthrie, 1998). 
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1.6.3.3 Ribosome Biogenesis 
Similar to the spliceosome, ribosome biogenesis involves a large complex of proteins as 
well as rRNAs. In yeast this number is approximately 80 proteins and 4 ribosomal (r) 
RNAs (de la Cruz et al., 1999). A number of putative RNA helicases, essential for yeast 
viability, have been suggested to be involved in ribosome biogenesis. It is possible that 
these RNA helicases may be required to establish and/or dissociate small nucleolar RNAs 
(snoRNA)-pre-RNA  base  pairs,  facilitate  the  activities  of  endo-  and  exo-nucleases  or 
recruit, rearrange or dissociate trans-acting factors during processing (de la Cruz et al., 
1999). 
 
1.6.3.4 RNA Export 
Upon processing, mRNA (in the form of RNPs) is transported from the nucleus to the 
cytoplasm via the nuclear pore complex. It is plausible that RNA helicases are required at 
this stage to alter the conformation and/or composition of these RNPs and allow transit 
through  the  nuclear  pore  complex  or  to  dissociate  mRNA  from  protein  once  in  the 
cytoplasm.  The  RNA  helicase  Dbp5p/Rat8p,  which  accumulates  around  the  nuclear 
envelope, has been reported to be involved in mRNA export. Poly(A)
+ RNA was shown to 
accumulate in the nucleus in the absence of functional Dbp5p/Rat8p (Tseng et al., 1998, 
Snay-Hodge et al., 1998). More recently, the DEAD-box helicase DDX3 has been shown 
to be required for nuclear export of incompletely spliced HIV RNA transcripts via the 
CRM1 export pathway (Yedavalli et al., 2004) (See section 1.6.4).  
 
1.6.3.5 Translation 
Translation of eukaryotic mRNA involves recruitment of the 40S ribosome subunit to the 
5’ end and involves initiation factors (eIFs). Upon recruitment, the 40S subunit scans the 
mRNA for the correct initiation codon before recruitment of the 60S ribosome subunit and 
initiation of translation. eIF4A is a DEAD-box RNA helicase that is, along with other eIFs, 
required for 40S ribosome binding. eIF4A has ATP-dependent helicase activity (Rozen et 
al., 1990), suggesting its function may be in unwinding secondary structures in the 5’UTR 
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involved in translation. Conditional Ded1p mutants showed severely impaired translation 
with evidence suggesting initiation of translation was affected, indicating a similar role to 
that of eIF4A (Chuang et al., 1997).  
 
1.6.3.6 RNA Decay 
Degradation of defective RNA molecules occurs rapidly in Saccaromyces cerevisiae by 
both  5’®3’  and  3’®5’  exonucleolytic  processing.  The  RNA  helicase  Ski2p  is  a 
component  of  the  3’®5’  exosome  complex  (Anderson  and  Parker,  1998),  indicating 
involvement  in  RNA  degradation.  In  an  alternative  degradation  pathway,  eukaryotic 
mRNA containing premature stop codons is subjected to decay via the nonsense mediated 
decay  (NMD)  pathway.  Identification  of  molecules  containing  premature  stop  codons 
requires  a  surveillance  complex,  a  component  of  which  is  the  RNA  helicase  Upf1p 
(Mitchell and Tollervey, 2003), highlighting another RNA decay associated RNA helicase. 
 
1.6.4 DDX3 
DDX3  is  a  ubiquitous  cellular  protein  belonging  to  the  DEAD-box  family  of  RNA 
helicases,  possessing  ATPase  and  helicase  activities  (Yedavalli  et  al.,  2004).  Known 
homologues include mouse PL10 (Leroy et al., 1989), mDEAD3 (Gee and Conboy, 1994), 
Xenopus An3 (Gururajan et al., 1991) and yeast Ded1 (Jamieson and Beggs, 1991). The 
exact cellular function of DDX3 has yet to be identified however it has been suggested to 
be  involved  in  splicing  (Deckert et  al.,  2006,  Zhou  et  al.,  2002),  translation  initiation 
(Mamiya and Worman, 1999), cell cycle regulation (Chang et al., 2006, Chao et al., 2006), 
nucleo-cytoplasmic RNA shuttling (Yedavalli et al., 2004) and RNA transport (Kanai et 
al., 2004). An accumulation of data (Scott, 2002, Owsianka and Patel, 1999, Mamiya and 
Worman, 1999), suggest that DDX3  is primarily a  cytoplasmic  protein although some 
forms are detected in the nucleus. An involvement in splicing has been indicated by its 
presence  in highly purified and functional human spliceosomes and in  spliceosomal  B 
complexes which undergo catalytic activation leading to catalysis of pre-mRNA splicing 
(Zhou et al., 2002, Deckert et al., 2006). DDX3 also possesses an C-terminal arginine / 
serine rich RS-domain consisting of 7 serine-arginine or arginine-serine dipeptides, similar 
to that of other splicing factors (Owsianka and Patel, 1999). Related to splicing, DDX3 has David A Dalrymple    Chapter 1: Introduction 
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also been found in affinity-purified, spliced messenger-ribonucleoproteins (mRNPs) (Merz 
et al., 2006). DDX3 was present in mRNPs after treatment with heparin, suggesting a 
stable association. This association was also dependent on splicing, as, under the same 
physiological conditions, DDX3 did not associate with intron-less, m
7G-capped mRNAs 
(Merz et al., 2006). An association with kinesin RNA-transport granules has also been 
reported, however knockdown of DDX3 by RNAi did not affect RNA transport (Kanai et 
al., 2004). DDX3 has also been shown to be involved in cell cycle regulation and may 
have a role in tumourigenesis. DDX3 was overexpressed in liver cancer cell lines showing 
anchorage independent growth (AIG) (Huang et al., 2004). Overexpression of DDX3 in 
AIG-negative  Tong  cells  led  to  a  60-80-fold  increase  in  transformed  colonies  in  AIG 
assays. In contrast, 2 recent reports have indicated DDX3 may be down-regulated in liver 
tumour  cells  and  may  affect  cell  cycle  progression  via  regulation  of  p21
waf  gene 
expression. Firstly, an expression profile of DDX3 in liver tumour tissue and adjacent non-
tumour  parts  indicated  a  decrease  in  DDX3  expression  in  59%  of  cases  in  tumour 
compared to non-tumour tissue (Chang et al., 2006). DDX3 knockdown in NIH3T3 cells 
resulted in an accelerated proliferation rate. Interestingly, cyclin D1, a key regulator in 
early-mid G1 phase, was expressed at higher levels (and at earlier time points) while the 
cyclin-dependent kinase (cdk) inhibitor p21
waf was expressed at lower levels at all time 
points (Chang et al., 2006). Similarly, DDX3 was shown to exert an inhibitory effect on 
cell growth in Huh-7 and NIH3T3 cells (Chao et al., 2006). Overexpression of DDX3 
inhibited colony formation and slowed growth rates. Overexpression also led to a 2-4-fold 
upregulation  in  p21
waf-promoter  driven  luciferase  expression  and  endogenous  p21
waf 
expression, which required the ATPase activity of DDX3  but not  the  helicase  activity 
(Chao et al., 2006). Similar to the report by Chang et al., DDX3 expression was lower in 
liver tumour specimens compared to non-tumour specimens (Chao et al., 2006). These two 
reports  provide  firm  evidence  for  a  role  for  DDX3  in  cell  cycle  progression  and 
tumourigenicity via regulation of p21
waf gene expression.  
DDX3  also  functions  in  the  life  cycle  of  human  immunodeficiency  virus  (HIV)-1 
(Yedavalli et al., 2004). HIV-1 gene expression is regulated post-transcriptionally by HIV-
1  Rev-mediated  export  of  Rev  response  element  (RRE)-containing  un-spliced/partially 
spliced viral RNAs from the nucleus to the cytoplasm (Cullen, 2003). In doing so, Rev 
interacts with chromosome maintenance region 1 (CRM1) (Bogerd et al., 1998), which is 
involved  in  nucleo-cytoplasmic  shuttling  of  proteins,  small  nuclear  RNAs  and  rRNAs 
(Fornerod et al., 1997). DDX3 was identified as an HIV-1 Tat-induced cellular protein, 
with further analysis linking it to the Rev-RRE/CRM1 export pathway (Yedavalli et al., 
2004).  This  report  showed  that  DDX3  possesses  ATPase-dependent  RNA  unwinding David A Dalrymple    Chapter 1: Introduction 
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properties and that over-expression of DDX3 resulted in an increase in Rev-dependent 
expression of an RRE reporter plasmid while knockdown of DDX3 by antisense DDX3 
resulted in reduced expression of un-spliced RNA encoded p24 and p55 Gag proteins. Co-
immunoprecipitation studies showed interaction between DDX3 and Rev as well as DDX3 
and CRM1, while inhibition of CRM1 export by leptomycin B resulted in a build up of 
DDX3 in the nucleus. As the ATPase-dependent helicase activity of DDX3 is critical for 
Rev-RRE/CRM1  mediated  HIV  RNA  export,  it  is  possible  that  DDX3  is  required  for 
unwinding  of  viral  RNA/protein complexes  to  allow  passage  through  the  nuclear  pore 
(Yedavalli et al., 2004).    
The  interaction  between  HCV  core  and  DDX3  was  discovered  using  yeast-2-hybrid 
screening  and  confirmed  by  both  in  vitro  binding  studies  and  immunofluorescence 
analysis. The interaction domains were mapped by deletion analysis to be within the N-
terminal 59 residues of core protein (You et al., 1999, Owsianka and Patel, 1999) although 
interaction between this deletion mutant and DDX3 was weaker than binding using core 
residues  1-114,  indicating  that  residues  59-114  may  also  contribute  to  the  interaction 
(Owsianka and Patel, 1999).  The core-binding domain of DDX3 was mapped to the C-
terminal  409-622  residues  (Owsianka  and  Patel,  1999,  You  et  al.,  1999,  Mamiya  and 
Worman, 1999). The minimal region of DDX3 required for interaction (residues 553-622) 
includes almost all of a 50 amino acid domain rich in arginines and serines (residues 582-
632) which resembles the RS domains of splicing factors such as ASF/SF2 and SC-35. 
Although both core and DDX3 are expected to bind RNA, this was not a requirement for 
the interaction (Owsianka and Patel, 1999). In HeLa cells, DDX3 has a diffuse cytoplasmic 
distribution, although nuclear staining was seen with some anti-DDX3 antibodies (Mamiya 
and Worman, 1999, Owsianka and Patel, 1999, You et al., 1999). In cells expressing either 
core alone, or together with E1 and E2, the distribution of DDX3 is altered from a diffuse 
cytoplasmic localisation to discrete cytoplasmic foci on lipid droplets where it colocalises 
with HCV  core  protein. Nuclear  DDX3 was not  re-distributed  in the presence  of core 
protein (Owsianka and Patel, 1999). 
Although the interaction between HCV core and DDX3 is well established, the functional 
relevance of the interaction has still to be confirmed. DDX3 has been suggested to be 
involved in translation and that interaction with core protein may inhibit translation of 
capped mRNA (Mamiya and Worman, 1999). Mouse PL10 and DDX3 were able to rescue 
the lethality of cells with chromosomal deletion of the DDX3 yeast homologue Ded1, 
suggesting DDX3 can replace the function of Ded1. Expression of full-length core protein 
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Ded1 deletion yeast, consistent with the fact that core binds DDX3 and PL10 but not Ded1. 
Core protein also inhibited in vitro translation of luciferase from capped but not un-capped 
RNA, suggesting it may inhibit translation of capped mRNA, possibly by inhibiting DDX3 
function (Mamiya and Worman, 1999). It has also been suggested that DDX3 is involved 
in gene expression, however, in contrast to the findings of Mamiya and Worman (1999), it 
was reported that gene expression was enhanced in the presence of HCV core protein (You 
et al., 1999). Exogenous DDX3 enhanced luciferase reporter expression 1.5-3-fold in Huh7 
cells, while co-transfection with HCV core protein increased luciferase reporter expression 
5.5-34-fold. Core protein also enhanced DDX3 ATPase activity 4-5-fold, suggesting that 
core may modulate the activity of DDX3, thus affecting the function of DDX3 in gene 
expression (You et al., 1999). 
As yet, the exact function of DDX3 and its role in the life cycle of HCV is not known. It is 
possible that core protein recruits DDX3 from its normal cellular function for use in the 
viral  life  cycle,  for  example  during  replication  or  packaging  of  progeny  RNA. 
Alternatively, core may be sequestering DDX3 in order to prevent it from carrying out its 
normal  cellular  function,  possibly  to  reduce  protein  synthesis  or  affect  cell  cycle 
regulation.  
1.7 Aims 
The aim of this project is to identify critical residues of HCV core protein required for 
interaction with cellular DDX3. Mutation of these critical residues and analysis of their 
effects in the infectious JFH-1 cell culture system will allow study of the role of DDX3 in 
HCV  replication,  translation  and  production  of  progeny  virus.  It  is  also  hoped  that 
mutational abrogation of core-DDX3 interaction in HCV-infected cells may provide clues 
and future avenues for research on the possible role of this interaction in disrupting critical 
cellular  processes  which  may  lead  to  some  of  the  pathologies  associated  with  HCV 
infection. 
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2.1 Materials 
2.1.1 Chemical and Additional Reagent Suppliers 
Most analytical grade chemicals and reagents were supplied by Sigma Aldrich Ltd or BDH 
Laboratory Supplies. The remainder are listed below: 
Chemical / Reagent  Supplier 
30% Acrylamide / bis solution 37.5:1   Bio-Rad laboratories 
Absolute ethanol   Bamford Laboratories, UK 
Agarose   Melford 
Ampicillin (Penbritin)   Beecham Research 
Ammonium persulphate (APS)   Bio-Rad Laboratories 
Chloroform  Prolabo 
Citifluor
TM AF1 (Glycerol:PBS)    UKC Chemical Laboratories 
Coomassie Brilliant Blue  BioRad 
Coverslips (13 mm diameter)   VWR International 
Developer and fixer   Kodak X-OMAT 
DNA miniprep kit   Qiagen 
dNTPs    Amersham Biosciences 
Dried skimmed milk   Marvel 
Ethanol     Fisher Scientific 
Electroporation cuvettes (1mm)  Apollo 
Hybond ECL Nitrocellulose Membrane  Amersham Biosciences 
Immunolon II ELISA plates   Dynal, UK 
IPTG    Invitrogen 
Isopropanol     Prolabo 
Lambda DNA   Promega 
Luminol    Fluka 
Methanol    Prolabo 
Phosphoimager screens  BioRad 
Photographic film (S-film)   Kodak X-OMAT 
Pipette tips (Rnase free)  Molecular Bio Products 
QIAquick gel purification kit   Qiagen 
QIAquick nucleotide purification kit   Qiagen 
Rainbow protein markers   Amersham Biosciences 
TEMED    Bio-Rad Laboratories 
TMB substrate   Zymed Laboratories Inc. 
Tris    Roche 
TRIzol  Invitrogen 
Tween-20    Bio-Rad Laboratories 
Whatman 3mm filter paper   Whatman 
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2.1.2 Enzyme Suppliers 
Restriction endonuclease enzymes and buffers were supplied by New England Biolabs 
(NEB) and Promega. Other enzymes and their suppliers are shown below: 
Enzyme  Supplier 
Calf intestinal phosphatase    New England Biolabs 
Ribonuclease A    Sigma 
T4 DNA ligase    Invitrogen 
Taq DNA polymerase  Roche 
KOD Hotstart DNA polymerase  Novagen 
Expand High Fidelity PCR System  Roche 
Mung Bean nuclease  New England Biolabs 
Proteinase K  New England Biolabs 
M-MLV RT (including First-strand 
buffer, DTT, RNase-OUT) 
Invitrogen 
 
 
2.1.3 Immunological Reagent Suppliers 
Monoclonal antibodies (mAbs) and polyclonal antisera (pAbs) used in this study are shown 
below:  
2.1.3.1 Primary antibodies 
Antibody  Name  Type  Raised in  Source 
HCV core  R308  Polyclonal 
antiserum 
Rabbit  Hope & McLauchlan, (2000) 
HCV E2  AP33  Monoclonal 
antibody 
Mouse  Clayton et al., (2002) 
HCV NS5a  NS5a  Polyclonal 
antiserum 
Sheep  MacDanoald et al., (2003) 
DDX3  AO196  Monoclonal 
antibody 
Mouse  A.H. Patel, unpublished 
DDX3  R648  Polyclonal 
antiserum 
Rabbit  A.H. Patel, unpublished 
ADRP  ADRP 4  Polyclonal 
antiserum 
Sheep  Target-Adams et al., (2003) 
GFP  GFP  Polyclonal 
antiserum 
Rabbit  Abcam 
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2.1.3.2 Secondary antibodies 
Antibody  Source 
FITC-conjugated donkey anti-rabbit IgG  Jackson ImmunoResearch Laboratories Inc. 
TRITC-conjugated donkey anti-sheep IgG  Jackson ImmunoResearch Laboratories Inc. 
Cy5-conjugated donkey anti-mouse IgG   Jackson ImmunoResearch Laboratories Inc. 
FITC-conjugated donkey anti-sheep IgG  Molecular Probes 
Protein A-HRP (Whole molecule)  Sigma 
 
 
2.1.4 Cells 
Laboratory stocks of human hepatoma cell line Huh-7 (Nakabayashi et al., 1982) were 
used in this study. 
 
2.1.5 Cell Culture Supplier 
Phosphate buffered saline (PBS), versene, trypsin, and L-broth were all made in-house by 
the media department using standard recipes, while Dulbecco’s Modified Eagle’s medium 
(DMEM),  Foetal  calf  serum  (FCS),  Penicillin,  Streptomycin,  Glutamine,  Non-essential 
amino acids (NEAA) and OptiMEM were supplied by GIBCO-BRL
TM Life Technologies, 
Invitrogen. 
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2.1.6 Plasmid constructs 
Plasmid constructs used in this study are shown below. 
 
Name  Vector  Details  Source 
pGFP-SpAb  pKK223-3  Domain B of Staphylococcal protein A
194-271 
fused to the 3’end of GFP.  
Aoki et al., (2002) 
pGFP-Core1-59  pKK223-3  HCV (H77c strain) core residues 1-59 fused 
to the 3' end of GFP. 
D.A. Dalrymple, 
unpublished 
pGST-DDX3C  pGEX-2T  C-terminal 253 amino acids (409-662) of 
DDX3 fused to the 3’end of GST. 
Owsianka & Patel, (1999) 
pC-E1-E2  pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2.  
A.H. Patel, unpublished 
pC-E1-E2 
mut25 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutations R9K, 
V34G, Q57R 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut36 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutations V34D, 
R40W, T52S 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut90 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutation I30N 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut99 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutations V22D, 
V34D 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut110 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutations I30N, 
R43S 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut111 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutations K6E, 
D.A. Dalrymple, 
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Y35N 
pC-E1-E2 
mut115 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutations K10D, 
K12E, F24S 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut125 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutations N16I, 
Q29R, Y35N, Q57R 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut126 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutations Q8H, 
G26D, I30N, L36W 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut25b 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutation V34G 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut36b 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutation V34D 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut99b 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutation V34D 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut110b 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutation I30N 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut111b 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutation Y35N 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut125b 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutations Q29R, 
Y35N 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 
mut126b 
pcDNA3.1 
(+)Zeo 
HCV (H77c strain) sequence encoding core, 
E1 and E2. Core contains mutations G26D, 
I30N, L36W 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 F24A  pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. Core contains mutation F24A 
D.A. Dalrymple, 
unpublished 
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(+)Zeo  E1 and E2. Core contains mutation P25A  unpublished 
pC-E1-E2 G26A  pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. Core contains mutation G26A 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 G27A  pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. Core contains mutation G27A 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 G28A  pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. Core contains mutation G28A 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 Q29A  pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. Core contains mutation Q29A 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 I30A  pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. Core contains mutation I30A 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 V31A  pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. Core contains mutation V31A 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 G32A  pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. Core contains mutation G32A 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 G33A  pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. Core contains mutation G33A 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 V34A  pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. Core contains mutation V34A 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 Y35A  pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. Core contains mutation Y35A 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 L36A  pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. Core contains mutation L36A 
D.A. Dalrymple, 
unpublished 
pC-E1-E2 JFH-1   pcDNA3.1 
(+)Zeo 
HCV (JFH-1 strain) sequence encoding core, 
E1 and E2. 
D.A. Dalrymple, 
unpublished 
pJFH-1  pUC  Full length JFH-1 cDNA downstream of the 
T7 RNA polymerase promoter. 
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pJFH-1 GND  pUC  Full length JFH-1 cDNA carrying a mutation 
in the NS5B GDD motif, downstream of the 
T7 RNA polymerase promoter. 
Wakita et al., (2005) 
pJFH-1 (1-2837)  pGEM T 
Easy 
HCV (JFH-1 strain) nucleotides 1-2837   D.A. Dalrymple, 
unpublished 
pJFH-1 F24A  pUC  Full length JFH-1 cDNA carrying a mutation 
in core (F24A), downstream of the T7 RNA 
polymerase promoter. 
Wakita et al., (2005) 
pJFH-1 G27A  pUC  Full length JFH-1 cDNA carrying a mutation 
in core (G27A), downstream of the T7 RNA 
polymerase promoter. 
Wakita et al., (2005) 
pJFH-1 I30A  pUC  Full length JFH-1 cDNA carrying a mutation 
in core (I30A), downstream of the T7 RNA 
polymerase promoter. 
Wakita et al., (2005) 
pJFH-1 G33A  pUC  Full length JFH-1 cDNA carrying a mutation 
in core (G33A), downstream of the T7 RNA 
polymerase promoter. 
Wakita et al., (2005) 
pJFH-1 V34A  pUC  Full length JFH-1 cDNA carrying a mutation 
in core (V34A), downstream of the T7 RNA 
polymerase promoter. 
Wakita et al., (2005) 
pJFH-1 Y35A  pUC  Full length JFH-1 cDNA carrying a mutation 
in core (Y35A), downstream of the T7 RNA 
polymerase promoter. 
Wakita et al., (2005) 
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2.1.7 Bacterial Strains 
Plasmids  were  manipulated  and  grown  in  the  Escherichia  coli  (E.coli)  strain  JM109 
(Stratagene), (genotype e14-(McrA-) recA1 endA1 gyrA96 thi-1 hsdR17(rK- mK+) supE44 
relA1 D(lac-proAB) [F’ traD36 proAB lacI
qZDM15]). 
 
2.1.8 Solutions 
Standard solutions used in this study are shown below: 
Solutions  Contents 
Alkaline lysis buffer for plasmid 
purification 
0.2 M NaOH , 1 % SDS 
Neutralisation buffer for plasmid 
purification 
3 M potassium acetate 11.5 % glacial 
acetic acid 
Cell lysis buffer   20 mM Tris pH 7.5 , 150 mM NaCl ,         
1 mM EDTA , 1 % NP40 
Coomassie stain   0.2 % Coomassie brilliant blue dye R200,  
50 % methanol,  7 % acetic acid 
Destain   5 % (v/v) methanol, 7 % (v/v) acetic acid 
(in H20) 
DNA loading dye   30 % glycerol, 0.25 % bromophenol blue 
Electrochemiluminescence I   1 % luminol, 0.44 % coumaric acid,      
100 mM Tris-HCl pH 8.5 
Electrochemiluminescence II   30 % H2O2 , 100 mM Tris-HCl pH 8.5 
LB broth agar   L-broth, 15 % (w/v) agar 
Luria-Bertani (LB) broth   1 % NaCl, 1 % Bactopeptone, 0.5 % yeast 
extract 
PBS   PBSA, 68 mM CaCl22H2O,                       
4 mM MgCl26H2O 
PBSA    170 mM NaCl, 34 mM KCl, 10 mM 
Na2HPO4, 18 mM KH2PO4, 25 mM Tris-
HCl pH 7.2 
PBST    PBSA, 0.05 % Tween-20 
Protease inhibitors  20 mM AEBSF, 100 mM Benzamidine,  
50 mM EDTA, 100 mg/ml Apronitin,    
100 mg/ml Leupeptine 
SDS-PAGE resolving buffer   0.5 M Tris-HCl pH 8.9, 0.4 % SDS 
SDS-PAGE running buffer   40 mM Tris, 185 mM Glycine, 0.1 % SDS 
SDS-PAGE sample loading buffer  100 mM Tris-HCl pH 6.9, 2 % SDS,       
10 % glycerol, 5 % b mercaptoethanol,     
1 mg/ml bromophenol blue 
Stacking gel buffer  0.5 M Tris-HCl pH 6.9, 0.4 % SDS 
Trypsin solution  0.25 % Difco trypsin dissolved in PBS(A), 
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Versene  0.6 mM EDTA in PBS(A),                   
0.002 % phenol red 
10x TBE   8.9 M Tris-borate, 8.9 M boric acid,      
0.02 M EDTA (pH 8.0) 
 
 
2.2 Methods 
2.2.1 Tissue Culture 
2.2.1.1 Serial Passage of Cells 
Huh-7 cells were propagated at 37°C in Dulbeccos Modified Eagle’s Medium (DMEM) 
containing 10 % FCS, 1 % non-essential amino acids (NEAA) and 100 units / ml penicillin 
/ streptomycin. Passage of cells was carried out when cells reached 90 % confluency using 
trypsin (1:100). Cells were seeded in new flasks using the appropriate media and incubated 
in a humidified CO2 incubator at 37°C. 
 
2.2.1.2 Long Term Storage of Cells 
Aliquoted cells were stored in DMEM containing 25 % FCS and 10 % DMSO. Aliquots 
were left overnight at -70°C before being transferred to -180°C for long-term storage. 
 
2.2.1.3 Transfection of Cells with DNA 
DNA was transfected into cells using Genejuice transfection reagent (Novagen), according 
to the manufacturers instructions. 
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2.2.2 Preparation, Manipulation and Analysis of DNA 
2.2.2.1 Extraction of Plasmid DNA by Alkaline Lysis 
A single bacterial colony was inoculated in 5 ml LB broth containing ampicillin (final 
concentration 100 mg/ml). The culture was grown in a shaker (200 rpm) at 37°C for 16 hrs. 
200  ml  of  culture  was  added  to  200  ml  of  alkaline  lysis  buffer  and  mixed  gently. 
Neutralisation buffer (200 ml) was then added and the solution was again mixed gently. 
Samples were then centrifuged at 18,000 g for 2 minutes and the supernatant decanted into 
500 ml isopropanol. DNA was pelleted at 18,000 g for 1 minute and the supernatant was 
removed. The pellet was resuspended in 30 ml H2O (+ ribonuclease A, final concentration 
16  g/ml). 
 
2.2.2.2 Oligonucleotide Synthesis 
Oligonucleotides were ordered from Sigma-Genosys. 
 
2.2.2.3 Quantitation of DNA 
DNA (2  l) was added to 48 ml dH2O and the optical density (O.D.) measured using a 
BioPhotometer (Eppendorf). 
 
2.2.2.4 Restriction Enzyme Digestion of DNA 
All restriction enzyme digests of plasmid DNA were carried out at 37°C for at least 1 hr 
unless otherwise specified by the manufacturer. Ten units of each enzyme per mg DNA 
was used along with enzyme buffer in a total volume of 50 ml. Calf intestinal phosphatase 
(CIP) enzyme (10 units / mg DNA) was added to vector digestions to remove 5’ phosphates 
from the vector DNA, preventing vector self-ligation. 
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2.2.2.5 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to resolve DNA fragments produced by restriction 
enzyme digestion or PCR. Slab gels containing 1 % agarose were prepared in 0.5 % TBE 
containing ethidium bromide (1 mg/ml). DNA samples were mixed with 0.1 volumes of 
10x agarose gel loading buffer before being loaded into the wells of the gel. Gels were run 
at 100 V in 0.5x TBE buffer. On completion of electrophoresis, DNA was visualised using 
either short-wave UV light or long-wave UV light for preparative gels. A BioRad Gel Doc 
2000 imager using Quantity One software was used for analysis. 
 
2.2.2.6 Bacteriophage Lambda DNA Markers 
Digestion  of  bacteriophage  lambda  DNA  (40  mg)  with  EcoRI  and  HindIII  and  the 
appropriate buffer was carried out at 37°C for 2 hrs in a total volume of 400 ml. The 
reaction was then mixed with 1.4 ml dH2O and 200 ml 10x DNA loading dye. 
 
2.2.2.7 DNA Purification from Agarose Gels 
DNA fragments were excised from agarose gels under long-wave UV light using a sterile 
scalpel. DNA was recovered from the gel using the Qiagen gel extraction kit, following the 
manufacturers instructions. 
 
2.2.2.8 Ligation of DNA Fragments 
Using the appropriate ligation buffer, DNA fragments were mixed with T4 DNA ligase and 
incubated  overnight  at 16°C.  Following  ligation,  DNA  was  precipitated  by  adding  0.1 
volumes 3 M sodium acetate (pH 5.1) and 400 ml absolute ethanol and incubated at -20°C 
for 2 hrs. Ligated DNA was pelleted at 18,000 g for 15 mins, washed with 200 ml 70% 
ethanol, air dried and resuspended in 5 ml dH2O. 
 David A Dalrymple    Chapter 2: Materials and Methods 
 
93 
2.2.2.9 Production of Electrocompetent Cells 
LB-broth (400 ml) was inoculated with 5 ml of fresh overnight E. coli culture and grown at 
37°C to an OD600 of 0.5-0.8. The flask was chilled on ice for 30 mins and centrifuged at 
4,000 g for 5 mins at 4°C. Supernatant was removed and the pellet resuspended in 500 ml 
ice-cold dH2O. Cells were re-centrifuged as before and resuspended in 250 ml ice-cold 
dH2O.  Again cells were centrifuged as before and resuspended in 10 ml ice-cold dH2O 
(10% glycerol). Finally, cells were centrifuged as before and resuspended in 1 ml ice cold 
dH2O (10% glycerol) before being aliquoted into 70 ml aliquotes and stored for up to 6 
months at -70°C. 
 
2.2.2.10 Transformation of Electrocompetent E.coli Cells 
Ligated DNA was ethanol-precipitated and the pellet resuspended in 5 ml dH2O, 2 ml of 
which was added to 70 ml electrocompetent E.Coli in a pre-chilled 1 mm cuvette and 
electroporated (1.8 kV, 25 mF, 200 W) using a BioRad GenePulser Xcell. The E.coli were 
then resuspended in 1 ml L-broth and incubated at 37°C for 1 hr before being plated on 
LB-agar plates (+ ampicillin, final concentration 100  g/ml). Plates were then incubated 
overnight at 37°C.  
 
2.2.2.11 Storage of bacterial stocks 
Bacterial cultures were mixed with glycerol to a final concentration of 15 % and stored at   
-70°C. 
 
2.2.2.12 Sequencing 
Nucleotide  sequencing  was  carried  out  in-house,  using  an  ABI  377  DNA  sequencer. 
Sequences were analysed using Chromas (ABI) and Vector NTI (Invitrogen) software. 
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2.2.2.13 PCR Amplification of DNA 
PCR  (Mullis  et  al.,  1986)  was  carried  out  using  a  GeneAmp  PCR  machine  (Applied 
Biosystems). Briefly, cDNA or plasmid DNA was amplified using relevant primers (see 
appendix) in the presence of dNTPs, DNA polymerase and appropriate buffer according to 
the manufacturer's instructions. Cycle conditions were as follows -  
Denaturation  94ºC  3 min 
 
Denaturation  94ºC  45 sec 
Annealing  66ºC  1 min 
Elongation  72ºC  3 min 
 
Termination  72ºC  10 min 
 
2.2.2.14 Site-Directed Mutagenesis 
Site-directed mutagenesis was carried out using Quikchange (Stratagene) according to the 
manufacturer's instructions. 
 
2.2.3 RNA Electroporation 
2.2.3.1 Plasmid Linearisation for In Vitro Transcription 
Plasmid pJFH-1 (or pJFH-1 GND) was linearised by Xba I digestion and treated with 
Mung Bean nuclease to digest overhangs (30°C for 30 mins) before adding proteinase K 
(final concentration 100 mg/ml) and SDS (final concentration 0.5 %) to clean template of 
proteins and incubating at  50°C  for 30 mins. Neutral  phenol-chloroform  (100  ml) was 
added and the sample centrifuged (18,000 g for 2 mins). The aqueous (top) layer was 
placed  in  a  fresh  centrifuge  tube  and  0.1  volumes  5  M  NH4OAc  added  along  with  3 
volumes  100%  ethanol.  The  sample  was  stored  at  -20°C  for  30  mins  before  being 
centrifuged at 18,000 g for 15 mins and the pellet resuspended in 30 ml dH2O. 
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2.2.3.2 In Vitro Transcription 
In Vitro transcription was carried out using a T7 Megascript kit (Ambion) following the 
manufacturer's instructions. 
 
2.2.3.3 Cell Electroporation 
RNA (5  g) was electroporated into 1x10
7 cells using a BioRad GenePulser Xcell (250 V, 
950  mF),  following  the  manufacturers  instructions.  Cells  were  then  diluted  in  the 
appropriate media and plated out. 
 
2.2.3.4 Preparation of Total RNA 
Culture dishes (35 mm) containing electroporated cells were washed with PBSA then lysed 
using 750 ml TRIzol LS. Chloroform (200  l) was added and the sample shaken vigorously 
for 15 seconds before being incubated at RT for 15 mins. Samples were then centrifuged at 
18,000 g for 15 mins and the aqueous (upper) phase added to 500 ml isopropanol. This was 
incubated  at  RT  for  10  mins  before  being  centrifuged  at  18,000  g  for  15  mins.  After 
decanting, the pellet was washed in 75% EtOH, mixed by vortexing, and centrifuged at 
18,000 g for 10 mins. The pellet was then dried at RT and resuspended in 16 ml of "The 
RNA Storage Solution" (Ambion). RNA was stored at -70°C. 
 
2.2.3.5 First-Strand cDNA Synthesis 
The following reagents were added to a nuclease-free centrifuge tube – 1 ml gene specific 
primer (2 pmole / ml), 5 ml RNA, 1 ml 10 mM dNTPs and made up to 12 ml with sterile 
dH2O. The mixture was heated to 65°C for 5 mins and quickly chilled on ice (1 min). Upon 
brief centrifugation, the following were added – 4 ml 5x First-strand buffer, 2 ml 0.1 M 
DTT,  1  ml  Rnase-OUT.  The  contents  were  mixed  and  incubated  at  37°C  for  2  mins. 
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added  and  mixed  gently  before  incubation  at  37°C  for  50  mins.  The  reaction  was 
inactivated at 70°C for 15 mins. PCR was then carried out as in section 2.2.2.13. 
 
2.2.3.6 Real-Time PCR 
Total RNA (1  l) was reverse transcribed using random hexamers and reverse transcription 
kit (both Applied Biosystems) according to the manufacturers instructions (10 min at 25ºC, 
60  min  at  37ºC,  5  min  at  95ºC  then  cooled  to  4ºC)  with  the  reaction  composition  as 
follows:  
10 x Taqman buffer  4  l 
25 mM MgCl2   8.8  l 
10 mM dNTPs    8  l 
Random hexamers  2  l 
Rnase inhibitor  0.8  l 
Multiscribe RT  1  l 
H2O      14.4  l 
RNA      1  l     
 
Resultant cDNA  was  amplified using both  HCV-specific  (see appendix)  and GAPDH-
specific  primers  (Applied  Biosystems)  in  the  presence  of  FAM
TM  (HCV-specific)  and 
VIC®  (GAPDH-specific)  labelled  probes,  using  Applied  Biosystem’s  Fast  Universal 
Mastermix. Real-Time PCR was carried out using Applied Biosystems 7500 Fast Real-
Time PCR System using Fast Universal PCR conditions (95ºC for 20 seconds followed by 
40 cycles of 95ºC for 3 seconds and 60ºC for 30 seconds) and data analysed using Applied 
Biosystems software (SDS version 1.3.1), according to the manufacturers instructions. 
 
2.2.4 Protein Analysis 
2.2.4.1 Crude Protein Expression in Bacteria 
A single bacterial colony was inoculated in 5 ml L-broth (+ ampicillin, final concentration 
100   g/ml)  and  incubated  at  37°C  overnight.  The  next  day  1.5  ml  of  L-broth  was 
inoculated with overnight culture (1:50). The culture was grown at 37°C for 2.5 hrs before 
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16 hrs at 37°C before being spun (4,000 g for 2 mins) and the pellet resuspended in 250 ml 
PBS. Samples were freeze-thawed, sonicated and centrifuged (18,000 g for 15 mins) and 
the supernatant (soluble protein) was then subjected to SDS-PAGE or used in ELISA. 
 
2.2.4.2 Purification of GST-tagged Proteins 
L-broth  (400  ml)  (+  ampicillin,  final  concentration  100   g/ml)  was  inoculated  with 
overnight bacterial culture (1:50) and incubated at 37°C for 3 hrs. IPTG was then added 
(final concentration 0.1 mM) and the culture was incubated for a further 4 hrs at 37°C. The 
culture was then centrifuged (4,000 g for 5 mins) and the pellet resuspended in 20 ml 
PBSA  (+  protease  inhibitors 1:100). Samples were  freeze-thawed twice then sonicated 
before 10 % Triton-100 was added (final concentration 1 %). This was then incubated at 
RT for 30 mins before being centrifuged (18,000 g for 10 mins). One millilitre of slurry 
(equilibrated  in  PBS)  of  50  %  glutathione-agarose  beads  was  incubated  with  the 
supernatant at RT for 2 hrs before being centrifuged (100 g for 1 min). Supernatant was 
stored for analysis and the pellet was washed three times in PBS with supernatant being 
collected for analysis after each wash. Bound protein was then eluted using PBS containing 
15 mM reduced glutathione. A fraction of each sample was run on a polyacrylamide gel 
followed by coomassie staining. Clean samples containing the desired protein were then 
assayed for protein concentration and used in ELISA. 
 
2.2.4.3 Denaturing Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Sample loading buffer was added to protein samples (1:1 v/v) before being denatured by 
boiling. Resolving gels (10 %) were used to analyse proteins [resolving gel buffer (1.5 ml), 
dH20 (2.5 ml), 30% Acrylamide / bis solution 37.5:1 (2 ml), 25 % w/v APS (20 ml) and 
temed (15 ml)]. Gels were poured and levelled using 1 ml dH20. When set, gels were 
overlayed  with  4  %  stacking  gel  [stacking  gel  buffer  (1  ml),  dH20  (2.5  ml),  30% 
Acrylamide / bis solution 37.5:1 (0.532 ml), 25 % APS (20 ml) and temed (15 ml)] before 
placing a comb in the overlay. Gels were placed in one times running buffer and samples 
loaded into wells. Gels were run for 3 hrs at 80 V or until the loading dye ran off the 
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the  manufacturer's  instructions.  Gels  were  then  either  western  blotted  or  stained  with 
coomassie stain. 
 
2.2.4.4 Western Immuno-blotting of Polyacrylamide Gels 
Proteins  separated  on  polyacrylamide  gels  were  transferred  to  Hybond
TM-ECL
TM 
nitrocellulose membranes essentially as described (Towbin et al., 1979) using a BioRad 
transblot SD blotting device. Transfer was carried out at 20 V for 20 mins and membranes 
were incubated in PBST containing 5 % milk powder to block non-specific binding of 
antibody.  Membranes  were  washed  three  times  in  PBST  at  RT  and  probed  with  the 
appropriate antibody (diluted in PBSA) for 2 hrs at RT. The membrane was again washed 
three times with PBST and incubated with the appropriate secondary antibody conjugated 
to HRP for 2 hrs at RT. Finally the membrane was washed three times in PBST and bound 
antibody was detected using Enhanced Chemiluminescence Reagents I and II (ECL I & II) 
(Amersham Pharmacia Biotech) in equal ratio. Bands were visualised by autoradiography 
using Kodak X-OMAT film and a Konica SRX-101-A film processor. 
2.2.4.5 Coomassie Staining 
Proteins separated on a polyacrylamide gel were stained with Coomassie Brilliant Blue for 
30 mins at RT then washed with coomassie destain at RT until background staining was 
removed. Protein bands were viewed using a lightbox. 
 
2.2.4.6 Coomassie Protein Assay Reagent 
Purified protein (20  l) / BSA standard (range 0.125 - 1.5 mg/ml) was added to 980 ml of 
coomassie  reagent  (Pierce)  and  absorbance  measured  at  595  nm  using  a  Genios  plate 
reader (Tecan). A standard curve was then prepared by plotting each BSA standard against 
its concentration in mg/ml. 
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2.2.4.7 Enzyme-Linked Immunosorbent Assay 
Immulon II flat-bottom plates were coated with protein (in PBSA) and incubated at RT 
overnight. Wells were blocked with PBST (2% milk powder) for 2 hrs at RT and washed 
three times with PBST before addition of ligand (in PBSA) and incubation for 2 hrs at RT. 
Plates were washed three times with PBST and primary antibody added for 1 hr at RT 
before being washed three times with PBST again. HRP conjugated secondary antibody 
was then added (1 hr RT) and plates again washed three times with PBST. TMB (100  l) 
was added for 10 mins at RT (in dark) before the reaction was stopped using 100 ml 0.5 M 
H2SO4. Absorbance was then measured at 450 nm using a Genios plate reader (Tecan). 
 
2.2.4.8 Indirect Immunofluorescence 
Cells  (grown  on  13  mm  coverslips)  were  washed  three  times  with  PBS  and  fixed  in 
methanol at -20°C for 30 mins. Coverslips were then washed three times with PBSA and 
incubated with primary antibody (diluted in PBST) for 1 hr at RT. Coverslips were again 
washed three times with PBST and incubated with the relevant secondary antibody for 1 hr 
at RT. Finally, coverslips were washed in PBS twice and dH2O once before being mounted 
downwards on microscope slides using citifluor. Cells were viewed under UV light using 
LSM510 software and a ZEISS confocal microscope. 
 
2.2.4.9 Fluorescence Assay 
Crude  cell  lysate  was  serially  diluted  in  PBSA  and  added  to  a  black  96-well  plate. 
Fluorescence was measured at 485 nm using a Genios plate reader (Tecan).  
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3.1 Introduction 
HCV core protein associates with lipid droplets in the cytoplasm of cells (Moradpour et al., 
1996). Using Yeast-2-hybrid screening, an interaction between HCV core protein and the 
cellular  DEAD-box  RNA  helicase  DDX3  has  been  reported  by  3  independent  groups 
(Mamiya and Worman, 1999, Owsianka and Patel, 1999, You et al., 1999). Comparative 
proteomic  analysis  of  lipid  droplet  proteins  in  core-expressing  and  non-expressing 
hepatoma cell lines also indicated that DDX3 associates with lipid droplets only in the 
presence of HCV core protein (Sato et al., 2006). In order to understand the significance of 
core-DDX3 interaction in terms of virus replication and pathogenesis, the HCV life cycle 
must be studied in a system where the interaction between core and DDX3 is inhibited. 
One approach would be to knockdown DDX3 expression by siRNA. However, it has been 
reported that knockdown of mouse DDX3 in NIH-3T3 cells leads to premature entry into 
S-phase (Chang et al., 2006). Assuming the same is true in hepatocytes, this may offset the 
virus life cycle. Another approach is to mutate residues of core, which are critical for the 
interaction  with  DDX3,  thus  disrupting  core-DDX3  interaction.  This  approach  would 
ensure the normal cellular role of DDX3 was not affected. 
Previously, it has been reported that amino acids 1-59 of core protein are involved in the 
interaction with DDX3 (Owsianka and Patel, 1999). In order to discover critical residues 
within this region, a library of core1-59 (HCV core residues 1-59) mutants was constructed 
by  error-prone  PCR.  The  mutated  sequences  were  cloned  downstream  of  Green 
Fluorescent Protein (GFP) and analysed by GFP-display (Aoki et al., 2000b) to confirm 
the presence of mutations. GFP-display is a gel electrophoresis technique for detecting 
single amino acid mutations in a polypeptide. GFP is stable in the presence of protein 
denaturing  solutions  such  as  8  M  urea  and  1%  sodium  dodecyl  sulphate  (SDS)  and 
therefore does not lose its fluorescence in SDS-PAGE (Ward, 1998). This allows GFP to 
act as a chemical label attached to a polyprotein. It is known that the migration of a protein 
in a urea-containing SDS-PAGE gel can vary due to the introduction of even a single 
amino acid substitution mutation. This is believed to be due to the interplay between urea, 
dodecyl ions and their strength of binding to different amino acids (Aoki et al., 2000b, 
Aoki et al., 2002). If the protein to be mutated is fused in-frame to GFP then the fusion 
proteins carrying mutations can be readily identified in urea/SDS-PAGE gel simply by 
exposing the gel under UV light and examining the protein migration profiles. Here, the 
intention  was  to  rapidly  screen  the  library  to  identify  clones  carrying  amino  acid 
substitutions in core and transfer mutated sequences into a full-length core background in a David A Dalrymple    Chapter 3: Results 
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mammalian expression vector for further analysis. Unfortunately, the GFP-display assay 
was not reproducible in my hands and failed to generate meaningful results. Therefore, a 
high  throughput  assay  was  designed  with  a  view  to  rapidly  screen  large  numbers  of 
substitution mutants of HCV core1-59. This assay was performed in an ELISA format in 
which a soluble GST-DDX3 fusion protein, previously used to delineate the domain of 
DDX3 interacting with core (Owsianka and Patel, 1999), was bound to the ELISA plate. 
The N-terminal 59 amino acids of core protein (containing single or multiple amino acid 
substitutions generated by error-prone PCR) was cloned downstream of green fluorescent 
protein (GFP) in a bacterial expression vector (pKK223-3). The mutants were analysed for 
their ability to bind DDX3. Bound mutants were detected using a rabbit polyclonal anti-
GFP  antiserum  in  order  to  rule  out  false  negatives  occurring  due  to  core  antibody 
recognition sites being mutated during error-prone PCR. Mutants unable to bind DDX3 
were then transferred into an expression vector (pcDNA 3.1(+)zeo) containing core, E1 
and E2 sequence (derived from HCV strain H77c). Mutant core protein was then studied in 
a  transient  transfection  system  and  abolishment  of  the  interaction  with  cellular  DDX3 
confirmed  by  immunofluorescence  in  transfected  cells.  Upon  nucleotide  sequencing  of 
core mutants unable to bind DDX3, systematic reversal of mutations to wild type lead to 
the  identification  of  a  13  amino  acid  region  containing  essential  residues.  Sequential 
alanine substitutions were then introduced across this region in wild type pC-E1-E2 to 
identify individual residues of core protein required for the interaction between core and 
DDX3.   David A Dalrymple    Chapter 3: Results 
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3.2 Results 
3.2.1 Cloning of Core1-59 into GFP Expressing pKK223-3 Vector 
Bacterial  expression  vector  pKK223-3  (Amersham  Pharmacia  Biotech,  Sweden), 
containing the B domain of Staphylococcus aureus protein A (SpAb) fused to GFP, was 
kindly donated by Takashi Aoki (Department of Biochemistry, Health Sciences University 
of Hokkaido, Japan) (Aoki et al., 2002). The construct was digested with HindIII / PstI, 
and the SpAb fragment removed and replaced by a HindIII / PstI digested PCR product of 
nucleotides  1-177,  encoding  amino  acids  1-59,  of  HCV  core  (strain  H77c).  This  was 
generated by PCR using template pCS2 (an expression plasmid containing core, E1 and E2 
sequence  derived  from  H77c)  and  primers  AP233 
(AAACTGCAGCACGATAATACCATGGGC, PstI site underlined, core initiation codon 
in bold) and AP234 (CCCAAGCTTCTATTAGGGGATAGGCTGACGTCTACC, HindIII 
site  underlinded)  (Fig.  3.1).  Correct  sequence  of  the  PCR  product  was  confirmed  by 
nucleotide  sequence  analysis.  Crude  bacterial  lysates  containing  GFP-Core1-59  fusions 
(GFP fused to amino acids 1-59 of HCV core) were produced (see methods), and the 
presence of  GFP-Core1-59 confirmed by exposure of the lysates to UV light to detect 
fluorescence. 
  
3.2.2 Construction of Mutant GFP-Core1-59 Library 
To construct a library of mutant core1-59 proteins, error-prone PCR (EP-PCR) was used. 
This method is ideal for introducing random mutations into a defined segment of DNA. 
The  low  fidelity  of  Taq  DNA  polymerase  means  this  enzyme  can  misincorporate 
nucleotides with a frequency as high as 0.02% per position (Eckert and Kunkel, 1991). The 
fidelity of Taq can be further decreased by differing the relative dNTP concentrations, 
using a high Mg
2+ concentration and including Mn
2+ in the reaction (Leung et al., 1989). 
EP-PCR can have various outcomes including no nucleotide substitutions in the product, 
silent substitutions (a nucleotide substitution occurs which does not alter the amino acid), 
or amino acid substitutions (a nucleotide substitution occurs which either alters the amino 
acid or introduces a premature stop codon). Of these 4 possible outcomes from EP-PCR, 
the PCR products of interest in this project are those in which a nucleotide substitution 
results in an amino acid change. Using primers AP233 and AP234 and pCS2 as a template David A Dalrymple    Chapter 3: Results 
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     PstI                                                 Start 
AP233 – 5’ AAA CTG CAG CAC GAT AAT ACC ATG GGC 3’ 
 
        HindIII       Stop Stop 
AP234 – 5’ CCC AAG CTT CTA TTA GGG GAT AGG CTG ACG TCT ACC 3’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Construction of pGFP-core1-59. Vector pKK223-3 containing GFP sequence 
upstream of the B domain of Staphylococcus aureus protein A (SpAb) (Aoki et al., 2002), 
was  digested  with  PstI  and  HindIII  to  release  and  replace  SpAb  with  PCR  generated 
nucleotides 1-177 of HCV genotype 1a H77c strain (encoding amino acids 1-59 of core 
sequence),  followed  by  two  stop  codons.  A)  AP233  and  AP234  primer  sequences. 
Restriction sites PstI and HindIII are underlined, core protein start codon shown in bold 
and stop codons in italics. B) Schematic diagram of cloning strategy. 
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as before (section 3.2.1), EP-PCR was performed to generate mutant core1-59 molecules. 
These products were then inserted into the cloning vector pGEM-T Easy for sequencing. 
Nucleotide sequence analysis of a subset of these mutants showed that between 1 and 3 
nucleotide mutations occurred per PCR molecule, translating to 0-3 amino acid changes 
per core1-59 molecule, some of which were stop codons (Fig. 3.2). These molecules were 
then released from pGEM-T Easy by digestion with HindIII and PstI and sub-cloned into 
pGFP-SpAb (after removal of the SpAb fragment). 
 
3.2.3 GFP-Display Assay 
Constructs pGFP-SpAb and pGFP-SpAb (N214D) were a kind gift from T. Aoki. Fusion 
proteins expressed from these constructs in bacteria have previously been shown to migrate 
at different rates on urea / SDS-PAGE gels (Aoki et al., 2002). Inconsistent results meant 
we were unsuccessful in our attempts to reproduce these results. Constructs were expressed 
in bacteria and crude bacterial lysate fractionated on a 12% polyacrylamide gel containing 
0.2% SDS and 6 M urea. Fluorescent proteins were visualised by exposing the gel under 
UV light. Results were inconsistent, with differences in migration seen on some occasions 
but  not  on  others,  although  the  reason  for  this  is  unclear  (Fig.  3.3).  Despite  this,  we 
attempted to detect differences in migration between our wild type and mutant GFP-core1-
59 fusion proteins. Crude bacterial cell lysates were separated on a 12% polyacrylamide gel, 
containing 0.2% SDS and 6 M urea. Unfortunately, differences in migration patterns were 
not detected with mutant proteins (Fig. 3.4). The reason for this was unknown although it 
is possible that certain amino acid changes have more effect on migration compared to 
others, depending on their isoelectric point. Multiple amino acid changes may also cancel 
out the differences in isoelectric points of individual mutations. 
 
3.2.4 Core – DDX3 ELISA Design 
As the GFP-display assay was not consistently reproducible it was decided to design a 
rapid screening assay that could make use of the pre-made GFP-core1-59 mutant library to 
identify mutants of interest. This assay was in ELISA format, in which a soluble GST-
DDX3C fusion protein (GST fused to residues 409-662 of DDX3), previously used to 
delineate the domain of DDX3 interacting with core (Owsianka and Patel, 1999) was David A Dalrymple    Chapter 3: Results 
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MUTANT        NUCLEOTIDE CHANGES      AMINO ACID CHANGES          
 
  1  170(A-T)         Q57L 
               
2  26(G-A)           R9K 
           101(T-G)         V34G 
          170(A-G)         Q57R 
                                             
  3  46(A-T)         N16Y 
                                        
  4  40(A-G)         N14D 
98(G-T)         G33V 
110(T-A)         L37Stop 
                                       
  5  34(A-T)         K12Stop 
                                         
  6  16(A-G)           K6E 
23(A-T)           Q8L 
                                                    
  7  37(C-T)         R13C 
41(A-C)         N14T 
                                         
  8  107(T-A)         L36Stop 
                          
  9  102(T-A)         No Change 
                                             
  10    65(T-G)         V22G 
109(T-A)         L37M 
130(T-A)         L44M 
 
 
 
 
 
 
 
 
Figure 3.2: Identification of mutations in an initial subset of core1-59
 mutants. Error-prone 
PCR was shown to introduce between 1 and 3 nucleotide changes per PCR molecule. These 
mutations translated to 0 to 3 amino acid changes per molecule or into premature stop codons. David A Dalrymple    Chapter 3: Results 
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Figure 3.3: Detection of GFP-fused SpAb in bacterial cell lysates. Crude 
bacterial lysates containing wild type or mutant GFP-SpAb were fractionated 
on  a  12%  polyacrylamide  gel  containing  0.2%  SDS  and  6  M  urea  on  2 
separate experiments. GFP-fused proteins were detected by viewing gel under 
UV light. The two gels show that the results were not reproducible in my 
hands.
GFP-SpAb GFP-SpAb
(N214D)
GFP-SpAb GFP-SpAb
(N214D)
GFP-SpAb GFP-SpAb
(N214D)
GFP-SpAb GFP-SpAb
(N214D)David A Dalrymple    Chapter 3: Results 
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Figure 3.4: Detection of GFP-fused core1-59. Crude bacterial lysates containing wild 
type or mutant GFP- core1-59 were separated on a 12% polyacrylamide gel containing 
0.2% SDS and 6 M urea. GFP-fused proteins were detected by viewing gel under UV 
light.  
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bound to the wells of an ELISA plate. Crude bacterial cell lysate containing GFP-core1-59 
mutants, after normalising for GFP fluorescence, was then incubated with the GST-DDX3. 
Bound GFP-core1-59 was detected with rabbit polyclonal anti-GFP antiserum followed by 
protein  A-HRP.  HRP  enzymatic  activity  was  then  measured  upon  addition  of  TMB 
substrate (see methods). 
 
3.2.5 Purification of GST-DDX3 fusion protein 
GST-DDX3C-expressing E. coli were lysed by freeze-thaw and sonication and incubated 
with glutathione-agarose beads. Unbound protein was washed off and bound GST-DDX3C 
eluted from the beads using reduced glutathione. Most GST-DDX3C remained bound to 
the beads but sufficient protein was eluted for use in ELISA. As shown in Fig. 3.5, GST-
DDX3C fusion protein of expected molecular weight was expressed at least partially in a 
soluble  form  and  could  be  affinity-purified  using  glutathione  agarose.  By  Coomassie 
protein assay it was calculated that 0.3 mg/ml purified soluble GST-DDX3C was expressed.  
 
3.2.6 Construction of GFP as a Negative Control  
To use as a negative control for our ELISA, GFP alone was expressed in E. coli. Using 
primers quickchange 1 (GATGGACTATACAAACTGTAGCACGATAATACCATG) and 
quickchange 2 (CATGGTATTATCGTGCTACAGTTTGTATAGTTCATC), site-directed 
mutagenesis was carried out on pGFP-Core1-59 in order to introduce a stop codon (CAG ® 
TAG) in the PstI site between the GFP and core1-59 sequences (red nucleotides indicate 
site-directed  substitution;  see  Fig.  3.1).  The  substitution  was  confirmed  by  nucleotide 
sequence analysis.  
 
3.2.7 Recognition of Bacterially Expressed Proteins by Antisera 
The ELISA assay designed required bacterially expressed GST-DDX3C to be bound to 
wells of an ELISA plate followed by incubation with crude bacterial lysate containing GFP 
or GFP-Core1-59 fusion proteins. GFP protein binding GST-DDX3C would then be detected  David A Dalrymple    Chapter 3: Results 
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A 
B 
Figure 3.5: Purification of GST-DDX3C. (A) Schematic diagram of GST-DDX3C in the 
pGEX-6P-3 vector (Pharmacia) used for ELISA. The GST-coding sequence is not drawn to 
scale. (B) Coomassie brilliant blue-stained SDS-PAGE (10%) of amino acids 409-622 of 
DDX3  (fused  to  GST).  E.  coli  expressing  GST-DDX3  were  lysed  by  freeze-thaw  and 
sonication  before  addition  of  glutathione-agarose  beads  to  bind  GST-DDX3C.  Samples 
were  then  washed  in  PBS  and  GST-DDX3C  eluted  from  glutathione-agarose  beads  by  
addition of reduced glutathione. Samples harvested from each stage were analysed by SDS-
PAGE and Coomassie brilliant blue staining. (M- Rainbow markers, T- Total cell lysate, W- 
Wash, E- Elution, B- Beads). 
GST-DDX3C 
pGEX-6P3 
  GST                 DDX3C (409-622) 
14.3kDa 
21.5kDa 
    30kDa 
   46kDa 
   66kDa 
97.4kDa 
220kDa 
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by a combination of rabbit polyclonal anti-GFP antiserum followed by protein A-HRP. 
TMB substrate is then added and the enzymatic reaction stopped using H2SO4 after an 
appropriate  time.  HRP  enzymatic  activity  (indicative  of  GFP-core1-59  binding  to  GST-
DDX3) would then be measured by optical density. A number of validation experiments 
were initially carried out in order to test the specificity of the ELISA. Antibodies were 
tested for their affinity and specificity to bacterially expressed fusion proteins bound to 
Immulon II ELISA plates. Either GST-DDX3C or crude bacterial lysate containing GFP or 
GFP-core1-59  was  bound  to  Immulon  II  plates  overnight  and  probed  with  either  rabbit 
polyclonal anti-GFP, anti-core (R308) or anti-DDX3 (R648) antisera followed by protein 
A-HRP and then incubated with TMB substrate. Rabbit polyclonal antisera against both 
GFP and HCV core (R308) recognised GFP-core1-59, indicating that the fusion of GFP and 
core1-59 did not affect antibody recognition sites. Anti-GFP, and not anti-core, was able to 
detect the negative control GFP, while only rabbit polyclonal anti-DDX3 antiserum (R648) 
recognised GST-DDX3C (Fig. 3.6).  
 
3.2.8 Optimization of Protein Concentration for ELISA 
Using crude bacterial lysate as a source  of GFP-Core1-59 meant it was not  possible to 
quantify the amount of ligand (GFP or GFP-core1-59) present in each sample by standard 
Coomassie  protein  assay  since  other  bacterial  proteins  would  affect  quantification.  To 
ensure equal amounts of each ligand were used in our assay we normalised our lysates 
based on GFP fluorescence. Varying dilutions of crude bacterial lysate were analysed by 
optical  density  and  fluorescence  plots  calculated  (Fig.  3.7).  In  order  to  find  optimal 
concentrations  of  both  DDX3C  and  ligand  for  ELISA,  titrations  were  carried  out  on 
Immulon II plates. Concentration of GST-DDX3C (coated on plate) was serially diluted 3-
fold from left to right across the plate while GFP-Core1-59 concentration remained the same 
for each well (20,000 Relative Fluorescence Units, RFU). Bound protein was detected 
using  rabbit  polyclonal  anti-GFP  antiserum  (1:5,000)  followed  by  protein  A-HRP 
(1:10,000). ELISA plates were then incubated with TMB substrate, the reaction stopped 
with  H2SO4  after  an  appropriate  time,  and  absorbance  levels  read  by  optical  density. 
Results showed that 0.67  g of GST-DDX3C/well was optimal for the ELISA (Fig. 3.8a).  
In order to find the optimal concentration of GFP/GFP-core1-59, a similar experiment was 
carried  out  in  which  crude  bacterial  lysates  were  titrated  across  GST-DDX3C  coated 
ELISA plates (GST-DDX3C was used at its previously optimized concentration of 0.67 David A Dalrymple    Chapter 3: Results 
112 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Antibody recognition of bacterially expressed fusion proteins. Proteins to be 
used in the ELISA were analysed for their ability to be recognised by various antibodies. 
GST-DDX3C or crude bacterial lysate containing either GFP or GFP-core1-59 was bound 
to Immulon II plates and incubated with anti-DDX3 R648, anti-GFP or anti-core R308 
antiserum, followed by protein A-HRP. TMB was added and HRP enzymatic activity 
measured  by  optical  density  at  450  nm.  Polyclonal  anti-DDX3  antibody  detected 
DDX3C while polyclonal anti-GFP and polyclonal anti-core antibodies did not. Anti-
GFP antibody efficiently detected both GFP and GFP-core1-59 while only anti-GFP and 
not anti-core antibody detected GFP. 
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Figure 3.7: Relative  fluorescence  intensity of  GFP-core1-59  mutants. Increasing 
concentrations (1, 5 or 10  l in 100  l PBS) of crude bacterial lysates containing 
either wild type, mutant 1 or mutant 2 GFP- core1-59 protein were analysed for GFP 
fluorescence levels by optical density.  Relative fluorescence units were used to 
normalise  lysates  before  use  in  ELISA.  All  samples  were  normalised  to  a 
fluorescence of 20,000 RFU. A) GFP- core1-59, B) GFP- core1-59 mutant 1, C) GFP- 
core1-59 mutant 2. 
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Figure 3.8: Optimization of GST-DDX3C/GFP-core1-59 levels for ELISA. A) Wells of an 
Immulon II plate were coated with a series of 3-fold diluted GST-DDX3C from left to 
right across the plate. Crude bacterial lysate containing GFP- core1-59 was incubated with 
the bound GST-DDX3C at a constant RFU of 20,000. Upon incubation firstly with anti-
GFP  antibody,  then  protein  A-HRP  followed  by  TMB  substrate,  optical  density  was 
calculated (see methods). Results suggest that 0.67 mg of GST-DDX3C was optimal for 
the assay. B) Wells of an Immulon II plate were coated with dilutions of crude bacterial 
lysate containing either GFP or GFP- core1-59 (normalised for GFP content). Optimized 
levels of GST-DDX3 (0.67 mg/well, Fig. 3.8A) were incubated with bound crude lysate. 
Upon incubation firstly with anti-GFP antibody, then protein A-HRP followed by TMB 
substrate, optical density was calculated. Results showed that relative fluorescence units 
of 20,000 gave optimal contrast between GFP and GFP- core1-59. 
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 g/well). Protein bound to GST-DDX3C was detected using rabbit polyclonal anti-GFP 
antiserum followed by protein A-HRP. ELISA were carried out as described above and 
absorbance levels read by optical density as before. From this titration it was confirmed 
that  the  concentration  of  GFP-core1-59  used  in  our  previous  GST-DDX3C  titration 
(fluorescence = 20,000 RFU) gave optimal contrast between GFP-core1-59 and GFP (Fig. 
3.8b).  
 
3.2.9 Identification of GFP-core1-59
 Mutants Unable to Bind DDX3C  
Of 130 mutants tested by ELISA, 9 were found to have less than 50% absorbance levels 
compared  to  that  of  wild-type  GFP-Core1-59,  indicating  a  reduced  affinity  for  GST-
DDX3C, whereas other mutants bound GST-DDX3C efficiently (Fig. 3.9). In order to 
confirm these results, all 9 mutants were individually subcloned into the HCV strain H77c 
encoded core, E1 and E2 background in a mammalian expression vector pcDNA3.1 (+)Zeo 
(Fig.  3.10).  This  was  achieved  using  a  triple  fragment  cloning  strategy.  Briefly,  to 
overcome restriction site problems, pC-E1-E2 was digested with PstI and ClaI to provide 
the vector backbone and 3’ end of core-E1-E2 insert. Similarly, pC-E1-E2 was digested 
with XhoI and ClaI, producing a 195 bp insert, which, together with the vector backbone 
fragment, was ligated to mutant core1-59 sequence (digested with PstI and XhoI). These 
mutant pC-E1-E2 constructs were then analysed in a transient transfection system.  
 
3.2.10  Identification  of  Core  Residues  Required  For  Interaction 
With Cellular DDX3 
Wild type or mutant pC-E1-E2 was transfected into 95% confluent naïve Huh7 cells on 
coverslips using GeneJuice Transfection Reagent (Novagen). Two days post-transfection, 
cells were fixed in methanol, permeablised with PBS-T and probed for core and E2 by 
immunofluorescence  to  confirm  that  all  transfections  had  been  efficient  and  that  viral 
proteins  were  being  expressed  in  transfected  cells  (Fig.  3.11).  E2  was  distributed 
throughout  the  cytoplasm  while  core  was  seen  in  typical  punctate  cytoplasmic  spots.  
Initial experiments to identify core mutants unable to interact with DDX3 relied on crude 
bacterial lysates containing core residues 1-59 fused to GFP and affinity purified DDX3 C- 
terminus fused to GST. To investigate the interaction between full-length HCV core David A Dalrymple    Chapter 3: Results 
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Figure  3.9:  Reactivity  of  GFP-  core1-59  mutants  to  GST-DDX3C.  Crude 
bacterial  extracts  expressing  GFP-  core1-59  mutants  (normalised  to  20,000 
RFU) were added to wells of Immulon II plates coated with 0.67  g GST-
DDX3C. Bound protein was detected using anti-GFP antiserum followed by 
protein A- HRP. Each mutant was tested in triplicate and error bars shown. A) 
Mutants  binding  GST-DDX3C.  B)  Mutants  unable  to  bind  GST-DDX3C. 
Sample names represent mutant sample number. 
B 
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Figure  3.10:  Cloning  strategy  for  insertion  of  mutations  into  core-E1-E2  expressing 
vector. Single fragment cloning of mutant core1-59 was not possible due to two other XhoI 
sites (red) in  pcDNA3.1 (+)Zeo CE1E2. A) Mutant  core  sequence was digested from 
pKK223-3 GFP- core1-59 using restriction enzymes PstI and XhoI. B) pcDNA3.1 (+)Zeo 
containing  core,  E1  and  E2  sequence  was  digested  with  XhoI  and  ClaI  to  produce 
fragment 2, and, in a separate reaction, digested with PstI and ClaI to produce fragment 3 
(including the vector backbone). C) Digested fragments 2, 3 and mutant core1-59 were then 
ligated together to produce mutant core-E1-E2 in the pcDNA3.1 (+)Zeo background.  
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Figure 3.11: Expression and localisation of transiently transfected HCV 
structural proteins core and E2. Mutant core sequences of interest were 
cloned  into  core-E1-E2  expression  plasmid  pC-E1-E2  and  transiently 
transfected  into  Huh7  cells  (see  methods).  Forty-eight  hrs  post-
transfection, cells were fixed in methanol, permeablised with PBS-T and 
probed  with  rabbit  polyclonal  core  antiserum  (R308)  and  mouse 
monoclonal anti-E2 antibody (AP33), followed by anti-rabbit FITC and 
anti-mouse Cy5, respectively.
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mutants  and  cellular  DDX3,  cells  transfected  with  mutant  pC-E1-E2  were  fixed  in 
methanol  48  hrs  post-transfection,  permeablised  with  PBS-T  and  analysed  by 
immunofluorescence for core and DDX3. The results obtained were in accordance with the 
data from our initial ELISA screen in that all 9 mutant core proteins failed to interact with 
DDX3 in the way wild-type core did (Fig. 3.12). Instead, DDX3 was seen to have a typical 
diffuse  cytoplasmic  localisation  similar  to  that  in  non-transfected  cells.  Nucleotide 
sequence analysis was carried out on these 9 mutants and each was found to have between 
1 and 4 amino acid substitutions (Fig 3.13). Of interest, mutant 90 had only one amino acid 
substitution (I30N) indicating this residue must have a negative effect on the interaction of 
core  with  DDX3.  It  was  also  noted  that  all  9  mutants  had  at  least  one  amino  acid 
substitution  in the region spanning amino acids 24-36,  indicating that this region may 
harbour amino acids that are critical for the core-DDX3 interaction. To test this hypothesis, 
site-directed mutagenesis was carried out to revert any mutation out-with this 13 amino 
acid region back to wild type. As previously stated, site-directed mutagenesis requires PCR 
amplification  of  the  total  plasmid,  introducing  the  possibility  of  random  PCR  errors 
throughout the synthesised product. To overcome this possibility, site-directed mutagenesis 
was carried out on the original pGFP-core1-59 mutant constructs. Primers were designed 
which would individually substitute each “out-lying” mutation for wild type. Each “out-
lying” mutation was systematically reverted to wild type by site-directed mutagenesis and 
substitutions  confirmed  by  nucleotide  sequence  analysis.  These  new  mutant  core1-59 
fragments were then sub-cloned into pC-E1-E2 as previously described (section 3.2.9).  
These new mutants (designated “mutant Xb”) were transiently transfected into Huh7 cells 
as before. Two days post-transfection, cells were fixed in methanol and permeablised with 
PBS-T. To investigate the interaction between these mutants and cellular DDX3, cells were 
probed by immunofluorescence for core and DDX3. As with the original 9 mutants unable 
to interact with DDX3, none of these new core mutants interacted with DDX3 (Fig. 3.14), 
indicating that this 13 amino acid region of core is involved in the interaction between core 
and DDX3. As expected, all transfected cells expressed HCV viral protein E2 (data not 
shown). 
To determine which residues in this 13 amino acid region were essential for the interaction 
between  core and DDX3, alanine-scanning  mutagenesis across amino  acids  24-36 was 
performed, in which each amino acid in this region was sequentially mutated to alanine. 
Alanine was chosen as the replacement residue as it is the most common amino acid in 
proteins (Klapper, 1977). This non-polar, hydrophobic amino acid (Fig. 3.15) is the second 
smallest of all amino acids (behind glycine) and does not impose any unwanted steric David A Dalrymple    Chapter 3: Results 
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Figure 3.12: Analysis of the interaction  between mutant core proteins 
and  DDX3.  Mutant  core  sequences  of  interest  cloned  into  core-E1-E2 
expression plasmid pC-E1-E2 were transiently transfected into Huh7 cells 
(see  methods).  Forty-eight  hrs  post-transfection,  cells  were  fixed  in 
methanol, permeablised with PBS-T and probed with rabbit polyclonal 
core  antiserum  (R308)  and  mouse  monoclonal  anti-DDX3  (AO196), 
followed by anti-rabbit FITC and anti-mouse Cy5, respectively.David A Dalrymple    Chapter 3: Results 
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aa No.    1                                                                   59 
Core    MSTNPKPQRK  TKRNTNRRPQ  DVKFPGGGQI  VGGVYLLPRR  GPRLGVRATR  KTSERSQPR 
Mutant 25  --------K-  ----------  ----------  ---G------  ----------  ------R—- 
Mutant 36  ----------  ----------  ----------  ---D-----W  ----------  -S-----—- 
Mutant 90  ----------  ----------  ---------N  ----------  ----------  -------—- 
Mutant 99  ----------  ----------  -D--------  ---D------  ----------  -------—- 
Mutant 110  ----------  ----------  ---------N  ----------  --S-------  -------—- 
Mutant 111  -----E----  ----------  ----------  ----N-----  ----------  -------—- 
Mutant 115  ---------D  -E--------  ---S------  ----------  ----------  -------—- 
Mutant 125  ----------  -----I----  --------R-  ----N-----  ----------  ------R—- 
Mutant 126  -------H--  ----------  -----D---N  -----W----  ----------  -------—- 
 
Figure 3.13: Nucleotide sequence analysis of core mutants unable to interact with cellular DDX3. The 9 core mutants 
unable to bind DDX3 both in ELISA and transient transfection assay were analysed by nucleotide sequencing.  Amino 
acid substitutions found in these 9 mutants are shown (red). The green box denotes a region in which all 9 HCV core 
mutants unable to bind DDX3 had at least one mutation. In order to confirm if the substitutions within this central region 
were  responsible  for  abolishing  the  core-DDX3  interaction,  site-directed  mutagenesis  was  used  to  revert  out-lying 
substitutions (red) back to wild type. These new core mutants (designated “mutant Xb”), were then analysed for core-
DDX3 interaction by immunofluorescence in the transient transfection assay as described in section 3.2.9. 
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Figure 3.14: Analysis of the interaction between mutant core proteins and 
DDX3. Mutant core proteins constructed by site-directed mutagenesis were 
transiently transfected into Huh7 cells. Forty-eight hrs  post-transfection, 
cells were fixed in methanol, permeablised with PBS-T and probed with 
rabbit  polyclonal  core  antiserum  (R308)  and  mouse  monoclonal  anti-
DDX3 antibody (AO196), followed by anti-rabbit FITC and  anti-mouse 
Cy5, respectively.
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Figure  3.15: Structure  of  alanine.  The  shaded  area  shows  the  basic 
amino  acid  backbone  common  to  all  amino  acids  (amino  group, 
carboxyl  group, hydrogen atom and a-carbon  (green))  while  the  side 
chain specific to alanine (CH3) is attached to the a-carbon by the ß-
carbon (red).David A Dalrymple    Chapter 3: Results 
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effects, unlike those with bulky side chains such as tryptophan. The elimination of side 
chains  beyond  the  β-carbon  (as  in  alanine)  allows  a  more  informative  analysis  of  the 
importance  of  specific  side  chains,  thus  reducing  the  functional  comparisons  required 
between  mutant  and  wild-type  protein.  For  these  reasons,  alanine  was  chosen  as  the 
replacement residue for mutagenesis.  To overcome the possibility of unwanted mutations 
(caused by PCR), site-directed mutagenesis was carried out on pGFP-core1-59 (wild type) 
as before. Primers were designed to introduce specific nucleotide substitutions into the 
wild  type  core  construct.  These  nucleotide  substitutions  resulted  in  amino  acid 
substitutions from wild type sequence to alanine. This proceduce was carried out for each 
of the 13 HCV core residues between 24 and 36 and mutagenesis confirmed by nucleotide 
sequence analysis. As before, these alanine mutant sequences were subcloned into pC-E1-
E2 and transiently transfected into Huh7 cells. Two days post-transfection, cells were fixed 
in  methanol,  permeablised  with  PBS-T  and  probed  for  core  and  DDX3. 
Immunofluorescence  analysis  of  these  transfected  cells  showed  interesting  results.  All 
alanine mutants showed typical punctate cytoplasmic core staining similar to wild type 
core protein, however, while some mutants (P25A, G26A, G28A, Q29A, V31A, G32A and 
L36A) showed distinct colocalisation between core and DDX3 (similar to that seen with 
wild  type  HCV  core),  other  mutants  (F24A,  G27A,  I30A,  G33A,  V34A  and  Y35A) 
showed no interaction with DDX3 at all (Fig. 3.16). In cells transfected with these core 
mutants,  DDX3  had  a  diffuse  cytoplasmic  localisation,  similar  to  that  seen  in  non-
transfected cells.    In  total,  6  residues  within  this  13-residue  region  were  shown  to  be 
critical for interaction with cellular DDX3 (residues 24, 27, 30, 33, 34 and 35). When 
substituted for alanine, these residues led to the inhibition of interaction between HCV core 
and cellular DDX3.  
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Figure  3.16: Analysis  of  alanine-substitute  mutant  core-DDX3 
interaction.  Using  site-directed  mutagenesis  to  introduce  nucleotide 
changes,  residues  24-36  of  wild  type  HCV  core  were  sequentially 
substituted for alanine (within pC-E1-E2). Alanine mutants were then 
transiently transfected into Huh7 cells. Forty-eight hrs post-transfection, 
cells were fixed in methanol, permeablised with PBS-T and probed with 
rabbit  polyclonal  anti-core  antiserum  (R308)  and  mouse  monoclonal 
anti-DDX3 antibody (AO196), followed by anti-rabbit FITC and anti-
mouse Cy5, respectively. 
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3.3 Discussion 
The aim of this chapter was to identify individual residues of core protein required for the 
interaction between core and DDX3. The discovery of such residues would enable further 
studies on virus replication in which DDX3 did not interact with core protein, allowing 
direct  comparisons  of  replication  kinetics  with  and  without  DDX3  interaction.  If 
interaction is essential for viral replication in cell culture, mutant viruses will not replicate. 
However, it is also possible that the interaction is required for some other process in the 
virus life cycle such as translation (DDX3 has been shown to rescue yeast lacking the 
translation factor and DDX3 homologue Ded1p (Mamiya and Worman, 1999)), packaging 
of viral RNA (the helicase activity of DDX3 may be required for packaging viral RNA into 
particles) or release of viral RNA in newly infected cells. As well as having an effect on 
the virus life cycle, it is also possibile that the interaction between core and DDX3 plays a 
role in the pathogenesis of the virus, doing so by inhibiting some cellular process.  
In order to identify critical residues of core required for this interaction it was necessary to 
generate and test a large number of core mutants. To identify these residues, EP-PCR was 
used to produce a library of core1-59 mutants, each carrying 0-4 amino acid substitutions. 
Since  EP-PCR  products  carrying  premature  stop  codons  or  having  no  amino  acid 
substitutions  were  of  little  interest,  a  method  for  identifying  mutants  with  amino  acid 
substitutions was required. GFP-display is a technique used for identifying single amino 
acid substitutions in proteins (Aoki et al., 2000b). Proteins fused to GFP are expressed in 
bacteria and crude lysates separated by SDS-PAGE in the presence of urea. GFP is stable 
in the presence of urea (Ward, 1998) and therefore can act as a chemical label attached to 
the  fused  protein.  The  interplay  between  urea,  SDS  ions  and  the  strength  of  binding 
between the ions and specific amino acids is believed to determine the mobility of the 
polyprotein through the gel (Aoki et al., 2000b, Aoki et al., 2002). Single amino acid 
substitutions  can  therefore  alter  the  mobility  of  the  polyprotein.  The  core1-59  mutants 
produced by EP-PCR were cloned downstream of GFP in a bacterial expression vector 
(pKK223-3)  and  expressed  in  E.  coli.  Crude  bacterial  lysates  containing  GFP-core1-59 
mutants  were  separated  by  SDS-PAGE  containing  6  M  urea  however  differences  in 
mobility were not seen between mutants. Using constructs donated by T. Aoki (University 
of Hokkaido, Japan) -shown to have different mobility patterns under these conditions 
despite only one amino acid substitution (SpAb and SpAb N214D, (Aoki et al., 2002))- 
inconsistent mobility patterns were seen. This may simply be due to experimental error as 
accurate urea concentration is critical for this technique (Aoki et al., 2000b). David A Dalrymple    Chapter 3: Results 
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To overcome this problem, and still make use of the GFP-core1-59 library, an ELISA based 
assay was designed allowing rapid screening of the mutant library. GST-tagged DDX3C 
(DDX3 amino acids 409-622) was coated on ELISA plates and incubated with either wild-
type core (fused to GFP) or error-prone PCR produced mutant core (also fused to GFP). 
Bound protein was detected with rabbit polyclonal anti-GFP antiserum followed by protein 
A-HRP. This assay allowed us to quickly identify possible core mutants with low affinity 
for DDX3. Although mutants with premature stop codons may also have no affinity for 
GST-DDX3C,  these  were easily  identified by nucleotide sequence analysis. In  total,  9 
mutant core proteins were found to have low binding affinity for DDX3 while having no 
premature  stop  codons.  Upon  sub-cloning  of  these  mutant  core1-59  sequences  into  a 
mammalian expression vector (pcDNA 3.1(+)zeo)  containing core, E1 and E2 sequence, 
transient transfection of naïve Huh-7 cells followed by immunofluorescence of transfected 
cells  (probing  for core and  DDX3),  confirmed none  of  the  core  mutants  were able  to 
interact with cellular DDX3. DDX3 remained diffusely localised throughout the cytoplasm 
as in non-transfected cells while core showed typical cytoplasmic staining similar to that of 
wild type core. 
Nucleotide sequence analysis showed that a variety of mutations were present in the 9 non-
binding mutants. Interestingly, mutant 90 had only one amino acid substitution (I30N), 
indicating  this  residue  was  essential  for  core-DDX3  interaction.  Concentrating  on  this 
region of core, it was noted that all mutants had at least one amino acid substitution within 
a 13-residue area surrounding amino acid 30. To confirm if the substitutions located within 
this 13-residue region were responsible for abolishing the interaction between core and 
DDX3, site-directed mutagenesis was used to revert “out-lying” mutations back to wild 
type. These new core mutants (containing only the mutations found between amino acids 
24-36) were transiently transfected into Huh7 cells as before and core-DDX3 interaction 
analysed by immunofluorescence. Again, none of the 9 mutants were able to interact with 
DDX3, indicating that the mutations within this 13-residue region of core were responsible 
for abolishing the interaction with DDX3. In order to identify which of these 13 residues 
were involved in the interaction between core and DDX3, alanine-scanning mutagenesis 
was carried out across this region. Each of the 13 residues between amino acids 24 and 36 
of core were substituted individually for alanine and transfection studies carried out as 
before. While 7 of the 13 substitutions had no adverse effect on the interaction between 
core and DDX3, 6 alanine substitutions abolished the interaction completely. Substituting 
any one  of residues 24, 27, 30,  33,  34 and 35  for alanine was enough to abolish the 
colocalisation between core and DDX3. David A Dalrymple    Chapter 3: Results 
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Residues 19-41 of core protein, written on a classical 3.6 amino acids per turn α-helix (the 
proposed structure of a polypeptide produced by the ribosome before native folding (Lim, 
1978))  show the proximity of these 6 essential amino acids to  each other (Fig.  3.17). 
Residues 24, 27, 30, 34 and 35 all reside on the same side of the α-helix, however in 
contrast, residue 33 appears on the opposite side of the structure. The close proximity of 
these residues in this α-helix model would suggest that this is indeed the binding site for 
DDX3. In order to identify any major structural alterations these mutations may have on 
core, the putative structure of mutant core protein was compared to that of the wild type 
NMR structures proposed by Ladaviere et al. (unpublished data, Protein Data Bank I.D. 
1CWX). Ladaviere et al. described four different structures using residues 2-45 of core, 
fortunately however the region of interest in the present study (including a proposed helical 
structure between residues 30 and 39) was identical in each model. Using the molecular 
modelling program AMBER 99 (Ponder and Case, 2003) to find the minimum energetic 
position (minimisation) of each mutant structure, the 6 core mutations were individually 
inserted into the proposed core structure and compared to that of the wild type model (Fig. 
3.18). Put simply, if adjacent amino acids can be imagined jostling for position next to 
each other, then the minimum energetic position is the most naturally comfortable position 
for each amino acid in that environment. With the exception of residue 33 which, when 
mutated to alanine caused a slight “kink” in the helix structure, none of the mutations had 
any significant effect on the predicted secondary structure of core within this region and all 
retained  the  predicted  helix  (D.  Gatherer,  personal  communication),  suggesting  that 
mutation  of  these  residues  inhibits  interaction  with  DDX3  not  by  altering  the  overall 
structure of core but instead by alterations to the interacting surface domain required by 
DDX3. These alterations to the interacting surface domain are caused by the presence of a 
different side chain when the amino acids are replaced with alanine. Figure 3.19 shows the 
properties and side chain of each amino acid involved in the interaction as well as that of 
alanine. Although each amino acid is similar in charge and polarity to alanine (with the 
exception of tyrosine which is non-polar compared to alanine which is polar), amino acids 
isoleucine, phenylalanine, tyrosine and valine have large side chains whereas alanine has 
only a small side chain, suggesting these large side chains may play a role in binding 
DDX3. It should be noted however that glycine, which is essential at residues 27 and 33 of 
core (for interaction with DDX3), has a small side chain similar to alanine. 
Analysis of 52 core protein amino acid sequences from different genotypes showed that 
HCV core has a highly conserved amino acid sequence across all genotypes with 85.3% -
100% conservation observed (Bukh et al., 1994). Here, the amino acid sequence of the first 
59 residues of core protein were analysed from 112 isolates from all genotypes. This David A Dalrymple    Chapter 3: Results 
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Figure  3.17:  Relative  positions  of  HCV  core  residues  required  for 
interaction  with  DDX3.  HCV  core  residues  19-41  are  written  on  a 
classical a–helix (3.6 amino acids per turn). Red residues indicate those 
required  for  interaction  between  core  and  DDX3.  Black  and  grey 
residues distinguish amino acids on front and rear of 3D helix.David A Dalrymple    Chapter 3: Results 
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Figure 3.18 : Analysis of predicted structural changes in core between residues 
21 and 39 due to alanine mutations. Using an NMR model of core proposed by 
Ladaviere et al. (Protein Data Bank I.D. 1CWZ), amino acids 24, 27, 30. 33, 34 
and 35 were individually mutated to alanine and mutant structures minimised 
by AMBER99 to find the minimum energetic position of each residue. 
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Figure  3.19:  Properties  of  the  amino  acids  essential  for  interaction  with 
DDX3 and comparison with alanine. Structures in red indicate amino acid 
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region was found to be highly conserved, with intra-genotypic identity ranging from 79.7% 
(genotype 3b) to 98.3% (genotype 2c) (Fig. 3.20). Interestingly, of 104 isolates analysed 
covering all genotypes (excluding those from genotype 3b), the 6 residues shown to be 
required for the interaction between core and DDX3 were 100% conserved (Fig. 3.21). 
Analysis of the 8 genotype 3b isolates showed some interesting results. Four of the isolates 
had 100% conservation of the essential amino acids 24, 27, 30, 33, 34 & 35 while the other 
4 had a glycine to glutamic acid substitution at residue 33. As well as this substitution at 
residue 33, these 4 isolates also share common substitutions at residues 26 (Gly – Arg), 43 
(Arg – Gln) and 48 (Ala – Glu) (Fig. 3.21), however the infectivity of these isolates is 
unknown.   
The highly conserved nature of these 6 residues indicates that the interaction between core 
protein and cellular DDX3 may play some essential role in the virus life cycle. In the 
following chapter, these identified residues of core are introduced into the newly described 
infectious JFH-1 system in order to study the effects the abolition of this interaction has on 
virus infectivity, replication and particle release. 
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Figure  3.20:  Amino  acid  identity  within  HCV  genotypes.    Amino 
Acids 1-59 of  HCV core protein  isolates were analysed for identity 
with other isolates from the same genotype. Analysis was carried out 
using Vector NTI (Invitrogen). David A Dalrymple    Chapter 3: Results 
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Figure 3.21:  Alignment of HCV core residues 1-59.  HCV core isolates were aligned by 
genotype  using  Vector  NTI  software  (Invitrogen).  Black  residues  on  green  background 
represent similar residues, green residues on white background represent weakly similar 
residues and black residues on white background represent non-similar residues.  
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4. Analysis of Critical HCV Core Residues in an 
Infectious Cell Culture System      
145 
4.1 Introduction  
The lack of cell culture or small animal model for HCV infection has made studying the 
virus life cycle and virus-host interactions extremely difficult. Most HCV studies so far 
have made use of infected patients (Thimme et al., 2001, Takaki et al., 2000, Lechner et 
al., 2000), chimpanzees (Logvinoff et al., 2004, Bukh, 2004, Shoukry et al., 2004, Thimme 
et al., 2002) and more recently replicon systems (Ikeda et al., 2002, Lohmann et al., 1999). 
Replicon systems have allowed translation and replication studies to be performed, as well 
as  leading  to  the  elucidation  of  some  of  the  virus-host  interactions  required  for  these 
processes (Gale, 2003, Katze et al., 2002, Dubuisson and Rice, 1996, Kapadia and Chisari, 
2005). The major drawbacks of the replicon system are that replication is very inefficient 
without  adaptive  mutations  (Lohmann  et  al.,  2001,  Blight  et  al.,  2000)  and  infectious 
virions are not produced. Recently however, Wakita and colleagues (Kato et al., 2001, 
Kato et al., 2003) have developed an HCV genotype 2a replicon (strain JFH-1) that can 
replicate efficiently in a variety of hepatic and non-hepatic cell lines without requiring 
adaptive  mutations.  Since  this  report,  a  number  of  publications  have  presented  data 
describing robust HCV infection in vitro, resulting in the production of infectious virus 
particles (Lindenbach et al., 2005, Wakita et al., 2005, Zhong et al., 2005). This data 
collectively shows that in vitro transcribed JFH-1 RNA can be electroporated into naïve 
Huh-7  cells  and  produce  10
4-10
5 infectious  units  per  ml  of culture  supernatant.  These 
particles can then infect naïve cells, spreading throughout the culture and can be serially 
passaged without loss in infectivity. 
The development of this JFH-1 system has allowed most aspects of the HCV life cycle to 
be studied, from receptor binding, through translation and replication to particle assembly 
and release. Of particular interest, the consequences of interrupting virus-host interactions 
can  now  be  studied  in  the  context  of  the  life  cycle  of  the  fully  infectious  virus.  The 
previous chapter  identified critical residues of core protein  required for the interaction 
between core and DDX3. In order to study the effects this interaction has upon the virus 
life cycle, we aimed to introduce these critical mutations individually into JFH-1 clones. 
This chapter details the establishment of the JFH-1 cell culture system in our hands as well 
as comparing and contrasting the differences between wild type JFH-1 and JFH-1 clones 
containing the mutations described in the previous chapter. Site-directed mutagenesis was 
used to introduce specific substitutions into JFH-1 clones and viral RNA produced by in 
vitro  transcription.  This  RNA  was  electroporated  into  naïve  Huh7  cells  and 
immunofluorescence analysis performed to study the cellular localisation of HCV core David A Dalrymple    Chapter 4: Results   
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protein and HCV mutant core proteins, as well as to look at the effect these proteins have 
on the cellular distribution of DDX3. Reverse-transcription PCR (RT-PCR) was used to 
detect negative strand HCV specific RNA in total cell extracts, indicative of viral genome 
replication, and Western immuno-blot analysis used to detect viral proteins in infected cell 
extracts. Production of infectious particles was studied by harvesting culture medium from 
infected cultures and using this filtered medium to infect naïve Huh-7 cells. Infection was 
confirmed by immunofluorescence and Western immuno-blot detection of viral proteins 
and  detection  of  replicating  negative  strand  viral  RNA  by  RT-PCR.  Finally,  relative 
quantities  of  RNA  were  calculated  using  Real-Time  PCR  in  order  to  detect  subtle 
differences between the replication efficiencies of wild type and mutant viruses. 
The first part of this chapter focuses on setting up the JFH-1 infectious system. HCV JFH-
1  RNA  was  in  vitro-transcribed  by  T7  polymerase  from  linearised  plasmid  DNA  and 
electroporated into Huh7 cells. The presence of HCV proteins in Huh7 cells was confirmed 
by immunofluorescence and Western immuno-blot analysis while replicating HCV RNA 
was detected by RT-PCR. Colocalisation between HCV JFH-1 core and cellular DDX3 
was also confirmed by immunofluorescence. Upon confirmation of replicating HCV RNA 
and  HCV  protein  production,  the  secretion  of  infectious  particles  was  confirmed  by 
infection  of  naïve  Huh7  cells  with  filtered  medium  from  electroporated  cells  and 
subsequent detection of HCV specific proteins and RNA.  
In the second part of this chapter, the 6 mutations found to abolish genotype 1a core-DDX3 
interaction were individually transferred into JFH-1 (genotype 2a) backgrounds by site-
directed mutagenesis. Mutant constructs were in vitro transcribed and RNA electroporated 
into  naïve  Huh7  cells.  Cells  carrying  electroporated  viral  RNA  were  analysed  for  the 
effects on HCV core and cellular DDX3 localisation, viral RNA replication and production 
of infectious particles. By immunofluorescence, mutant core protein was analysed for its 
ability to bind DDX3 and for its ability to be targeted to the lipid droplets while replication 
of mutant JFH-1 RNA was studied by RT-PCR. Mutant RNA was then tested for its ability 
to produce infectious particles and their replication efficiency compared to that of wild 
type JFH-1. 
This  comprehensive  analysis  of  mutant  and  wild-type  virus  will  contribute  to  the 
understanding of the interaction between core and DDX3 in terms of virus replication and 
progeny particle production. 
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4.2 Results 
4.2.1  Electroporation  of  In  Vitro  Transcribed  JFH-1  RNA  and 
Analysis of Viral Protein Expression and RNA Replication  
Before looking at the effects the 6 HCV core mutations may have on the virus life cycle it 
was important to first analyse the behaviour of wild type JFH-1 in our hands. As a negative 
control for all experiments, JFH-1 GND was used. JFH-1 GND contains a mutation (GDD-
GND) in the active site of the NS5B polymerase, blocking replication. Plasmids pJFH-1 
and  pJFH-1  GND  (kindly  donated  by  T.  Wakita,  Tokyo  Metropolitan  Institute  for 
Neuroscience, Japan) were linearised (see Materials and Methods section) and 1mg of each 
linearised  plasmid  in  vitro-transcribed  using  Megascript  (Ambion),  following  the 
manufacturers instructions. Following in vitro transcription and DNA digestion, RNA was 
precipitated and resuspended in 20ml RNA Storage Solution (Ambion). RNA was stored at 
-70°C.   
For each electroporation (using a BioRad GenePulser Xcell), 5x10
6 Huh7 cells were used. 
Cells were trypsinised, washed twice with PBS and resuspended in 400 ml PBS before 
addition of 5 mg in vitro-transcribed RNA. Electroporation (270 V, 960  F) was carried out 
using a 4 mm gap cuvette. Electroporated cells were resuspended in 10 ml DMEM (+ 
additives) and plated out on coverslips, 35 mm dishes and in flasks. 
Seventy-two hours post-electroporation, coverslips were fixed using methanol. In order to 
confirm that electroporation of HCV RNA had been successful, coverslips were probed for 
core and E2 using appropriate antibodies. In the case of Huh7 cells electroporated with 
JFH-1 wild type RNA, approximately 5-10 % of cells were positive for core and E2 (Fig. 
4.1). No cells electroporated with the replication deficient JFH-1 GND RNA were positive 
for viral proteins. To confirm that core was targeted to the lipid droplets as described 
previously  (Moradpour  et  al.,  1996),  cells  were  probed  for  core  and  cellular  ADRP 
(Adipocyte  differentiation-related  protein)  which  is  only  found  on  lipid  droplets 
(Brasaemle et al., 1997) and therefore commonly used as a marker for these structures. As 
expected,  core  protein  colocalised  with  ADRP,  indicating  that  JFH-1  core  protein  is 
targeted to the surface of lipid droplets (Fig. 4.2). Again, no core protein was detected in 
cells electroporated with JFH-1 GND RNA. Finally, to study the effect JFH-1 core protein 
had on cellular DDX3, cells were probed for core and DDX3. Figure 4.3 confirms that 
JFH-1 core protein also sequesters cellular DDX3 in a similar manner while in cells David A Dalrymple    Chapter 4: Results   
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Figure  4.1:  Detection  of  HCV  structural  proteins  in  Huh7  cells 
electroporated  with  HCV  JFH-1  RNA.  Naïve  Huh7  cells  were 
electroporated with 5  g of in vitro transcribed JFH-1 RNA. Seventy-two 
hours  post-electroporation,  cells  were  fixed  and  probed  with  rabbit 
polyclonal  anti-core  antiserum  (R308)  and  mouse  monoclonal  anti-E2 
antibody (AP33) as in Chapter 3. A) Huh7 cells electroporated with HCV 
JFH-1 GND RNA. B) Huh7 cells electroporated with HCV JFH-1 RNA.David A Dalrymple    Chapter 4: Results   
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Figure 4.2: Co-localisation of core protein with ADRP  in  Huh7 cells 
electroporated with  HCV JFH-1 RNA. Huh7 cells  were electroporated 
with 5 g of  in vitro transcribed  JFH-1 RNA. Seventy-two  hours post-
electroporation, cells were fixed and probed with rabbit polyclonal anti-
core antiserum (R308) and sheep polyclonal anti-ADRP antiserum as in 
Chapter 3. A) Huh7 cells electroporated with HCV JFH-1 GND RNA. B) 
Huh7 cells electroporated with HCV JFH-1 RNA.
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Figure  4.3:  Co-localisation  of  core  protein  with  DDX3  in  Huh7  cells 
electroporated with HCV JFH-1 RNA. Huh7 cells were electroporated with 
5  g of  in  vitro  transcribed  JFH-1  RNA.  Seventy-two  hours  post-
electroporation, cells were fixed and probed with rabbit polyclonal anti-
core  antiserum  (R308)  and  mouse  monoclonal  anti-DDX3  antibody 
(AO196) as in Chapter 3. A) Huh7 cells electroporated with HCV JFH-1 
GND RNA. B) Huh7 cells electroporated with HCV JFH-1 RNA.
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electroporated with JFH-1 GND RNA, DDX3 remains located throughout the cytoplasm. 
Due  to  excessive  fluorescence  emmited  from  the  punctate  spots  of  DDX3  upon 
colocalisation with core in wild-type samples, the gain of the FITC laser was turned down 
when viewing DDX3 in wild-type samples throughout the remainder of this thesis to avoid 
excessive fluorescence from DDX3. In doing this, diffuse cytoplasmic DDX3 staining in 
non-infected cells  surrounding those  expressing HCV proteins could not  be seen. This 
leads to the question of whether, in the presence of core, diffuse cytoplasmic staining of 
DDX3 remains as well as that seen colocalising with core (suggesting an up-regulation of 
DDX3  expression),  or  if  DDX3  is  simply  redistributed  from  its  diffuse  cytoplasmic 
localisation  to  colocalise  with  core.  Evidence  from  previous  studies  in  our  laboratory 
indicate that DDX3 expression is not upregulated in core-expressing cells and that DDX3 
is indeed sequestered from its normal cellular location. This is confirmed by the fact that 
DDX3 protein levels are similar in both JFH-1 wild-type and JFH-1 GND samples in this 
work,  as  shown  by  Western  blot  (Figs.  4.6,  4.9,  4.14).  To  confirm  that  JFH-1  core 
sequesters DDX3 to lipid droplets, cells were probed for DDX3 and ADRP. Figure 4.4 
confirms  that  when  DDX3  is  found  in  punctate  cytoplasmic  spots  (indicative  of 
colocalisation with HCV core protein), DDX3 colocalises with ADRP, confirming that 
HCV core sequesters DDX3 to lipid droplets. In the case of the JFH-1 GND electroporated 
cells, there was no colocalisation between DDX3 and ADRP. 
To confirm that HCV RNA was replicating in electroporated cells, confluent 35 mm dishes 
were harvested for total RNA 72 hrs post electroporation. Dishes were washed with PBS 
and cells lysed with 750 ml TRIzol. Total RNA was extracted from cells (see methods) and 
stored at -70°C. Reverse transcription PCR (RT-PCR) was used to detect replicating viral 
RNA. To confirm the RNA detected was replicating RNA as opposed to input RNA, a 
strand-specific primer was used for RT which binds negative strand HCV RNA. Detection 
of negative strand RNA provides confirmation that replication is occurring as this is only 
produced during replication. Using primer JFH-1 NegRT (TTGCGAGTGCCCCGGGA), 
identical to nucleotides 304-320 of the JFH-1 genomic sequence, cDNA was produced by 
reverse transcription. cDNA was then used to amplify full-length core sequence by PCR 
using  primers  JFH-1  RTPCR1  (GGTCTCGTAGACCGTGCACC)  and  JFH-1  RTPCR2 
(GTATTCTTCACCTGGGCAGC). Figure 4.5 shows that a band of correct size (610 nt) 
was only detected in cells electroporated with JFH-1 RNA and not JFH-1 GND RNA, 
confirming that viral RNA replication occurs in JFH-1 electroporated cells. 
Electroporated cells were also harvested in LB2 (see materials) 72 hrs post-electroporation 
for Western immuno-blot analysis. Cell lysate was separated by 10% SDS-PAGE, blotted  David A Dalrymple    Chapter 4: Results   
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Figure  4.4:  Co-localisation  of  DDX3  with  ADRP  in  Huh7  cells 
electroporated with HCV JFH-1 RNA. Huh7 cells were electroporated with 
5  g of  in  vitro  transcribed  JFH-1  RNA.  Seventy-two  hours  post-
electroporation, cells were fixed and probed with mouse monoclonal anti-
DDX3 antibody (AO196) and sheep polyclonal anti-ADRP antiserum as in 
Chapter 3. A) Huh7 cells electroporated with HCV JFH-1 GND RNA. B) 
Huh7 cells electroporated with HCV JFH-1 RNA.
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Figure 4.5: Detection of cDNA, generated from negative strand HCV RNA 
in  Huh7  cells  electroporated  with  HCV  JFH-1  RNA.  Huh7  cells  were 
electroporated with 5  g of in vitro transcribed JFH-1 RNA. Seventy-two 
hours post-electroporation, cells were washed with PBS, lysed using TRIzol 
(Invitrogen)  and total  RNA extracted.  RNA was reverse  transcribed  using 
primer  JFH-1  NegRT  and  resultant  cDNA  amplified  by  PCR  using  core 
primers JFH-1 RTPCR1 and JFH-1 RTPCR2. Lane 1 – cDNA generated from 
JFH-1  electroporated  cells,  lane  2  – cDNA  generated  from  JFH-1  GND 
electroporated  cells,  lane  3  – No  RT  control  (RNA  extract  from  JFH-1 
electroporated cells with no reverse transcription stage), lane 4 – H2O control 
reaction, lane 5 – 100 bp DNA ladder (Invitrogen). 
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on nitrocellulose membranes and probed with various antibodies. Firstly, membranes were 
probed for viral proteins core, E2 and NS5A. In all 3 cases, a band of correct size was 
detected  from  the  cell  lysate  electroporated  with  JFH-1  RNA  but  not  from  that 
electroporated with JFH-1 GND RNA (Fig. 4.6). DDX3 levels in JFH-1 and JFH-1 GND 
electroporated cells were also studied. DDX3 was detected in both cell lysates (Fig. 4.6). 
 
4.2.2 Production of Infectious HCV from In Vitro Transcribed JFH-
1 RNA 
Wakita et al. (2005) showed that cells electroporated with JFH-1 RNA secrete infectious 
HCV particles into the culture medium and these particles are capable of infecting naïve 
cells. In order to confirm this in our hands, medium was collected from electroporated cells 
72  hrs  post-electroporation  and  filtered  through  a  0.45  mm  filter  to  remove  cells  and 
cellular  debris.  Naïve  Huh7  cells  were  plated  out  at  5x10
4/ml  and  the  following  day 
incubated with filtered medium for 3 hrs at 37ºC before washing with PBS and overlay 
with appropriate culture medium. Seventy-two hrs post-infection, cells were washed in 
PBS and fixed with methanol. Cells were probed for core and DDX3. Cells infected with 
medium from JFH-1 electroporated cells were positive for core protein indicating these 
cells had been successfully infected with HCV particles. As expected, no core protein was 
present in cells infected with culture medium from JFH-1 GND electroporated cells. In 
cells infected with HCV particles, core protein colocalised with DDX3 in a similar way to 
that in electroporated cells (Fig. 4.7).  
Cells infected with the same medium were also harvested 72 hrs post-infection for RT-
PCR using TRIzol. Total RNA was extracted and, using primer JFH-1 NegRT to reverse 
transcribe  negative  strand,  replication  intermediate  viral  RNA,  and  primers  JFH-1 
RTPCR1 and JFH-1 RTPCR2 to amplify the resultant cDNA by PCR, replication was 
detected in cells infected with JFH-1 culture medium but not in cells infected with that of 
JFH-1 GND (Fig. 4.8).  
Finally, cells infected with culture medium were harvested 72 hrs post infection using LB2 
for  Western  immuno-blot  analysis.  Cell  lysates  were  separated  by  10%  SDS-PAGE, 
transferred to nitrocellulose membrane and probed for viral proteins core, E2 and NS5A, 
followed by the appropriate secondary antibodies. As in the case of electroporated cells 
(Fig. 4.6), viral proteins core, E2 and NS5A could be detected in cells infected with JFH-1 David A Dalrymple    Chapter 4: Results   
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Figure 4.6: Detection of HCV viral proteins in Huh7 cells electroporated with 
HCV  JFH-1  RNA.  Huh7  cells  were  electroporated  with  5  g of  in  vitro 
transcribed  JFH-1  RNA.  Seventy-two  hours  post-electroporation,  cells  were 
washed wth PBS and harvested using cell lysis buffer LB2. Total cell extracts 
were separated by SDS-PAGE (10%), transferred to nitrocellulose membrane 
and immunoblotted with A) rabbit polyclonal anti-core antiserum (R308), B) 
mouse  monoclonal anti-E2 antibody (AP33), C) sheep polyclonal anti-NS5A 
antiserum, and D) rabbit polyclonal anti-DDX3 antiserum (R648). 
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Figure  4.7:  Huh7  cells  electroporated  with  HCV  JFH-1  RNA  secrete 
infectious  HCV  particles  into  the  culture  supernatant.  Huh7  cells  were 
electroporated  with  5  g of  in  vitro  transcribed  JFH-1  RNA.  Seventy-two 
hours  post-electroporation,  medium  was  harvested,  0.45  m filtered  and 
incubated with naïve Huh7 cells for 3 hrs at 37°C before washing with PBS 
and  overlay  with  appropriate  culture  medium.  Seventy-two  hours  post-
infection,  cells  were  fixed  and  probed  with  rabbit  polyclonal  anti-core 
antiserum (R308) and mouse monoclonal anti-DDX3 antibody (AO196) as in 
Chapter 3. A) Cells incubated with supernatant from HCV JFH-1 GND RNA 
electroporated Huh7 cells, B) cells incubated with supernatant from HCV JFH-
1 RNA electroporated Huh7 cells.
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Figure  4.8:  Detection  of  cDNA,  generated  from  negative  strand  HCV 
RNA  in  Huh7  cells  infected  with  medium  from  HCV  JFH-1  RNA 
electroporated cells. Medium from Huh7 cells electroporated with 5  g of 
in vitro transcribed JFH-1 RNA was incubated with naïve Huh7 cells for 3 
hrs at 37°C followed by washing with PBS and overlay with appropriate 
culture  medium.  Seventy-two  hours  post-infection,  total  RNA  was 
extracted, reverse transcribed and resultant cDNA amplified as in Fig. 4.5. 
Lane 1 – cDNA generated from JFH-1 electroporated cells, lane 2 – cDNA 
generated from JFH-1 GND electroporated cells, lane 3 – No RT control 
(RNA extract from JFH-1 electroporated cells with no reverse transcription 
stage),  lane  4  – H2O  control  reaction,  lane  5  – 100 bp DNA  ladder 
(Invitrogen). 
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culture medium but not in cells infected with that of JFH-1 GND (Fig. 4.9). Again, DDX3 
could be detected at similar levels in both cell lysates using mouse monoclonal anti-DDX3 
antibody AO196.   
 
4.2.3 Analysis of HCV Core Mutants in HCVcc Infectious System 
4.2.3.1 Cloning of Mutant Core Protein into JFH-1 Background 
The 6 residues of HCV core shown to abolish core-DDX3 interaction (Chapter 3) were 
discovered using a genotype 1a (H77c strain) core protein. As H77c and JFH-1 have 96.6% 
homology within the first 59 amino acids of core, it was assumed the same residues of 
JFH-1 core protein would be responsible for the interaction with DDX3. To confirm this, 
the 6 residues of core shown to abolish core-DDX3 interaction were individually changed 
to alanine within the JFH-1 construct in order to study the effects of these mutations had on 
core  localisation,  core-DDX3  interaction  and  the  life  cycle  of  JFH-1.  Site-directed 
mutagenesis was used to introduce alanine substitutions at the target sites in core. As site-
directed mutagenesis involves amplifying the whole template by PCR, it is possible that 
unwanted errors occur during amplification. The construct containing the full-length JFH-1 
sequence (pJFH-1) is over 12 kb in length and is therefore not suitable for nucleotide 
sequence analysis to check for unwanted PCR errors. To overcome this, a smaller fragment 
of JFH-1 core sequence was sub-cloned into pGEMT and site-directed mutagenesis carried 
out in  this construct. Nucleotides  1-2614 were amplified from  pJFH-1 cDNA  by PCR 
using  primers  JFH-12  (GCCAGTGAATTCTAATACGAC,  EcoRI  restriction  site 
underlined)  and  AP357  (CATATGCATGAATTCTCTAGATTATGCTTCGGCCTG 
GCCCAA, EcoRI restriction site underlined). Upon restriction digest with EcoRI, the PCR 
product was cloned into pGEMT (pGEMT JFH-1 1-2614) and sequence confirmed by 
nucleotide  sequence  analysis.  The  6  alanine  substitutions  (F24A,  G27A,  I30A,  G33A, 
V34A and Y35A) were then individually introduced into pGEMT JFH-1 1-2614 by site-
directed mutagenesis and confirmed by nucleotide sequence analysis. Nucleotides 1-1369 
of  JFH-1  (including  desired  mutation)  were  then  sub-cloned  back  into  pJFH-1  using 
restriction sites EcoRI and BsiWI. Mutant pJFH-1 was then linearised, in vitro transcribed 
and electroporated into naïve Huh7 cells (see Materials and Methods).  
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Figure  4.9:  Detection  of  HCV  proteins  in  Huh7  cells  infected  with 
medium from HCV JFH-1 RNA electroporated cells. Medium from Huh7 
cells  electroporated  with  5  g of  in  vitro  transcribed  JFH-1  RNA  was 
incubated with naïve Huh7 cells for 3 hrs at 37°C followed by washing 
with PBS and overlay with appropriate culture medium. Seventy-two hours 
post-infection  cell  lysate was  used  for  Western  immunoblotting as  in 
Figure  4.6.  A)  rabbit  polyclonal  anti-core  antiserum  (R308),  B)  mouse 
monoclonal  anti-E2  antibody  (AP33),  C)  sheep  polyclonal  anti-NS5A 
antiserum, and D) rabbit polyclonal anti-DDX3 antiserum (R648). 
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4.2.3.2 Cellular Localisation of Mutated JFH-1 Core Protein and Interaction 
with DDX3 
Naïve Huh7 cells, electroporated with 5  g of mutant HCV JFH-1 RNA and plated on 
coverslips, were washed with PBS and fixed in methanol 72 hours post-electroporation. To 
confirm  that  electroporation  of  mutant  JFH-1  RNA  had  been  successful,  cells  were 
permeablised with PBS-T and probed for core and E2. As seen before (Fig. 4.1), cells 
electroporated  with  wild  type  JFH-1  RNA  showed  typical  E2  staining  throughout  the 
cytoplasm and globular core staining, also in the cytoplasm (Fig. 4.10). Analysis of cells 
electroporated  with  mutant  JFH-1  RNA  showed  similar  results.  For  all  6  JFH-1  core 
mutants, E2 was distributed throughout the cytoplasm and core had a globular cytoplasmic 
localisation  (Fig.  4.10).  One  interesting  observation  however,  was  the  fact  that  while 
cultures electroporated with mutants F24A, G27A, I30A, V34A and Y35A showed clusters 
of infected cells, mutant G33A culture presented only with isolated groups of one or two 
infected cells. As expected, no viral proteins were detected in cells electroporated with 
JFH-1 GND cDNA.  
To determine if the 6 residues of core were critical for the interaction between core and 
DDX3 in the context of HCV genotype 2a JFH-1 strain, electroporated cells were probed 
for core and DDX3. While wild type JFH-1 core protein colocalised with cellular DDX3, 
mutant core proteins did not (Fig. 4.11), thus confirming the results shown in the transient 
transfection system using genotype 1a H77c strain. In each case, mutant JFH-1 core was 
seen to have a typical globular cytoplasmic localisation while DDX3 was diffusely located 
throughout the cytoplasm similar to its distribution in naïve Huh7 cells. The exception to 
this  was  JFH-1  mutant  V34A.  Some  cells  electroporated  with  JFH-1  V34A  showed 
colocalisation between core and DDX3 while others did not (Fig. 4.11 V34A (i) & (ii)).  
Wild type core protein is targeted to the lipid droplets by motifs located in domain 2 of 
core protein (Hope and McLauchlan, 2000b). As the 6 alanine substitutions introduced 
here are all in domain 1 of core, these mutations are not expected to interfere with the 
targeting of core to the lipid droplets. To confirm this, electroporated cells were probed for 
core and ADRP. All 6 mutant core proteins colocalised with ADRP in a similar pattern to 
that of wild type core (Fig. 4.12), confirming that the mutations in core had no effect on its 
targeting to the lipid droplets. 
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Figure  4.10:  Detection  of  HCV  structural  proteins  in  Huh7  cells 
electroporated with mutant HCV JFH-1 RNA. Huh7 cells were electroporated 
with 5  g of in vitro transcribed mutant JFH-1 RNA. Seventy-two hours post-
electroporation, cells were fixed and probed with rabbit polyclonal anti-core 
antiserum  (R308)  and  mouse  monoclonal  anti-E2  antibody  (AP33)  as  in 
chapter 3. David A Dalrymple    Chapter 4: Results   
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Figure 4.11: Co-localisation of core protein with DDX3  in  Huh7 cells 
electroporated  with  mutant  HCV  JFH-1  RNA.  Huh7  cells  were 
electroporated  with  5  g of  in  vitro  transcribed  mutant  JFH-1  RNA. 
Seventy-two hours post-electroporation, cells were fixed and probed with 
rabbit polyclonal anti-core antiserum (R308) and mouse monoclonal anti-
DDX3 antibody (AO196) as in Chapter 3. 
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Figure 4.12: Co-localisation of core protein with ADRP  in  Huh7 cells 
electroporated  with  mutant  HCV  JFH-1  RNA.  Huh7  cells  were 
electroporated  with  5  g of  in  vitro  transcribed  mutant  JFH-1  RNA. 
Seventy-two hours post-electroporation, cells were fixed and probed with 
rabbit polyclonal anti-core  antiserum (R308) and  sheep polyclonal anti-
ADRP antiserum as in Chapter 3. 
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4.2.3.3 Replication of Mutant JFH-1 RNA  
To confirm that mutant JFH-1 RNA was replicating in electroporated cells, RT-PCR was 
used to detect negative strand, replication intermediate viral RNA. Electroporated cells 
were  washed  with  PBS,  lysed  in  TRIzol  and  total  RNA  extracted  for  RT-PCR  (see 
methods).  Using  primer  JFH-1  NegRT  to  reverse  transcribe  negative  strand  RNA  and 
primers  JFH-1  RTPCR1  and  JFH-1  RTPCR2  to  PCR  amplify  the  resultant  cDNA, 
replication intermediate negative strand JFH-1 RNA was detected in the case of all mutants 
(Fig. 4.13), suggesting that abolishing the interaction between HCV core and DDX3 does 
not prevent replication of viral RNA. 
 
4.2.3.4 Detection of Viral Proteins by Western Immuno-Blot Analysis  
To confirm that viral proteins were being processed correctly from translated mutant JFH-1 
RNA,  Western  immuno-blot  analysis  was  performed  to  study  the  expression  of  viral 
proteins  core,  E2  and  NS5A.  As  shown  in  Fig  4.14  (A-C),  correctly  sized  bands 
representing core, E2 and NS5A were seen in all mutant JFH-1 electroporated cell lysates. 
Interestingly, lysate from cells electroporated with JFH-1 G33A RNA showed reduced 
levels of core, E2 and NS5A. The lower levels of viral proteins observed in mutant G33A 
lysate may be accounted for by the observation that while large clusters of infected cells 
were seen in other mutant transfected cell cultures (by immunofluorescence), only isolated 
groups of one or two cells were seen with G33A cultures (section 4.2.3.2). This would 
explain the differences observed by Western blot analysis, as it would seem there are less 
infected cells  in the G33A culture  resulting in less total  viral protein expression. This 
difference  was  not  observed  when  analysing  viral  RNA  replication,  possibly  due  to 
excessive PCR cycles being used, thus masking the result.  Cellular levels of DDX3 were 
similar for all samples, ruling out any possibility of experimental error (Fig. 4.14D). 
 
4.2.3.5 Analysis of Mutant Virus Infectivity 
The above results suggest that the interaction between core and DDX3 is not essential for 
viral RNA replication or polyprotein processing. It is possible however that the interaction 
is required for either the production of progeny particles or their ability to infect naïve David A Dalrymple    Chapter 4: Results   
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Figure 4.13: Detection of cDNA,  generated  from  negative  strand 
HCV RNA  in Huh7 cells electroporated with  mutant  HCV JFH-1 
RNA.  Huh7  cells  were  electroporated  with  5  g of  in  vitro 
transcribed  mutant  JFH-1  RNA.  Seventy-two  hours  post-
electroporation, total RNA was extracted, reverse transcribed  and 
resultant  cDNA  amplified  as  in  Figure  4.5.  “No  RT”  is  a  PCR 
control  with  no  RT  stage  using  RNA  extracted  from  JFH-1 
electroporated cells, H2O is a no RNA control reaction.David A Dalrymple    Chapter 4: Results   
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Figure  4.14:  Detection  of  HCV  viral  proteins  in  Huh7  cells 
electroporated  with  mutant  HCV  JFH-1  RNA.  Huh7  cells  were 
electroporated  with  5  g of  in  vitro  transcribed  mutant  JFH-1  RNA. 
Seventy-two hours post-electroporation, cell lysate was used for Western 
immunoblotting as in Figure 4.6. A) rabbit polyclonal anti-core antiserum 
(R308),  B)  mouse  monoclonal  anti-E2  antibody  (AP33),  C)  sheep 
polyclonal  anti-NS5A  antiserum,  and  D)  rabbit  polyclonal  anti-DDX3 
antiserum (R648). David A Dalrymple    Chapter 4: Results   
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cells.  To  investigate  this,  naïve  Huh7  cells  were  electroporated  with  5   g  of  in  vitro 
transcribed mutant JFH-1 RNA. Seventy-two hours post-electroporation, culture medium 
was harvested from cells and filtered through a 0.45 mm filter. Naïve Huh7 cells were 
plated out at 5x10
4 cells/ml and the following day incubated with filtered medium for 3 hrs 
at 37ºC. Cells were then washed with PBS and overlayed with appropriate culture medium. 
Seventy-two hours post infection cells were harvested for immunofluorescence and RT-
PCR. 
Infected cells were washed with PBS and fixed in methanol before being permeablised 
with PBS-T. Cells were then stained with rabbit polyclonal anti-core antiserum (R308) to 
confirm HCV infection and mouse monoclonal anti-DDX3 antibody (AO196) to identify 
any  colocalisation  with  DDX3.  By  immunofluorescence,  JFH-1  mutants  F24A,  G27A, 
I30A, V34A and Y35A were shown to be able to infect naïve Huh7 cells and, as seen in 
electroporated cells, mutant core protein had a globular cytoplasmic localisation and, as 
expected, did not colocalise with DDX3, which remained diffuse throughout the cytoplasm 
(Fig.  4.15).  Also,  in  a  similar  pattern  to  that  seen  in  electroporated  cells,  some  cells 
infected with JFH-1 V34A virus showed colocalisation between core and DDX3 while in 
other cells there was no colocalisation (Fig. 4.15; V34A (i) & (ii)). Interestingly, there was 
no  infection  identified  in  cells  incubated  with  culture  medium  from  the  JFH-1  G33A 
culture (Fig. 4.15; G33A), suggesting this mutation may have an adverse effect on the 
production of infectious progeny particles. 
Infected  cells  were  also  analysed  for  replicating  viral  RNA.  In  accordance  with  the 
immunofluorescence  data,  mutant  viruses  F24A,  G27A,  I30A,  V34A  and  Y35A  all 
replicated in infected cells as determined by the presence of negative strand replication 
intermediate HCV RNA (Fig. 4.16). Culture medium from cells electroporated with G33A 
mutant RNA was unable to infect naïve Huh7 cells as shown by immunofluorescence. 
Similarly,  no  negative  strand  HCV  RNA  could  be  detected  in  infected  cells,  thus 
confirming that infectious HCV particles were not produced from the JFH-1 G33A mutant 
RNA (Fig. 4.16).  
 
4.2.3.6 Mutant Viruses Continue to Produce Infectious Virus Particles 
Initial experiments suggested that inhibiting the interaction between core and DDX3 does 
not significantly affect viral RNA replication, polyprotein processing or the production of  David A Dalrymple    Chapter 4: Results   
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Figure 4.15: Huh7 cells electroporated  with  mutant HCV JFH-1 RNA 
secrete infectious HCV particles into the culture medium. Medium from 
Huh7 cells electroporated with 5  g of in vitro transcribed mutant JFH-1 
RNA was incubated with naïve Huh7 cells for 3 hrs at 37°C followed by 
washing and overlay with appropriate culture medium. Three days post-
infection, cells were  fixed and probed  with rabbit polyclonal  anti-core 
antiserum (R308) and mouse monoclonal anti-DDX3 antibody (AO196) 
as in Chapter 3. 
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Figure 4.16: Detection of cDNA, generated from negative strand HCV 
RNA in Huh7 cells infected with medium from mutant HCV JFH-1 RNA 
electroporated Huh7 cells. Medium from Huh7 cells electroporated with 5
 g of in vitro transcribed JFH-1 RNA was  incubated with  naïve  Huh7 
cells for 3 hrs at 37°C followed by washing with PBS and overlay with 
appropriate culture medium. Seventy-two hours post-infection, total RNA 
was extracted, reverse  transcribed  and resultant cDNA amplified as  in 
Figure 4.5. “No RT” is extract from JFH-1 electroporated cells with no 
reverse transcription stage, H2O is no RNA control reaction.David A Dalrymple    Chapter 4: Results   
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infectious viral particles. It does, however, seem that the amino acid substitution G33A has 
an inhibitory  effect on the  production of infectious virus particles while not  adversely 
affecting  replication  of  viral  RNA.  To  determine  if  mutant  viruses  can  continue  to 
propagate over long periods of time, 5  g of in vitro transcribed mutant JFH-1 RNA was 
electroporated  into  naïve  Huh7  cells.  Electroporated  cultures  were  propagated  for  10 
passages and re-analysed for virus infection. At each of the 10 passages, cells were plated 
on  dishes  and  coverslips  for  analysis.  To  confirm  the  presence  of  virus  and  cellular 
localisation of DDX3, passaged cells were grown for 72 hrs before being washed with PBS 
and  fixed  in methanol. Cells  were  permeablised  with  PBS-T  and  probed  for core and 
DDX3. HCV core protein was detected in all mutant cultures with its typical cytoplasmic 
globular  staining,  indicating  that  JFH-1  mutant  viruses  unable  to  bind  DDX3  are  still 
capable of propagation in cell culture (Fig. 4.17). As in electroporated cells, mutant core 
proteins did not colocalise with DDX3 with the exception of some cells in the V34A virus 
culture (Fig. 4.17; V34A). Interestingly, although cells electroporated with JFH-1 G33A 
RNA (which did not produce infectious particles) did not show colocalisation between core 
and  DDX3,  after  10  passages  some  cells  contained  core  protein  that  colocalised  with 
DDX3 while in other cells there was no colocalisation (Fig. 4.17; G33A), similar to that 
seen with mutant V34A. Also of note was the fact that while in G33A electroporated cells 
only isolated cells showed signs of HCV protein expression, at passage 10 large clusters of 
cells were seen which expressed mutant G33A viral proteins.  
Passaged cells were also washed with PBS and harvested with TRIzol before extraction of 
total  RNA.  RT-PCR  was  carried  out  as  before  to  detect  replicating,  negative  strand 
intermediate HCV JFH-1 RNA. Using primer JFH-1 NegRT to reverse transcribe negative 
strand RNA and primers JFH-1 RTPCR1 and JFH-1 RTPCR2 to PCR amplify the resultant 
cDNA. Negative strand, replication intermediate JFH-1 RNA was detected in the case of 
all  culture  samples  (including  G33A),  thus  confirming  that  viral  RNA  replication  was 
occurring despite the inhibition of core – DDX3 interaction (Fig. 4.18). 
To confirm that the replicating mutant JFH-1 RNA detected in passage 10 cultures was 
producing infectious virus particles, medium from passage 10 cultures was used to infect 
naïve Huh7 cells. Naïve Huh7 cells were seeded at 5x10
4 cells/ml on coverslips and 35 mm 
dishes. The following day, cells were incubated with filtered medium from passage 10 
cultures  for  3  hours  before  washing  with  PBS  and  overlay  with  appropriate  culture 
medium.  Seventy-two  hours  post-infection,  cells  were  washed  in  PBS  and  fixed  with 
methanol before being permeablised with PBS-T. To confirm infection and localisation of 
cellular DDX3, cells were probed for core and DDX3. As with culture medium from David A Dalrymple    Chapter 4: Results   
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Figure 4.17: Co-localisation of core protein with DDX3 in cultured Huh7 
cells. Huh7 cells were electroporated  with 5  g of  in vitro  transcribed 
mutant JFH-1 RNA. Cells were cultured through 10 passages then plated 
on coverslips. Seventy-two hours post plating, cells were fixed and probed 
with rabbit polyclonal anti-core antiserum (R308) and mouse monoclonal 
anti-DDX3 antibody (AO196) as in Chapter 3. 
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Figure 4.18: Detection of cDNA, generated from negative strand HCV 
RNA in cultured Huh7 cells. Huh7 cells were electroporated with 5  g of 
in vitro transcribed mutant JFH-1 RNA. Cells were cultured through 10 
passages then plated on coverslips. Seventy-two hours post-plating, total 
RNA was extracted, reverse transcribed and resultant cDNA amplified as 
in Figure 4.5. “No RT” is RNA extract from JFH-1 electroporated cells 
with no reverse transcription stage, H2O is no RNA control reaction.David A Dalrymple    Chapter 4: Results   
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electroporated cells (section 4.2.3.5), medium from mutant virus cultures at passage 10 was 
capable  of  infecting  naïve  Huh7  cells.  Again,  as  before,  there  was  no  colocalisation 
between mutant core and DDX3 except for a percentage of cells infected with medium 
from  the  V34A  culture,  in  which  some  cells  showed  colocalisation  (Fig.  4.19). 
Interestingly,  unlike  culture  medium  from  cells  electroporated  with  G33A  RNA, 
supernatant from passage 10 cells carrying JFH-1 G33A RNA was capable of infecting 
naïve Huh7 cells. This result indicates that infectious particles were now being produced 
from this mutant RNA (Fig. 4.19; G33A). Also of note, the core protein produced by this 
infectious JFH-1 G33A mutant virus colocalised with DDX3 in a similar manner to that of 
wild type HCV core. 
The presence of replicating JFH-1 mutant RNA in infected cells was confirmed by RT-
PCR. Negative strand, replication intermediate JFH-1 RNA was detected in all culture 
samples,  including  cells  incubated  with  JFH-1  G33A  medium  (Fig.  4.20).  This  result 
confirms that viral RNA replication was occurring despite the inhibition of core – DDX3 
interaction.  
 
4.2.3.7 Nucleotide Sequence Analysis of Viral cDNA 
RT-PCR products from passage 10 infection experiments (Fig. 4.20) were purified using 
Qiagen Gel Extraction Kit and sequenced to confirm the presence of the initial alanine 
substitutions inserted by site-directed mutagenesis (section 4.2.3.1). Nucleotide sequence 
analysis  confirmed  that  all  mutants  retained  their  initial  alanine  substitution  after 
propagation for 10 passages (Fig. 4.21). Mutants F24A, G27A, I30A, V34A and Y35A had 
no other mutations within the JFH-1 core sequence, nor did the wild type. Interestingly 
however,  JFH-1  mutant  G33A,  which  did  not  produce  infectious  particles  after  initial 
electroporation, but was capable of infecting naïve Huh7 cells after propagation for 10 
passages, had developed a second mutation in the amino acid sequence of core (Fig. 4.21). 
This mutation, at residue 32 of core (G32D), was directly upstream of the initial G33A 
mutation,  suggesting  this  may  be  a  compensatory  mutation  allowing  production  of 
infectious particles. This possibility is investigated further in Chapter 5. 
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Figure 4.19: Colocalisation of core protein with DDX3 in cells infected 
with passage 10 supernatant. Huh7 cells electroporated with 5  g of in 
vitro  transcribed  mutant  JFH-1  RNA  were  cultured  for  10  passages. 
Culture medium was incubated with naïve Huh7 cells for 3 hrs at 37°C
before washing with PBS and overlay with appropriate culture medium. 
Seventy-two hours post-infection, cells were fixed and probed with rabbit 
polyclonal anti-core antiserum (R308) and mouse monoclonal anti-DDX3 
antibody (AO196) as in Chapter 3. 
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Figure 4.20: Detection of cDNA, generated from negative strand HCV 
RNA  in  cells  infected  with  passage  10  supernatant.  Huh7  cells 
electroporated with 5  g of  in vitro transcribed  mutant JFH-1 RNA 
were cultured  for 10 passages. Culture  medium  was  incubated  with
naïve  Huh7  cells  for  3  hrs  at  37°C before  washing  with  PBS  and 
overlay  with  appropriate  culture  medium.  Seventy-two  hours  post 
infection, total  RNA was extracted, reverse transcribed and resultant 
cDNA amplified as in Figure 4.5. “No RT” is RNA extract from JFH-1 
electroporated cells with no reverse transcription stage, H2O is no RNA 
control reaction.David A Dalrymple    Chapter 4: Results   
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Figure 4.21: Nucleotide sequence analysis of propagated mutant JFH-1 viruses. Huh7 cells electroporated with 5  g
of in vitro transcribed mutant JFH-1 RNA were cultured for 10 passages. Culture medium was incubated with naïve 
Huh7 cells for 3 hrs at 37°C before washing with PBS and overlay with appropriate culture medium. Seventy-two 
hours post-infection, cells were washed with PBS, harvested using TRIzol (Invitrogen) and total RNA extracted. RNA 
was reverse transcribed using JFH-1 NegRT (ttgcgagtgccccggga) and resultant cDNA amplified by PCR using core 
primers JFH-1 RTPCR1 (ggtctcgtagaccgtgcacc) and JFH-1 RTPCR2 (gtattcttcacctgggcagc). PCR products were gel 
purified using a gel extraction kit (Qiagen) and sequenced using core specific primers JFH-1 RTPCR1 and JFH-1 
RTPCR2. Red residues represent original site-directed mutations, green residue represent new mutation. Only amino 
acids 1-59 are shown here, all mutants and wild type had identical sequence to original JFH-1 sequence from residue 
60-191.
JFH-1 SEQ. MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VGGVYLLPRR GPRLGVRTTR KTSERSQPR
Wild type P10 MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VGGVYLLPRR GPRLGVRTTR KTSERSQPR
F24A P10 MSTNPKPQRK TKRNTNRRPE DVKAPGGGQI VGGVYLLPRR GPRLGVRTTR KTSERSQPR
G27A P10 MSTNPKPQRK TKRNTNRRPE DVKFPGAGQI VGGVYLLPRR GPRLGVRTTR KTSERSQPR
I30A P10 MSTNPKPQRK TKRNTNRRPE DVKFPGGGQA VGGVYLLPRR GPRLGVRTTR KTSERSQPR
G33A P10 MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VDAVYLLPRR GPRLGVRTTR KTSERSQPR
V34A P10 MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VGGAYLLPRR GPRLGVRTTR KTSERSQPR
Y35A P10 MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VGGVALLPRR GPRLGVRTTR KTSERSQPR
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4.2.3.8 Analysis of Mutant Virus Replication and Translation Efficiencies 
The previous results indicate that although the substitution mutations in core abolish the 
interaction with cellular DDX3, neither viral RNA replication nor production of infectious 
progeny  particles  are  abolished  (although  efficiency  may  be  affected).  It  is  possible 
however that DDX3 is required for enhancing replication or translation efficiency and, 
without it, these processes continue but at a slower rate.  
To determine the replication efficiency of the mutant viruses, the tissue culture infectious 
dose50 (TCID50, dilution of culture medium required to infect 50% of the wells) of each 
harvested virus medium was calculated and naïve Huh7 cells infected at equal TCID50 
levels. Seventy-two hours post-infection, total RNA was harvested from infected cells and 
Real-Time PCR conducted to determine relative viral RNA levels in each sample.  
To produce sufficient virus for titration, electroporated cells were cultivated for 5 passages 
before culture supernatant was harvested and filtered through a 0.45  m filter. Naïve Huh7 
cells were seeded at 5x10
3 cells/well in flat-bottomed 96-well plates. The following day, 
cells were overlayed with filtered virus supernatant (serially diluted 10-fold from neat to 
10
-7, 6 wells per dilution) for 3 hrs at 37ºC before washing with PBS and addition of 
appropriate culture medium. Seventy-two hours post infection cells were washed with PBS 
and fixed in methanol. Cells were then permeablised with PBS-T and probed for NS5A.  
Immunofluorescence was used to count the number of wells positive for NS5A at each 
dilution. From this, the TCID50 was calculated (Fig. 4.22). As titration results for each 
virus were almost identical, all naïve Huh7 cells were infected with neat medium for the 
RNA quantitation assay. Seventy-two hours post infection cells were washed with PBS, 
harvested in TRIzol and total RNA extracted. Relative viral RNA quantitation was carried 
out  using  a  Real-Time  PCR  system  (Applied  Biosystems).  This  system  involves  the 
amplification of two transcripts, one the target sequence (viral RNA), and the other an 
endogenous control (GAPDH) in order to normalise the samples for total RNA levels. An 
oligonucleotide probe is constructed with a fluorescent reporter dye bound to the 5’ end 
and a quencher on the 3’ end. While the probe is intact, the proximity of the quencher 
greatly  reduces  the fluorescence  emitted  by  the  reporter  dye.  If  the  target  sequence  is 
present, the probe anneals between primer sites and is cleaved by the 5’ nuclease activity 
of the DNA polymerase during extension. Cleavage of the probe releases the reporter dye 
from the quencher, thus increasing the reporter dye signal, which is measured at each cycle 
of the PCR reaction. With each cycle, more reporter dye molecules are cleaved from their David A Dalrymple    Chapter 4: Results   
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  WT  F24A  G27A  I30A  G33A  V34A  Y35A 
Neat  6  6  6  6  6  6  6 
10
-1  6  6  6  6  6  6  6 
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-2  6  6  6  6  6  6  6 
10
-3  2  1  1  1  0  2  2 
10
-4  0  0  0  0  0  0  0 
10
-5  0  0  0  0  0  0  0 
10
-6  0  0  0  0  0  0  0 
10
-7  0  0  0  0  0  0  0 
log TCID50/ml  -3.83  -3.67  -3.67  -3.67  -3.5  -3.83  -3.83 
Figure 4.22: Titration of mutant virus supernatant. Huh7 cells electroporated 
with 5 g of in vitro transcribed mutant JFH-1 RNA were cultured for 5 passages. 
Passage  5 supernatant was  incubated  with naïve  Huh7  cells for 3 hrs before 
washing with PBS and overlay with appropriate culture medium. 72 hrs post 
infection, cells were washed with PBS, fixed in methanol and permeablised with 
PBS-T.  Cells  were  then  probed  with  sheep  polyclonal  anti-NS5A  antiserum, 
followed  by  FITC-labelled  anti-sheep  secondary  antibody.  The  number  of 
NS5A-positive wells per dilution was counted and TCID50 dilution calculated 
(see Materials and Methods). David A Dalrymple    Chapter 4: Results   
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respective quenchers resulting in an increase in fluorescence intensity proportional to the 
amount of amplicon produced. In order to remove the possibility of pipetting errors when 
splitting samples into two reactions, both reactions (sample and endogenous control) can 
be carried out in the same tube using different reporter dye molecules. In the case of HCV 
infected cells, GAPDH has been validated as an endogenous control (Pugnale et al., 2006). 
Reverse  transcription  and  Real-Time  PCR  were  carried  out  according  to  the 
manufacturer’s guidelines (Applied Biosystems). Briefly, random hexamers were used to 
produce  cDNA  from  total  RNA  samples.  Primers  RA16 
(TCTGCGGAACCGGTGAGTAC)  and  RA17  (GCACTCGCAAGCACCCTATC) 
(binding the HCV 5’NCR) were used to amplify cDNA while a FAM™ labelled probe 
bound the 5’NCR between these primers. GAPDH was detected using Applied Biosystems 
Human GAPDH endogenous control primers and a VIC® labelled probe. Real-Time PCR 
was carried out using Applied Biosystems 7500 Fast Real-Time PCR System and data 
analysed using Applied Biosystems software (SDS version 1.3.1). The analysis software 
automatically sets the baseline and threshold and calculates the cycle threshold (CT) value 
of each sample relative to a positive reference and normalises samples to GAPDH. Wild 
type  JFH-1  containing  sample  was  used  as  a  calibrator,  against  which  the  relative 
quantification of the other samples was measured. When analysing JFH-1 mutant RNA 
levels relative to JFH-1 wild type RNA levels, all mutants showed greatly reduced RNA 
levels (Fig. 4.23). Mutant viruses F24A, G27A, I30A, V34A and Y35A showed less than 
3% RNA levels of that of wild type. Mutant G33A (containing the compensatory mutation 
G32D) showed 57% RNA levels of that of wild type, indicating that this compensatory 
mutation may be having an effect on viral RNA replication. 
Infections at equal TCID50 were also carried out to determine any differences in translation 
efficiency between wild type JFH-1 and mutant virus unable to sequester DDX3 (assuming 
equal uptake of virus samples). Naïve Huh7 cells were infected with passage 5 supernatant 
as before and 72 hrs post-infection washed with PBS and harvested in LB2. Proteins were 
separated by 10% SDS-PAGE and blotted on nitrocellulose membrane before being probed 
with various antibodies to detect viral proteins as well as cellular DDX3. Core protein was 
most abundant in wld-type JFH-1 infected cells while reduced in all JFH-1 mutant infected 
cells (Fig. 4.24A). E2 was again most abundant in wild-type JFH-1 infected cells, with 
mutant infected cells containing decreased levels of E2. Finally, NS5A levels were also 
highest in wild-type JFH-1 infected cells although mutant virus G33A had comparable 
levels (Fig. 4.24C). The remainder of the mutants had lower levels of NS5A in agreement 
with core and E2 data, and Real-Time PCR analysis. DDX3 levels were similar in all David A Dalrymple    Chapter 4: Results   
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WT GND Y35A V34A G33A 
(inc. G32D)
I30A G27A F24A
Figure 4.23: Real-Time PCR analysis. Naïve Huh7 cells were incubated with culture medium taken from mutant virus (at 
equal TCID50 dilution) for 3 hrs at 37°C followed by washing with PBS and overlay with appropriate culture  medium. 
Seventy-two hours post-infection, cells were washed with PBS, lysed using TRIzol (Invitrogen) and total RNA extracted. 
RNA was reverse transcribed using random hexamers (Applied Biosystems, according to manufacturers instructions) and 
resultant cDNAs amplified  by  PCR  using  HCV  core  5’UTR  specific  primers  and  GAPDH  specific  primers  (Applied 
Biosystems),  in  the presence of FAM and VIC probes (Applied  Biosystems, according  to  manufacturers  instructions). 
Relative fluorescence intensity of samples was measured using Applied Biosystems 7500 Fast Real-Time PCR System and 
data analysed using Applied Biosystems software. (Experiment carried out in triplicate, error bars shown).David A Dalrymple    Chapter 4: Results   
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Figure 4.24:  Detection of HCV  viral proteins  in  infected  Huh7 cells. 
Naïve Huh7 cells were incubated with culture medium from mutant virus 
(at equal TCID50 dilution) for 3 hrs at 37°C followed by washing with 
PBS and overlay  with appropriate culture  medium. Seventy-two  hours 
post-infection, lysates were used for Western immunoblotting as in Figure 
4.6.  A)  rabbit  polyclonal  anti-core  antiserum  (R308),  B)  mouse 
monoclonal  anti-E2  antibody  (AP33),  C)  sheep  polyclonal  anti-NS5A 
antiserum, and D) rabbit polyclonal anti-DDX3 antiserum (R648). 
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infected cell lysates indicating that samples contained equal amount of total protein (Fig. 
4.24D). Slight background bands were seen in GND samples probed for E2 and NS5A, 
possibly due to contamination from the wild type sample during loading of the gel since no 
band was seen when GND was probed for core, nor was GND positive for E2 or NS5A in 
previous experiments (Fig. 4.6). David A Dalrymple    Chapter 4: Results   
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4.3 Discussion 
The recent discovery of a genotype 2a HCV clone (JFH-1) capable of undergoing a fully 
infectious life cycle in cell culture without the need for adaptive mutations (Wakita et al., 
2005) has allowed many previously un-investigated aspects of the HCV life cycle to be 
studied. Of particular interest is the interplay between viral proteins and host factors. In the 
previous chapter, 6 HCV core residues were identified which, when substituted for alanine, 
abolished the interaction between core and DDX3 in a transient transfection system. To 
understand more about this interaction in terms of a fully infectious replication system, 
these alanine substitutions were introduced individually into the JFH-1 background and 
their effects on the JFH-1 life cycle studied in cell culture. 
Before analysing the effects of abolishing this interaction on the virus life cycle, the JFH-1 
cell culture model was set up and core-DDX3 interaction confirmed in this new system. 
Plasmid containing full length JFH-1 sequence was linearised and RNA produced by in 
vitro transcription. This RNA was then electroporated into naïve Huh7 cells for analysis. 
Viral proteins were detected in electroporated cells by immunofluorescence and Western 
immuno-blot analysis. By immunofluorescence, core protein was detected in the cytoplasm 
of electroporated cells, having a globular staining pattern. Core protein was also shown to 
colocalise with the lipid droplet marker ADRP, indicating that it was targeted to the lipid 
droplets as previously described (Moradpour et al., 1996).  HCV glycoprotein E2 was 
detected throughout the cytoplasm of electroporated cells. Core protein was also shown to 
colocalise with DDX3. In naïve Huh7 cells, DDX3 is diffusely distributed throughout the 
cytoplasm and is also found in the nucleus. However, in the presence of HCV JFH-1 core 
protein,  DDX3  is  redistributed  and  colocalises  with  core.  The  site  of  colocalisation 
between core and DDX3 was confirmed to be lipid droplets by colocalisation between 
DDX3 and ADRP in core expressing cells. HCV RNA was detected in electroporated cells 
by RT-PCR. To confirm the RNA detected was replicating RNA and not input RNA, a 
primer was designed to reverse transcribe negative strand HCV RNA. Negative strand 
RNA is only produced during replication and can therefore be used as an indicator of viral 
RNA replication. Negative strand RNA was detected in cells electroporated with JFH-1 
RNA, confirming that viral RNA replication was occurring. Production of infectious HCV 
JFH-1  particles  was  confirmed  by  infection  of  naïve  Huh7  cells  with  filtered  culture 
medium  from  electroporated  cells.    By  immunofluorescence,  JFH-1  core  protein  was 
detected in infected Huh7 cells and shown to colocalise with DDX3. Core, E2 and NS5A 
were  also  detected  in  infected  Huh7  cells  by  Western  immuno-blot  analysis  and  the David A Dalrymple    Chapter 4: Results   
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presence of replicating RNA shown by RT-PCR, again using a reverse transcription primer 
against negative strand, replication intermediate HCV RNA.    
To investigate the effect of abolishing the interaction between core and DDX3 on the life 
cycle of HCV (in a cell culture system), the 6 HCV core residues shown in the previous 
Chapter to abolish core-DDX3 interaction were individually substituted for alanine within 
the  JFH-1  clone  by  site-directed  mutagenesis.  By  immunofluorescence,  mutant  core 
protein was detected in the cytoplasm of electroporated cells and was shown to colocalise 
with ADRP on lipid droplets, similar to that seen with wild type JFH-1 core protein. In 
accordance with the transient transfection data in Chapter 3, mutant core protein did not 
colocalise  with  cellular  DDX3.  Instead,  DDX3  was  located  diffusely  throughout  the 
cytoplasm as in naïve Huh7 cells. A percentage of core-mutant V34A did colocalise with 
DDX3 however. Nucleotide sequence analysis confirmed that JFH-1 V34A mutant RNA 
did possess the site-directed mutation introduced prior to in vitro transcription and RNA 
electroporation. It is therefore possible that in this cell culture system, HCV core mutation 
V34A  is  not  as  efficient  at  blocking  interaction  with  DDX3  compared  to  the  other 
mutations identified. Mutant G33A also showed an interesting phenotype in that while all 
other mutant and wild-type RNA transfected cultures showed clusters of infected cells, 
only isolated groups of one or two cells were seen expressing G33A mutant viral proteins. 
Western blot analysis also confirmed the presence of viral proteins in electroporated cells. 
Mutant core, E2 and NS5A were detected and all were of predicted molecular weight, 
although lower levels were detected in the G33A lysate, possibly due to the lack of large 
clusters of infected cells. One hypothesis regarding the function of DDX3 in the life cycle 
of HCV is that DDX3 is required for viral RNA replication. To study this, RT-PCR was 
used to detect negative strand, replication intermediate HCV RNA in electroporated cells. 
Replicating  viral  RNA  was  detected  in  cells  electroporated  with  each  of  the  6  JFH-1 
mutants  indicating  that  core  interaction  with  DDX3  is  not  essential  for  HCV  RNA 
replication.  
Another hypothesis to explain why core interacts with DDX3 is that the helicase activity of 
DDX3 is required for packaging viral RNA into progeny particles. If DDX3 is required for 
this  purpose  then  blocking  interaction  between  core  and  DDX3  should  prevent  the 
production of infectious progeny particles. Medium from cells electroporated with mutant 
JFH-1 RNA was filtered and incubated with naïve Huh7 cells. HCV infection was detected 
in all but one culture by immunofluorescence and RT-PCR. Mutant core protein had a 
typical cytoplasmic staining pattern and showed no colocalisation with DDX3 (except for a 
percentage of cells infected with JFH-1 V34A mutant virus). Interestingly, no core protein David A Dalrymple    Chapter 4: Results   
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was  detected  in  the  Huh7  culture  incubated  with  medium  from  JFH-1  G33A  RNA 
electroporated cells. Similarly, replicating viral RNA was detected in all infected cultures 
except for that incubated with medium from JFH-1 G33A RNA electroporated cells. The 
absence  of  infection  in  cultures  incubated  with  G33A  culture  medium  suggests  that 
infectious viral particles are not being produced and / or secreted by this viral RNA. This 
observation  ties  in  with  the  fact  that  no  clusters  of  infected  cells  were  seen  upon 
electroporation  with  G33A  RNA,  suggesting  infection  was  unable  to  spread  to 
neighbouring cells. It is also interesting to note that structural analysis of core containing 
the G33A mutation showed that this mutation caused a slight “kink” in the helix between 
residues 30 and 39 (section 3.3, Figure 3.18). One possible hypothesis for the lack of 
infectious mutant G33A virus is that this mutation causes some structural change in core, 
which then results in production of aberrant HCV particles that are either not released from 
the infected cell or are unable to bind and / or enter uninfected cells.   
Electroporated cultures were grown through ten cell passages and re-analysed in a similar 
manner to determine whether the mutant virus infection could be sustained. Cells remained 
positive for HCV core protein as shown by immunofluorescence with infection spreading 
throughout the culture. While wild  type  core  colocalised with  DDX3, the mutant core 
proteins were still unable to colocalise with the cellular protein. However, core mutant 
G33A (from which electroporated RNA did not produce infectious particles), now showed 
colocalisation with DDX3. As no infectious particles were produce from this mutant RNA 
after electroporation, it would be expected that during continuous cell passaging, numbers 
of  HCV core positive cells  would diminish.  Instead  however, G33A  mutant virus had 
spread throughout the culture, similar to the other mutants and wild type virus. Infection 
studies on medium from these passage 10 cultures indicated (by immuno-staining for core 
and negative strand RT-PCR) that all mutants (including G33A) were capable of infecting 
naïve Huh7 cells. Sequence analysis of viral RNA in these infected cells showed that all 
mutants still possessed their original mutation in core. In addition, mutant G33A RNA had 
a second mutation, located one amino acid upstream at residue 32 of core (G32D). It is 
possible that this is a compensatory mutation selected in the replicating G33A RNA by its 
ability to produce infectious HCV particles. It is not clear whether the mutation at residue 
33 of core is blocking particle production within the cell or if particles are being secreted 
but are unable to enter or uncoat within naïve cells. Further investigation of mutant G33A 
is described in Chapter 5. 
As DDX3 is not essential for viral RNA replication or production of infectious particles, 
more detailed analysis of mutant virus replication and translation efficiencies were carried David A Dalrymple    Chapter 4: Results   
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out to detect any subtle differences compared to wild type virus. Naïve Huh7 cells were 
infected at equal TCID50 levels (after titration of culture medium) and cells harvested for 
total RNA and protein. Using Real-Time PCR, viral RNA levels in infected cells were 
analysed. Compared to wild type JFH-1, total viral RNA levels in mutants were greatly 
reduced  (approximately  50-100  fold  lower).  Mutant  G33A  however,    (also  containing 
mutation G32D), had RNA levels higher than other mutants yet still lower than wild type 
(approximately 2 fold lower). Similar results were obtained from Western immuno-blot 
analysis of viral protein levels in infected cells. Again, levels of core, E2 and NS5A were 
greatly reduced in mutant infected cells compared to wild type and again, mutant G33A 
infected cells had higher levels of viral proteins compared to other mutants. These results 
are in contradiction with those in Figures 4.13 and 4.14 which suggest that there is no 
significant difference in levels of viral RNA replication and translation between wild-type 
and mutant HCV RNA. One possible theory for this discrepancy is that electroporation of 
naïve cells with 5  g of RNA results in cells being “overloaded” with viral RNA and as 
such the RT-PCR and western blot data shown are the result of saturation. Infection of 
naïve cells with virus-containing culture medium however, may result in less viral RNA 
entering  cells  (compared  to  electroporation  of  5   g  RNA),  therefore  allowing  more 
accurate analysis of both viral RNA replication and translation. In order to detect these 
differences using electroporated cells, RNA and protein extract could have been serially 
diluted before analysis in order to avoid saturation. Another option would have been to 
carry out a time-course, allowing the study of RNA replication and translation at time 
points earlier than 72 hours (before saturation occurred). This would have been of interest 
as the sensitivity of RT-PCR would allow detection of negative strand viral RNA at much 
earlier time points, possibly before saturation. To overcome this issue of saturation, less 
RNA could have been used for electroporation. However, as previous publications using 
the JFH-1 system have used 10  g of RNA (Zhong et al., 2005), our starting material was 
not  thought  excessive  at  the  time.  As  it  has  become  evident  that  this  may  result  in 
“overloading” of the cell culture model, re-analysis of RNA volumes may be required. 
These results suggest that abolishing the interaction between core and DDX3 may have an 
inhibitory effect, either directly or indirectly, on viral RNA replication and translation. The 
higher  level  of  replication  and  translation  in  mutant  G33A/G32D  compared  to  other 
mutants may be explained in that it is possible the compensatory mutation (G32D) has, as 
well as enabling production of infectious particles, reversed the effects on replication and 
translation  caused  by  the  abolishment  of  the  core-DDX3  interaction.  This  explanation 
would seem plausible since mutant G33A can now interact with DDX3.  David A Dalrymple    Chapter 4: Results   
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The results in this chapter suggest that the interaction between HCV core and cellular 
DDX3  is  not  essential  for  maintenance  of  infectious  replicating  virus.  From  this  data 
however, it is plausible to suggest that DDX3 is required for enhancing some part of the 
virus life cycle involved in replication and translation. These results will serve as a basis 
for future detailed investigations into the replication and translation efficiency of HCV in 
the absence of core-DDX3 interaction.        
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5. Further Analysis of HCV Core Mutant G33A 
 David A Dalrymple    Chapter 5: Results   
 
202 
5.1 Introduction 
The previous chapters identified 6 conserved amino acids of HCV core protein that are 
required for the interaction with cellular DDX3 and analysed the effect mutating these 
residues had on the virus life cycle (in the context of genotype 2a JFH-1 strain). Although 
the 6 mutant core proteins did not colocalise with cellular DDX3, the viruses were able to 
replicate and produce infectious virus particles. The exception to this was the discovery 
that mutation of HCV core amino acid 33 from glycine to alanine inhibited the production 
of infectious virus particles, while the viral RNA was still capable of replication. Western 
blot analysis of this mutant indicated that mutant core was being processed correctly as it 
was of similar molecular weight to all other mutant core proteins as well as wild type 
(Figure  4.14A).  The  fact  that  there  was  significantly  less  core  protein  in  this  sample 
compared to wild type and other mutants may be explained by the fact that in the 72 hours 
between electroporation of RNA and harvesting of samples, wild type and mutant viruses 
have infected neighbouring cells in the culture while mutant G33A remained only in the 
initially electroporated cells. However, a slower replication rate may also be a factor. From 
these initial experiments it cannot be confirmed whether this mutation is preventing the 
assembly of virus particles or if particles are being secreted but are non-infectious. After 
culturing  electroporated  cells  for  10  passages,  it  was  noted  that  culture  medium  from 
mutant  G33A  culture  could  infect  naïve  Huh7  cells.  Subsequent  nucleotide  sequence 
analysis of the core gene from this infectious G33A mutant identified a second mutation 
that had arisen one residue upstream from the original mutation, at amino acid 32 (glycine 
–  aspartic  acid).  The  appearance  of  a  second  mutation,  along  with  infectious  particle 
production,  suggested  that  this might  be  a compensatory  mutation,  responsible  for  the 
production of infectious particles. In order to study this further, each mutant RNA was 
freshly electroporated and  culture medium analysed at each  cell passage for infectious 
particles, and nucleotide sequence analysis carried out to identify any other compensatory 
mutations in core. Presented here is a detailed analysis of compensatory mutations arising 
in  HCV  JFH-1  mutant  G33A  and  their  effect  on  the  production  of  infectious  virus 
particles. David A Dalrymple    Chapter 5: Results   
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5.2 Results 
5.2.1 Analysis of Infectious Particle Production by Mutant G33A 
As shown in Chapter 4, JFH-1 G33A mutant RNA did not produce infectious particles 
following electroporation, as measured by RT-PCR and immunofluorescence. However, 
after cultivation for several passages, infectious virus particles were eventually produced. 
In the first experiment, infectious JFH-1 G33A mutant RNA was found to possess a second 
mutation in core (G32D). To confirm these results and determine whether the secondary 
mutation was responsible for the production of infectious virus particles, further repetitions 
of these infection studies were carried out. In vitro transcribed RNA (JFH-1 wild type, 
JFH-1 F24A mutant and JFH-1 G33A mutant) was electroporated into naïve Huh7 cells as 
previously  described  (see  methods).  Seventy-two  hours  post-electroporation,  culture 
medium was harvested and cells trypsinised and passaged. Naïve Huh7 cell were seeded at 
5x10
4/ml and the following day incubated with filtered culture medium for 3 hrs at 37°C 
before washing  with PBS and  overlay with DMEM.  Seventy-two  hours  post-infection, 
cells were either fixed in methanol for immunofluorescence or harvested using TRIzol and 
total RNA  extracted. This process was repeated at each of  the first 5 passages  of the 
original electroporated cultures.  
Cells  fixed  in  methanol  were  permeablised  with  PBS-T  and  probed  in  an  indirect 
immunofluorescence assay for HCV core and cellular DDX3. Cells electroporated with 
JFH-1 G33A mutant RNA showed typical HCV core staining as seen before (Fig. 5.1A). 
HCV core mutant G33A could be detected in a percentage of cells. However, there was no 
colocalisation with cellular DDX3. Immunofluorescence experiments were repeated using 
cells infected with culture supernatant from passage 1-5. Cells infected with supernatant 
taken from JFH-1 G33A cultures up to and including passage 3 showed no signs of HCV 
infection (Fig. 5.1B), as described in Chapter 4. However, cells infected with passage 4 
JFH-1  G33A  culture  medium  were  positive  for  HCV  core  protein  (Fig.  5.1C). 
Interestingly, while core protein produced from non-infectious JFH-1 G33A RNA did not 
colocalise  with  DDX3,  core  protein  produced  from  infectious  JFH-1  G33A  RNA  did 
colocalise  with  DDX3.  Culture  medium  from  passage  5  JFH-1  G33A  mutant  RNA-
electroporated  cells  showed  more  HCV  infection  (Fig.  5.1D)  and  again,  mutant  core 
protein colocalised with DDX3. 
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Figure  5.1:  JFH-1  G33A  mutant  virus  infections.  Huh7  cells 
electroporated  with  5 µg JFH-1  G33A  mutant  RNA  were  serially 
passaged.  Before  each  passage,  culture  medium  was  harvested  and 
incubated with naïve Huh7 cells for 3 hrs before washing and overlay 
with  appropriate  culture  medium.  Seventy-two  hours  post-infection, 
cells were fixed and probed with rabbit polyclonal anti-core antiserum 
(R308)  and  mouse  monoclonal  anti-DDX3  antibody  (AO196)  as  in 
Chapter  3.  A)  electroporated  cells,  B)  cells  infected  with  passage  3 
supernatant,  C)  cells  infected  with  passage  4  supernatant,  D)  cells 
infected with passage 5 supernatant.
Core DDX3 Merge
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Core DDX3 Merge
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Huh7  cells  infected  with  filtered culture  medium  from  passages  3,  4 and  5  were also 
analysed for infection by the presence of negative strand replication intermediate JFH-1 
RNA. Total RNA was isolated and reverse transcribed using HCV negative strand specific 
primer JFH-1 NegRT, and the resultant cDNA was amplified by PCR using primers JFH-1 
RTPCR1  and  JFH-1  RTPCR2.  In  accordance  with  the  results  obtained  by 
immunofluorescence analysis (Fig. 5.1), no JFH-1 cDNA was detected in cells incubated 
with JFH-1 G33A mutant passage 3 culture medium, indicating there was no infection 
(Fig. 5.2A). Infection was clearly detected in cells incubated with passage 3 supernatant 
from wild type and mutant F24A cultures. Although this type of RT-PCR is not truly 
quantitative, cells incubated with culture medium from passage 4 G33A mutant appeared 
to  have  low  levels  of  replicating  JFH-1  RNA  (Fig.  5.2B),  in  agreement  with  the 
immunofluorescence data. Finally, incubation of naïve Huh7 cells with passage 5 JFH-1 
G33A  culture  medium  clearly  caused  infection  as  confirmed  by  detection  of  negative 
strand, replicating JFH-1 RNA, with quantities appearing similar to that in wild type and 
mutant F24A infected cells (Fig. 5.2B). 
As a final assay for detection of infectious virus particles, culture medium was titrated and 
TCID50 calculated for each sample. Naïve Huh7 cells were seeded at 5x10
3/well (96-well 
plate). The following day, culture medium was serially diluted 10-fold from neat – 10
-7 and 
incubated with the naïve Huh7 cells. Three hours post-infection, cells were washed with 
PBS and overlayed with DMEM. Seventy-two hours post-infection, cells were washed 
with PBS and fixed in methanol. Cells were then permeablised with PBS-T and analysed 
by  immunofluorescence  for  NS5A  (fluorescent  cells  were  viewed  under  UV  light). 
Titration of passage 3 culture medium gave similar results to both the immunofluorescence 
and RT-PCR results. No infection was detected from mutant G33A culture medium while 
both wild type and mutant F24A supernatant was capable of infecting cells at 10
-2 dilution 
(Table 5.1A). At passage 4, G33A culture medium was infectious, albeit only undiluted 
and at very low levels (Table 5.1B). Again, passage 4 culture medium from wild type and 
mutant F24A cultures was capable of infecting naïve cells at 10
-2 dilution. Finally, by 
passage 5, G33A culture medium infected naïve cells at dilutions up to 10
-2 (Table 5.1C).  
During initial analysis of JFH-1 G33A mutant virus, infectious RNA was shown to possess 
2 mutations in core. The first, introduced at residue 33 of core by site-directed mutagenesis 
and the second, inserted during replication. It is possible that this second mutation enabled 
the production of infectious particles from the non-infectious G33A mutant RNA. In order 
to identify any mutations that may have arisen during cultivation of JFH-1 G33A mutant 
virus, thus triggering the switch from non-infectious to infectious phenotype, nucleotide David A Dalrymple    Chapter 5: Results   
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Passage 3
No RT     H2O    GND       WT       F24A     G33A
Passage 4 Passage 5
No RT  H2O  GND WT   F24A  G33A GND  WT  F24A  G33A
A
B
Figure  5.2:  RT-PCR  analysis  of  mutant  G33A  infection.  Huh7  cells 
electroporated with G33A mutant RNA were serially passaged. Before 
each passage, culture medium was harvested, filtered and used to infect 
naïve  Huh7  cells.  Seventy-two  hours  post-infection,  total  RNA  was 
extracted, reverse transcribed and resultant cDNA amplified as in Figure 
4.5.  A)  cells  infected  with  passage  3  medium,  B)  cells  infected  with 
passage 4 and passage 5 medium. No RT is control reaction using extract 
from JFH-1 infected cells with no reverse transcription stage, H2O is no 
RNA control reaction.
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  Wild Type  F24A  G33A 
Neat  6  6  0 
10
-1  6  5  0 
10
-2  4  1  0 
10
-3  0  0  0 
10
-4  0  0  0 
10
-5  0  0  0 
10
-6  0  0  0 
10
-7  0  0  0 
log TCID50/ml  -3.12  -2.5  - 
 
 
  Wild Type  F24A  G33A 
Neat  6  6  6 
10
-1  6  6  6 
10
-2  4  6  2 
10
-3  1  1  0 
10
-4  0  0  0 
10
-5  0  0  0 
10
-6  0  0  0 
10
-7  0  0  0 
log TCID50/ml  -3.33  -3.66  -2.83 
 
  Wild Type  F24A  G33A 
Neat  6  6  2 
10
-1  3  3  0 
10
-2  1  1  0 
10
-3  0  0  0 
10
-4  0  0  0 
10
-5  0  0  0 
10
-6  0  0  0 
10
-7  0  0  0 
log TCID50/ml  -2.17  -2.17  -0.83 
Table  5.1:  Mutant  G33A  TCID50.  Huh7  cells  electroporated  with  G33A  mutant 
RNA were serially passaged. Before each passage, culture medium was harvested 
and serially diluted 10-fold before being used to infect naïve Huh7 cells. Seventy-
two  hours  post-infection,  cells  were  fixed  in  methanol,  permeablised  with  PBS 
(0.05% Tween) and probed with anti-NS5A antibody followed by anti-sheep FITC 
secondary antibody. Wells positive for NS5A were counted and TCID50 calculated 
(see Materials and Methods). A) Cells infected with passage 3 medium, B) cells 
infected with passage 4 medium, C) cells infected with passage 5 medium.  
 
A 
B 
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sequence analysis of the full HCV core region (amplified during RT-PCR experiments) 
was conducted following electroporation of fresh RNA in a repeat experiment. Using core 
specific primers JFH-1 RTPCR1 and JFH-1 RTPCR2, viral RNA was sequenced 72 hrs 
post-electroporation. The only mutation present was the G33A mutation inserted by site 
directed mutagenesis (Fig. 5.3A). Next, the infectious JFH-1 G33A RNA (amplified from 
cells infected with passage 5 G33A culture medium) was sequenced. Again, the original 
G33A mutation was present. However, a second mutation had arisen at residue 34 with 
valine being substituted for alanine (Fig. 5.3E). In order to identify when this mutation 
arose,  nucleotide  sequence analysis  was  carried  out  on  the  JFH-1  G33A  mutant  RNA 
extracted from cultivated cells at passage 1, 3 and 5. At passage 1, the sequence of JFH-1 
G33A core protein was identical to that of the electroporated G33A core sequence (Fig. 
5.3B). At passage 3, mutant G33A is still unable to produce infectious virus particles as 
shown  by  immunofluorescence,  RT-PCR  and  titration.  In  agreement  with  this,  the 
nucleotide sequence of G33A core protein is identical to that after electroporation (Fig. 
5.3C). Interestingly, at passage 5, when culture medium becomes infectious, two different 
HCV  core  nucleotide  sequences  can  be  detected  in  the  cultured  cells.  As  well  as  a 
thymidine at position 441 (core amino acid 34) of the JFH-1 nucleotide sequence (wild 
type JFH-1 sequence), a larger peak can be seen representing a cytosine at this position 
(Fig. 5.3D). This nucleotide mutation results in an amino acid substitution (V34A). The 
sequence containing the V34A mutation was the only sequence detected in cells infected 
with passage 5 JFH-1 G33A mutant culture medium, indicating that this mutation may be 
playing a role in the production of infectious virus particles. This mutation was not the 
same as the mutation detected in the first experiment (G32D), however, it is only situated 2 
residues downstream, and only 1 residue downstream of the original G33A mutation (Fig. 
5.4). 
In  total,  this  experiment  was  conducted  4  times,  i.e.  JFH-1  G33A  mutant  RNA  was 
electroporated into naïve Huh7 cells on 4 separate occasions, alongside wild type, GND 
and F24A mutant RNA. On each occasion, infectious virus particles were not produced 
within the first 3 passages of the cells. Infectious particles were eventually produced from 
cultured cells after 4-6 cell passages. On each occasion, naïve cells successfully infected 
with infectious G33A virus were harvested with TRIzol and total RNA extracted. Negative 
strand  viral  RNA  was  detected  by  RT-PCR  as  before  and  resultant  PCR  products 
sequenced.  The  nucleotide  sequence  analysis  results  are  shown  in  Figure  5.5.  In  each 
experiment a different mutation arose, however, each was located within the surrounding 
residues of the initial mutation at residue 33 (G32D, V34A, L36S and L37S). To rule out David A Dalrymple    Chapter 5: Results   
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Figure 5.3: Nucleotide sequence analysis of JFH-1 G33A mutant from 
repeat  experiment.  RT-PCR  products  from  various  passages  were 
sequenced  using  JFH-1  core  specific  primers  JFH-1  RTPCR1  and 
RTPCR2. A) Electroporated cells,  B) passage 1  cells, C)  passage  3 
cells, D) passage 5 cells, E) cells infected with passage 5 medium. Red 
box  indicates  original  G33A  mutation,  green  box  indicates 
compensatory V34A mutation.David A Dalrymple    Chapter 5: Results   
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                                           10         20         30         40         50        59 
JFH-1 Seq.      MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VGGVYLLPRR GPRLGVRTTR KTSERSQPR 
 
Wild type P5   MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VGGVYLLPRR GPRLGVRTTR KTSERSQPR 
 
F24A P5      MSTNPKPQRK TKRNTNRRPE DVKAPGGGQI VGGVYLLPRR GPRLGVRTTR KTSERSQPR 
 
G33A P5      MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VGAAYLLPRR GPRLGVRTTR KTSERSQPR 
 
 
 
 
 
 
 
 
 
Figure  5.4:  Sequence  analysis  of  infectious  G33A  mutant  from  repeat 
experiment. Culture medium from passage 5 cells was used to infect naïve Huh7 
cells. Cells were harvested 72 hrs post-infection and total RNA extracted. RT-
PCR products were sequenced using core specific primers JFH-1 RTPCR1 and 
JFH-1 RTPCR2. Red residues represent original site-directed mutations, green 
residues represent new mutation, and underlined residue represents the amino 
acid  changed  by  compensatory  mutation  in  original  experiment.  Only  amino 
acids 1-59 are shown here, all mutants and wild type had identical sequence to 
original JFH-1 sequence from residue 60-191. 
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JFH-1 Seq.       MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VGGVYLLPRR GPRLGVRTTR KTSERSQPR 
 
Experiment 1   MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VDAVYLLPRR GPRLGVRTTR KTSERSQPR 
 
Experiment 2   MSTNPKPQRK TKRNTNRRPE DVKAPGGGQI VGAAYLLPRR GPRLGVRTTR KTSERSQPR 
 
Experiment 3   MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VGAVYLSPRR GPRLGVRTTR KTSERSQPR 
 
Experiment 4   MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VGAVYSLPRR GPRLGVRTTR KTSERSQPR 
 
 
 
 
 
 
 
 
 
Figure  5.5:  Sequence  analysis  of  infectious  G33A  mutants  from  4  separate 
experiments. G33A RNA was electroporated into 4 separate Huh7 cultures. After 
at least 5 passages, infectious virus was produced. Total RNA was extracted 
from cells infected with medium from these cultures 72 hrs post-infection. RT-
PCR was carried out as before and PCR products sequenced using core specific 
primers JFH-1 RTPCR1 and JFH-1 RTPCR2. Red residues represent original 
site-directed  mutations,  green  residues  represent  new  mutations.  Only  amino 
acids 1-59 are shown here, all mutants and wild type had identical sequence to 
original JFH-1 sequence from residue 60-191. 
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sequencing errors, wild type RNA from each experiment was sequenced and no mutations 
detected. This indicates that this region of core protein may be critical for the production of 
infectious particles. It can therefore be hypothesised that, with the mutation of HCV core 
residue 33, the virus requires a compensatory mutation in the surrounding area of core in 
order to  allow  production of infectious particles. However, it cannot be ruled out  that 
production of infectious particles is also due to other additional mutations in the virus, out-
with core.  
 
5.2.2 Identification of further Mutations arising in Mutant G33A  
The above data led to the hypothesis that a compensatory mutation is required in order for 
JFH-1  G33A  mutant  RNA  to  produce  infectious  virus  particles.  To  confirm  that  the 
compensatory mutations identified do in fact allow production of infectious JFH-1 G33A 
virus  particles,  site-directed  mutagenesis  was  used  to  introduce  the  G33A  and  V34A 
mutations into the wild type JFH-1 sequence. The cloning strategy used was that described 
in  section  4.2.3.1  and  nucleotide  substitutions  were  confirmed  by  nucleotide  sequence 
analysis. The JFH-1 sequence (containing the double mutation) was sub-cloned back into 
pJFH-1 and new construct (pJFH-1 G33A-V34A) linearised, in vitro transcribed as before 
and electroporated into naïve Huh7 cells. Seventy-two hours post-electroporation,  cells 
were washed with PBS and fixed in methanol. Cells were then permeablised with PBS-T 
and probed by immunofluorescence for core and DDX3. As seen before, wild type core 
protein  colocalised  with  cellular  DDX3  (Fig.  5.6A)  while  there  was  no  colocalisation 
between  mutant  G33A  core  protein  and  DDX3  (Fig.  5.6B).  In  a  previous  experiment 
(section 5.2.1), a mutation at residue 34 (V34A) in JFH-1 G33A mutant RNA coincided 
with  the  production  of  infectious  virus  particles  from  this  mutant  RNA.  Naïve  cells 
infected  with  JFH-1  G33A  mutant  virus  (containing  V34A  mutation),  showed 
colocalisation between core and DDX3 (Fig. 5.1C/D). Similarly here, mutant core G33A-
V34A  colocalised  with  DDX3  in  a  manner  similar  to  wild  type  core  (Fig.  5.6C).  To 
confirm that JFH-1 G33A-V34A mutant RNA produced infectious virus particles, culture 
medium  was  harvested  from  cells  72  hrs  post-electroporation.  Naïve  Huh7  cells  were 
seeded at 5x10
4 cells/ml. The following day, culture medium was filtered and incubated 
with naïve cells. Three hours post-infection, cells were washed with PBS and overlayed 
with appropriate culture medium. Seventy-two hours post-infection cells were washed with 
PBS and  fixed  in methanol.  Cells  were then permeablised  with PBS-T and probed  by 
immunofluorescence for core and DDX3. As expected, medium from cells electroporated David A Dalrymple    Chapter 5: Results   
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Figure 5.6: Colocalisation of G33A-V34A mutant core with DDX3. Huh7 
cells were electroporated with in vitro transcribed JFH-1 mutant RNA G33A-
V34A. Seventy-two hours post-electroporation, cells were fixed and probed 
for core and DDX3 as in Chapter 3. A) Cells electroporated with wild type 
JFH-1  RNA,  B)  cells  electroporated  with  G33A  mutant  RNA,  C)  cells 
electroporated with G33A, V34A mutant RNA.David A Dalrymple    Chapter 5: Results   
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with wild type JFH-1 RNA was capable of infect naïve Huh7 cells, with core protein 
colocalising  with  DDX3  (Fig.  5.7A).  Again,  as  seen  previously,  the  absence  of  core 
staining  in  cells  incubated  with  medium  from  the  JFH-1  G33A  mutant  RNA 
electroporation confirmed infectious virus was not produced from JFH-1 G33A mutant 
RNA (Fig. 5.7B). Somewhat surprising however was the absence of core staining in cells 
incubated with supernatant from the JFH-1 G33A-V34A mutant RNA electroporation (Fig. 
5.7C),  thus  indicating  that  infectious  virus  particles  were  not  produced  despite  the 
compensatory mutation at residue 34. Therefore, it appears that the compensatory mutation 
was required to allow colocalisation with DDX3 but not production of infectious virus.  
Electroporated cultures were cultivated until passage 5 when immunofluorescence analysis 
was again carried out. Cells cultured for 5 passages were washed in PBS and fixed in 
methanol. Cells were then permeablised with PBS-T and probed for core and DDX3. As 
before, wild type core protein colocalised with DDX3 (Fig. 5.8A). Previous analysis of 
mutant G33A showed that G33A mutant core protein may colocalise with DDX3 after 
introduction of a second mutation. On this occasion, mutant G33A core protein colocalised 
with DDX3 in some cells (Fig. 5.8B) while in others there was no colocalisation (Fig. 
5.8C). No G33A-V34A mutant core protein was detected in cells cultured for 5 passages 
(Fig. 5.8D). It is possible that this is due to a lack of compensating mutation arising before 
cells  carrying  replicating  G33A-V34A  RNA  were  diluted  out  of  the  culture.  Culture 
medium was harvested from passage 5 cultures and incubated with naïve Huh7 cells as 
before.  Seventy-two  hours  post-infection,  cells  were  washed  with  PBS  and  fixed  in 
methanol.  Cells  were  then  permeablised  with  PBS-T  and  probed  for  core  and  DDX3. 
Infection was achieved using wild type culture medium (Fig. 5.9A) and also that from 
G33A (Fig. 5.9B and C). As with the G33A virus cultured for 5 passages (Fig. 5.8B and 
C),  infectious  JFH-1  G33A  mutant  virus  showed  a  mix  of  core  that  did  and  did  not 
colocalise with DDX3. 
To confirm these results, RT-PCR was carried on cells at each stage to detect replicating 
viral RNA. Replicating HCV RNA was detected in wild type, G33A and G33A-V34A 
electroporated cells 72 hrs post-electroporation (Fig. 5.10A). However, after 5 passages, 
replicating JFH-1 G33A-V34A mutant RNA was no longer detectable (Fig. 5.10A). In 
accordance with the immunofluorescence data, negative strand RNA was not detected in 
cells incubated with G33A or G33A-V34A medium (harvested 72 hrs post-electroporation) 
(Fig.  5.10B).  Replicating  RNA  was  detected  however,  in  cells  infected  with  culture 
medium from JFH-1 G33A mutant virus that had been cultured for 5 passages, but not 
from JFH-1 G33A-V34A mutant virus cultured for the same period of time (Fig. 5.10B). David A Dalrymple    Chapter 5: Results   
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Figure  5.7: Mutant  G33A-V34A  infection  studies.  Culture  medium  was 
harvested from electroporated cells 72 hrs post-electroporation and used to 
infect naïve Huh7 cells. Seventy-two hrs post-infection, cells were fixed and 
probed for core and DDX3 as in Chapter 3. A) wild type, B) G33A mutant, 
C) G33A-V34A mutant.David A Dalrymple    Chapter 5: Results   
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Figure  5.8: Passaging  of  Mutant  G33A-V34A  electroporated  cells.  Cells 
electroporated  with  in  vitro transcribed  RNA  were  passaged  5  times  and 
seeded on coverslips. Seventy-two hours post-seeding, cells were fixed and 
probed for core and DDX3 as in chapter 3. A) wild type, B) G33A mutant, C) 
G33A mutant, D) G33A-V34A mutant.
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Figure 5.9: Mutant G33A-V34A infection studies. Cells electroporated 
with in vitro transcribed RNA were passaged 5 times. Culture medium 
was then harvested and used to infect naïve Huh7 cells. Seventy-two 
hours post-infection, cells were fixed and probed for core and DDX3 as 
in  Chapter  3.  A)  wild  type,  B)  G33A  mutant,  C)  G33A  mutant,  D) 
G33A-V34A mutant.David A Dalrymple    Chapter 5: Results   
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Figure 5.10: Replication of mutant G33A-V34A RNA. RT-PCR 
was carried out on cells harvested using  TRIzol, using primer 
JFH-1 NegRT to detect negative strand replication intermediate 
viral RNA and primers JFH-1 RTPCR1 and JFH-1 RTPCR2 to 
amplify  the  subsequent  cDNA.  A)  electroporated  cells  and 
passage 5 cells, B) cells infected with supernatant from various
passages.  
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5.3 Discussion 
The previous chapter showed that, when electroporated into naïve Huh7 cells, in vitro 
transcribed JFH-1 G33A mutant RNA replicated efficiently but was unable to produce 
infectious progeny virus. After cultivation of cells with replicating viral RNA, infectious 
particles were produced. Nucleotide sequence analysis of this infectious RNA uncovered a 
mutation at residue 32 of core. Further analysis in this present Chapter has confirmed that 
JFH-1 G33A mutant RNA alone does not produce infectious RNA. Electroporated JFH-1 
G33A mutant RNA replicates within Huh7 cells and, as expected, core protein does not 
colocalise with cellular DDX3 as shown by RT-PCR and immunofluorescence. Medium 
from these cultures is not, however, capable of infecting naïve Huh7 cells. Whether or not 
particles are produced from this mutant RNA and are non-infectious is still unclear. Further 
studies are required in order to determine this, for example HCV core ELISA to detect core 
protein in the culture medium or perhaps RT-PCR to detect positive strand viral RNA in 
the medium. Care would be required in analysing supernatant by RT-PCR, however, as it 
is possible that in vitro transcribed RNA that did not enter cells during electroporation 
could be detected. Upon culture of electroporated cells, infectious JFH-1 G33A mutant 
virus particles are produced, normally after 4-6 passages. Infection was confirmed by both 
immunofluorescence  to  detect  core  protein  and  by  RT-PCR  detecting  negative  strand 
replication intermediate viral RNA. By immunofluorescence, core protein produced from 
infectious JFH-1 G33A mutant RNA was shown to colocalise with DDX3 in some cases. 
This is not believed to be the reason for the switch from non-infectious to infectious virus 
production since some infected cells did not show colocalisation between core and DDX3 
and mutant F24A, which does not show colocalisation between core and DDX3, produces 
infectious virus following electroporation. Also, if the interaction between core and DDX3 
is responsible for the production of infectious particles, then infectious particles would not 
have  been  produced  from  other  JFH-1  mutant  RNAs  analysed.  Nucleotide  sequence 
analysis  of  infectious  JFH-1  G33A  mutant  RNA  uncovered  a  second  mutation,  the 
appearance  of  which  coincided  with  the  production  of  infectious  particles.  In  total,  4 
mutations were discovered in separate experiments, each of which was within 4 residues of 
the original G33A mutation. It is therefore possible that while the G33A mutation has no 
effect on HCV RNA replication, it has an adverse effect on infectious particle production, 
possibly  by  affecting  the  structure  of  core  as  suggested  by  the  proposed  structural 
difference between wild type core and mutant G33A core (Fig. 3.18). A random replication 
error is then required in order to compensate for the structural change caused by the G33A 
mutation.  David A Dalrymple    Chapter 5: Results   
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To confirm that a mutation near residue 33 of core was responsible for the production of 
infectious  particles,  infection  studies  were  carried  out  on  JFH-1  RNA  containing  the 
original mutation G33A and a mutation at residue 34 (V34A), shown to be present in 
infectious JFH-1 G33A RNA. Culture medium from cells electroporated with this RNA 
was non-infectious for naïve Huh7 cells as shown by immunofluorescence and RT-PCR. 
This suggests that another compensatory mutation is required in order to allow production 
of infectious particles. No mutations were found in the core coding sequence other than the 
4 found between residues 32 and 37, indicating that the mutation is elsewhere within the 
JFH-1 genome. It is possible that a combination of mutations are required, only one of 
which  is  within  the  core  region,  or  perhaps  the  mutation  in  core  is  not  required  for 
infectious particle production. This seems unlikely however, since no other mutant RNA 
developed a similar mutation (Chapter 4). With the exception of 4 genotype 3b isolates, 
residue 33 of HCV core is completely conserved throughout all genotypes. The 4 genotype 
3b isolates with a mutation at residue 33 (glycine – glutamic acid) (Fig. 3.21) also have 
mutations at residues 8, 16, 20, 26, 43, 48, 50-53 and 55, any one of which could be 
compensating for the mutation at residue 33. It is also possible however, that these strains 
are not infectious. 
Having discovered that residue 33 of HCV core protein is essential for the production of 
infectious particles, future work should concentrate on identifying the mechanism behind 
this block, whether it is at the particle formation stage or during the infection process.        
 
221 
 
 
 
 
 
 
 
6. Nucleo-cytoplasmic Shuttling of DDX3     
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6.1 Introduction 
Although a function has not yet been assigned to DDX3 with regards to the life cycle of 
HCV,  it  has  been  shown  that  DDX3  is  involved  in  the  Rev-RRE  (rev  response 
element)/CRM1 pathway for the export of intron-containing HIV-1 transcripts (Yedavalli 
et al., 2004). Chromosomal region maintenance protein 1 (CRM1) was initially discovered 
in  S.  pombe  while  analysing  cold  sensitive  mutants  and  their  effect  on  chromosome 
structure (Adachi and Yanagida, 1989). An accumulation of evidence suggests that this 
evolutionarily conserved protein is an essential factor in the nuclear export of proteins 
containing  a  nuclear  export  signal  (Kudo  et  al.,  1997,  Nishi  et  al.,  1994,  Adachi  and 
Yanagida, 1989, Wolff et al., 1997). CRM1 has  also been shown  to be the target  for 
leptomycin B (LMB) (Nishi et al., 1994), a potent inhibitor of signal-dependent nuclear 
export  of  proteins  (Kudo  et  al.,  1998).  Studies  on  HIV-1  rev  protein suggest  that  rev 
transports  unspliced  and  partially  spliced  HIV-1  transcripts  from  the  nucleus  to  the 
cytoplasm by binding CRM1 (Askjaer et al., 1998, Otero et al., 1998, Bogerd et al., 1998), 
using a nucleo-cytoplasmic shuttling pathway (Fukuda et al., 1997). DDX3 binds CRM1 
and rev, shuttles between nucleus and cytoplasm and is required to have enzymatic activity 
(Yedavalli et al., 2004). Leptomycin B was also shown to block DDX3 export from the 
nucleus, presumably by acting on CRM1 (Yedavalli et al., 2004). Identification of DDX3 
as a nucleo-cytoplasmic shuttling protein was carried out using a transfected, HA-tagged 
DDX3. Here, in order to confirm if endogenous DDX3 is a nucleo-cytoplasmic shuttling 
protein, Huh7 cells were incubated with LMB before analysing the cellular localisation of 
DDX3, using a rabbit polyclonal anti-DDX3 antiserum (R648).  Using Nneo/C-5B (2-3) 
cells, which harbour an autonomously replicating, genome length, dicistronic, selectable 
HCV genotype 1b  RNA (Ikeda et al.,  2002), the  effect of LMB  on the colocalisation 
between HCV core and cellular DDX3 was also analysed.  David A Dalrymple    Chapter 6: Results   
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6.2 Results 
6.2.1 DDX3 is a nucleo-cytoplasmic shuttling protein 
Yedavalli  et  al.  (2004)  showed  that  exogenously  expressed,  HA-tagged  DDX3  binds 
CRM1 in the nucleus and shuttles between nucleus and cytoplasm and that LMB, a potent 
inhibitor of the CRM1 export pathway, blocked the export of HA-tagged DDX3 from the 
nucleus (Yedavalli et al., 2004). It was also shown that LMB blocked the export of HA-
tagged DDX3 from the nucleus. In order to confirm if endogenous DDX3 acted in the 
same way, Huh7 cells were incubated at 37ºC with 12.5 mM, 25 mM or 50 mM LMB in 
the appropriate culture medium. Two hrs post-incubation, cells were washed with PBS, 
fixed  in  methanol  and  permeablised  with  PBS-T  before  being  probed  for  DDX3.  At 
concentrations of as low as 12.5 mM, a build-up of endogenous DDX3 in the nucleus was 
seen, indicating  that, as with  HA-tagged exogenous  DDX3,  LMB is able to block the 
nuclear  export  of  cellular  DDX3  (Figure  6.1).  At  greater  concentrations  of  LMB,  no 
increase in nuclear build-up was seen. 
 
6.2.2 HCV core colocalises with DDX3 in the presence of LMB 
To confirm HCV core and cellular DDX3 colocalise in the presence of LMB, 2-3 cells 
were incubated at 37ºC with 12.5 mM LMB in the appropriate culture medium. Two hours 
post-incubation, cells were washed with PBS, fixed in methanol and permeablised with 
PBS-T  before  being  probed  with  mouse  monoclonal  anti-core  antibody  and  rabbit 
polyclonal  anti-DDX3  antiserum  (R648),  followed  by  the  appropriate  secondary 
antibodies. In the presence of LMB, a build-up of DDX3 was seen in the nucleus as before, 
and, similar to 2-3 cells in the absence of LMB, colocalisation was seen between core and 
DDX3 in the cytoplasm (Figure 6.2). 
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Figure 6.1: Leptomycin B inhibits DDX3 nuclear export. Huh7 
cells were seeded at 5x104 cells/ml. The following day, cells 
were  treated  with  CRM1  inhibitor  LMB  at  concentrations 
shown  for  2  hrs  at  37°C  before  being  fixed  in  methanol, 
permeablised  with  PBS-T  and  probed  with  rabbit  polyclonal 
anti-DDX3  antiserum  (R648),  followed  by  anti-rabbit  FITC. 
The panels on the right show close-up images, highlighting the 
build-up of DDX3 in the nucleus and absence in the nucleolus.David A Dalrymple    Chapter 6: Results   
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Figure 6.2: HCV core – DDX3 colocalisation in the presence of LMB. 
HCV replicon-harbouring Neo/C-5B (2-3) cells were seeded at 5x104
cells/ml. The following day, cells were treated with LMB (12.5 mM) for 
2 hrs at 37°C before being fixed in methanol, permeablised with PBS-T  
and  probed  with  mouse  monoclonal  anti-core  antibody  and  rabbit 
polyclonal  anti-DDX3 antiserum  (R648), followed by  the  appropriate 
secondary antibodies (anti-mouse FITC and anti-rabbit TRITC). A) No 
LMB,  B) 12.5mM LMB.
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6.3 Discussion 
The  results  shown  here  using  endogenous  DDX3  confirm  the  results  described  by 
Yedavalli et al. (2004). Leptomycin B mediated blockage of the CRM1 export pathway 
causes  a  build-up  of  DDX3  in  the  nucleus.  This  confirms  that  DDX3  is  a  nucleo-
cytoplasmic shuttling protein and relies on the CRM1 export pathway in order to shuttle 
from  nucleus  to  cytoplasm.  The  hypothesis  given  by  Yedavalli  et  al.  (2004)  for  the 
involvement of DDX3 in the Rev-RRE / CRM1 pathway is that DDX3 unwinds large HIV-
1 RNAs allowing them to pass through the nuclear pore and into the cytoplasm. As the 
HCV replication cycle takes place solely in the cytoplasm, a role for DDX3 in shuttling 
HCV  RNA  from  the  nucleus  to  the  cytoplasm  seems  highly  unlikely.  However,  it  is 
possible  that  in  the  case  of  HCV,  core  sequestration  of  DDX3  prevents  DDX3  from 
shuttling some cellular factor from nucleus to cytoplasm, possibly of antiviral nature.  
In  the  presence  of  LMB,  although  a  build-up  of  DDX3  was  seen  in  the  nucleus, 
colocalisation between core and DDX3 was still present in the cytoplasm of full-length 
replicon-harbouring  cells.  There  are  several  plausible  reasons  for  this.  Firstly, 
colocalisation may be due to DDX3 sequestered before the addition of LMB. As LMB is 
toxic to cells, it was not possible to determine whether after a long-term incubation the 
interaction would diminish due to a limiting amount of cytoplasmic DDX3. It may also be 
that there are various forms of DDX3 and the form sequestered by core is not the form 
required for nuclear shuttling. The possibility of multiple forms of DDX3 is backed up by 
the discovery of an antibody that detects a nuclear form of DDX3 (A. Patel, unpublished 
data).  
This work confirms that DDX3 is a nucleo-cytoplasmic shuttling protein, however, it is 
still unclear if its role in nuclear export is related to its sequestration by HCV core protein. 
It would be of interest to study the effects of co-infection with HIV-1 and HCV in terms of 
core-DDX3 colocalisation and DDX3 mediated export of Rev associated HIV-1 RNAs. 
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7.1 HCV core – DDX3 Interaction 
Since the initial description of an interaction between HCV core protein and the cellular 
DEAD-box RNA helicase DDX3, little more has been reported on the significance of this 
interaction,  while  the  true  cellular  function  of  DDX3  still  remains  undetermined.  To 
investigate the significance of the core-DDX3 interaction in terms of the HCV life cycle, a 
detailed analysis of the HCV core amino acids required for interaction was carried out. 
What follows is a description of the major findings of this research project, culminating in 
a discussion on the possible functional significance of the core-DDX3 interaction. 
 
7.1.1 Identification of Critical HCV Core Residues 
The region of core involved in the interaction with DDX3 was reported to be between 
amino acids 1 and 59 (Owsianka and Patel, 1999) or amino acids 1-40 (You et al., 1999). 
Analysis  of  a  library  of  HCV  core1-59  mutants,  each  containing  0-4  amino  acid 
substitutions, identified 9 mutants which, when fused to GFP and expressed in bacteria, 
showed reduced ability to bind GST-fused DDX3 in an ELISA assay (Fig 3.9). Systematic 
analysis of these 9 mutants expressed in Huh7 cells in the context of core, E1 and E2 
resulted in the identification of a 13-residue region (amino acids 24-36), 6 residues of 
which were critical for interaction with cellular DDX3 (Fig 3.16). None of the 6 mutations 
in core affected the localisation of core to the lipid droplets (Fig. 4.12). As residues out-
with positions 24-36 were not tested individually for interaction with DDX3 it is possible 
that other surrounding residues are also essential for the interaction, therefore it should be 
said that there are at least 6 residues of HCV core protein critical for interaction with 
cellular DDX3. 
These  6  residues  are  highly  conserved  throughout  all  HCV  genotypes,  with  only  4 
genotype 3B isolates showing any differences, each of which has a glutamine to glutamic 
acid substitution at residue 33 (Fig. 3.21), however the infectiousness of these isolates is 
not known. Analysis  of the positions  of  these  6 residues  on a  standard  α-helix  model 
unveiled their close proximity to one another (Fig. 3.17), suggesting a possible binding site 
for the cellular helicase DDX3.  
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7.1.2 Analysis of Core Mutants in HCVcc System and Effects on 
HCV Life Cycle 
To study the role of DDX3 in the HCV life cycle, the 6 critical amino acids of core were 
substituted for alanine within individual JFH-1 backgrounds. As in the transient expression 
system,  mutant  core  protein  did  not  colocalise  with  cellular  DDX3  (Fig  4.11),  thus 
confirming the essential role these residues play in the interaction with DDX3. Replication 
of HCV RNA was not abolished completely in the absence of core-DDX3 interaction, 
suggesting DDX3 is not essential for the unwinding of highly structured HCV 5’ or 3’ 
RNA. This is of no surprise since HCV encodes its own RNA helicase which is believed to 
carry out this function (Banerjee and Dasgupta, 2001, Lam and Frick, 2006). It is possible 
however, that DDX3 plays some accessory role since RNA replication levels of mutant 
viruses were >50-fold lower than that of wild type virus (Fig. 4.23). A detailed analysis of 
wild type and mutant RNA replication levels is currently being carried out.   
Ded1,  the  yeast  homologue  of  DDX3,  is  required  for  the  initiation  step  of  translation 
(Chuang et al., 1997). DDX3 rescues yeast cells with a lethal mutation in its ded1 gene 
(Mamiya and Worman, 1999), and can partially relieve the block in translation from the 
HCV  5’NCR  in  Sf21  insect  cells  (Scott,  2002),  suggesting  a  possible  involvement  of 
DDX3 both in cellular mRNA translation and in translation of the HCV genome. In the 
presence of HCV core, DDX3 was unable to rescue ded1 deletion mutants, suggesting that 
core protein may sequester DDX3 in order to reduce cellular mRNA translation and/or 
increase  translation  of  the  viral  RNA  from  the  HCV  5’NCR.  Western  immuno-blot 
analysis  did  not  show  any  differences  in  DDX3  levels  between  mutant  and  wild  type 
infected cultures (Fig. 4.9), suggesting the sequestration of DDX3 does not have a major 
effect on cellular mRNA translation. However, differences in levels of viral proteins were 
seen between mutant and wild type virus infected cultures (Fig. 4.24). Upon infection with 
equal TCID50 titres, all mutants showed reduced levels of core, E1 and E2 proteins as 
compared to wild type. This may indicate a reduction in translation due to the absence of 
sequestered DDX3. However, it may also be related to the reduced replication levels of the 
mutant viruses, which, as discussed above, may also be due to the absence of sequestered 
DDX3.   
Similarly, interaction between core and DDX3 is not essential for production of infectious 
virus particles. Infectious particles were produced by all mutant JFH-1 RNAs (except for 
mutant G33A, discussed later), producing similar titres to that of wild type (Fig. 4.22). David a Dalrymple    Chapter 7: Conclusions   
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Therefore, it is doubtful that DDX3 is involved in packaging viral RNA into viral particles, 
as such a role would have consequences on infectious titre in the absence of sequestered 
DDX3. It is interesting to note that, although replication levels of mutant HCV RNA were 
>50-fold  lower  than  that  of  wild  type  virus,  similar  titres  of  infectious  particles  were 
produced. However, a correlation between replication level and particle production has not 
yet been confirmed, therefore it is possible that replication of wild type HCV RNA results 
in excess viral RNA molecules being produced compared to number of infectious particles 
produced.  Mutant  HCV  RNA  could  therefore  theoretically  produce  less  HCV  RNA 
without affecting infectious particle numbers. 
From this work, it can be said that DDX3 is not essential for cell entry or virus replication, 
translation or release, however it is possible that DDX3 is an accessory protein which 
increases the efficiency of the virus life cycle, possibly by exerting some effect during 
replication or translation. On the other hand, the sequestration of DDX3 by core may be 
affecting some cellular process, thus proving advantageous to the virus, or producing some 
of  the  pathogenic  effects  associated  with  HCV  infection.  DDX3  has  been  detected  in 
purified,  functional,  human  spliceosome  complexes  (Zhou  et  al.,  2002)  and  also  in 
spliceosomal B complexes which undergo catalytic activation, leading to catalysis of pre-
mRNA splicing (Deckert et al., 2006), suggesting an involvement in splicing. As genomic 
HCV RNA acts as a template for translation, splicing is not required for HCV translation. 
Therefore it is doubtful that DDX3 is required for some HCV-related splicing event. It is 
possible however, that sequestration of DDX3 by core prevents or reduces cellular pre-
mRNA splicing, which may, in turn, have an effect on for example, cell cycle regulation 
by reduction of essential cell cycle regulators.  
Yedavalli et al. reported the involvement of DDX3 in the nucleo-cytoplasmic shuttling of 
un-spliced  and  partially  spliced  HIV-1  mRNAs  (Yedavalli  et  al.,  2004).  Nucleo-
cytoplasmic shuttling of endogenous DDX3 has been confirmed in the present study using 
leptomycin B to inhibit CRM1-mediated nuclear export (Chapter 6). DDX3 may therefore 
be involved in shuttling core protein to the nucleus. Although no nuclear staining of core 
protein was seen in this study, many reports have shown that core protein can have an 
effect on transcription from a number of cellular and viral promoters (see section 1.5.5.3), 
suggesting  nuclear  localisation.  Indeed,  a  specific  interaction  between  core  and  the 
proteasome activator PA28γ within the nucleus, suggested that the mature form of core 
localised to the nucleus where it was subsequently degraded by the nuclear proteasome 
(Moriishi et al., 2003). The degradation of core in the nucleus would explain the lack of 
evidence supporting the presence of core in the nucleus. This report showed that core David a Dalrymple    Chapter 7: Conclusions   
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localised  to  the  nucleus  both  in  the  presence  and  absence  of  the  PA28γ  binding  site, 
suggesting the possibility of alternative mechanisms for the nuclear localisation of core, 
other  than  that  involving  PA28γ.  HCV  core  has  several  putative  nuclear  localisation 
signals  (Suzuki  et  al.,  1995,  Suzuki  et  al.,  2005,  Chang  et  al.,  1994),  suggestive  of 
alternative mechanisms for core nuclear localisation. It  is possible  that DDX3 may be 
involved  in  an  alternative  nuclear  transportation  route.  Shuttling  of  DDX3  therefore, 
presents a potential route for the transport of HCV core to the nucleus where it may affect 
cellular transcription, possibly producing a more “virus-friendly” environment within the 
host cell. 
Finally, the sequestration of DDX3 by core may be having a direct effect on cell cycle 
regulation.  Two  independent  reports  have  suggested  that  DDX3  is  involved  in  the 
regulation of the cell cycle (Chang et al., 2006, Chao et al., 2006). Knockdown of DDX3 
expression led to an accelerated proliferation rate in NIH3T3 cells (Chang et al., 2006), 
while DDX3 expression levels were lower in HCV-infected liver tumour specimens as 
opposed to normal liver tumour specimens (Chao et al., 2006). Core protein may therefore 
be sequestering DDX3 in order to control the cell cycle and in doing so, having a role in 
progression to tumourigenicity. 
The identification of HCV core residues critical for interaction with the cellular DEAD-
box RNA helicase has allowed studies on the effects DDX3 has on the life cycle of HCV. 
Although it has been shown here that DDX3 is not essential for propagation of the virus in 
cell culture, it is possible that DDX3 exerts subtle enhancing effects on either viral RNA 
replication or translation. However, the wealth of information regarding the effects HCV 
core protein has on cellular processes suggests the interaction between core and DDX3 
may instead be causing some effect on the host cell. The discovery of the HCVcc system 
should allow future studies to analyse cellular processes in the presence of both wild type 
and mutant HCV, leading to a better understanding of the cellular function of DDX3 and 
its role in the life cycle of HCV. 
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7.2  Identification  of  HCV  Core  Residue  Critical  for 
Production of Infectious Particles 
As described above, 6 residues of HCV core protein were identified which are critical for 
interaction with the cellular DEAD-box RNA helicase DDX3. Although none of the 6 
residues, when mutated to alanine, prevented viral RNA replication or translation in an 
HCVcc system, only 5 of the 6 mutations permitted the production of infectious progeny 
particles. Mutation of HCV core residue 33 from glycine to alanine completely abolished 
the  production  of  infectious  particles  without  blocking  replication  of  viral  RNA  or 
translation  of  viral  proteins.  Immunofluorescence  data  shows  that  G33A  core  protein 
localises to the lipid droplets (Fig. 4.12), indicating the correct subcellular localisation of 
mutant core protein. One possible explanation for the lack of infectious progeny particles is 
that  amino  acid  33  is  essential  for  homo-oligomerisation  of  core  protein,  resulting  in 
formation of viral capsids. Mutation of amino acid 33 would therefore result in inhibition 
of  capsid  assembly.  Residues  1-75  of  core  have  been  shown  to  be  involved  in  core 
multimerisation (Matsumoto et al., 1996). However, although residues 1-68 of core were 
shown to be involved in assembly of capsids in a cell-free assay which were apparently 
indistinguishable from those isolated from HCV-infected patient serum (when analyzed by 
transmission electron microscopy) (Klein et al., 2004), deletion of residues 27-38 did not 
reduce the ability of core to assemble into capsids (Klein et al., 2005). The N-terminal 
region of core contains 2 basic regions (amino acids 6-23 and 39-67) separated by a neutral 
linker region (amino acids 27-38). Reducing the number of basic residues in the 2 basic 
regions reduces the ability of core to assemble into capsids, suggesting basic charge is 
important for capsid assembly (Klein et al., 2005). The fact that the neutral linker region 
(residues  27-38)  can  be  deleted  without  affecting  capsid  assembly,  rules  out  an 
involvement of amino acid 33 in capsid assembly in this system. However, the cell-free 
assay is carried out in an artificial environment and therefore may not be reliable. In vitro 
capsid assembly may not mimic authentic HCV capsid assembly due to the absence of 
fully matured core protein and replicating viral RNA, as well as the absence of a wide 
array of cellular proteins that may be involved within the permissive cellular environment. 
Therefore, the possible involvement of amino acid 33 of core protein in the successful 
assembly of HCV capsids cannot currently be ruled out. Another explanation for the lack 
of infectious particles produced by JFH-1 mutant G33A is that residue 33 may be required 
for  binding  viral  RNA.  Residues  1-75  of  core  have  been  shown  to  bind  HCV  RNA 
(Santolini et al., 1994) suggesting residue 33 may be involved in this function. However, it 
is likely that it is the basic residues within this region that are involved in RNA binding, as David a Dalrymple    Chapter 7: Conclusions   
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in  the  case  of  Sindbis  capsid  protein  (Geigenmuller-Gnirke  et  al.,  1993).  It  is  also 
conceivable  that  amino  acid  33  is  required  during  secretion  of  infectious  particles. 
Mutation of this residue would therefore block particle secretion. These possibilities are 
currently being investigated. 
Upon  passage  of  replicating  JFH-1  G33A  RNA,  infectious  particles  are  eventually 
produced. The viral RNA contained in these infectious particles, however, has a second 
mutation near the initial G33A mutation. The appearance of infectious particles coincides 
with the appearance of this second mutation, suggesting this is a compensatory mutation 
allowing production of infectious particles. However, when both the G33A mutation and 
the second mutation were introduced into wild type JFH-1 RNA, no infectious particles 
were  produced  following  electroporation  into  Huh7  cells.  This  suggests  that  another 
mutation may have arisen elsewhere in the viral genome of the original mutant G33A 
mutant  that  is  responsible for  the  production  of  infectious  particles, either  alone  or  in 
conjunction with the mutation identified near residue 33. Nucleotide sequence analysis of 
the full viral genome will be required in order to detect any further mutations responsible 
for the observed phenotype. 
This work has provided important information regarding the interaction between HCV core 
protein  and  the  cellular  DEAD-box  helicase  DDX3.  Future  work  can  now  use  this 
information  and  the  reagents  generated  to  investigate  such  issues  as  the  replication 
efficiency  of  HCV  in  the  absence  of  core-DDX3  interaction  as  well  as  more  detailed 
analysis on the function of HCV amino acid 33 in terms of the production of infectious 
progeny  virus.  As  the  results  here  suggest  a  possible  role  for  DDX3  in  HCV  RNA 
replication, one future study should be to carry out time course analysis over the first 48 
hours post RNA electroporation to detect differences in replication rates between mutant 
and  wild  type  RNA  before  secondary  infection  of  neighbouring  cells.  As  the  rate  of 
secondary infection may vary between cultures, analysis at eary time points would allow 
direct comparison between mutant and wild type electroporated RNA. At early time points 
there  would  also  be  less  replicating  viral  RNA,  therefore  reducing  the  possibility  of 
saturation during RT-PCR analysis. Reduced replication rates may not only indicate an 
involvement  of  DDX3  in  replication  but  also  in  translation  of  the  HCV  open  reading 
frame. Time course analysis could also be used to identify differences in rates of progeny 
particle release. Culture medium harvested at early time points and used to infect naïve 
cells would allow identification of any delay in production / release of infectious particles 
by  mutant  RNA.  While  the  work  presented  here  has  concentrated  on  interrupting  the 
association between core and DDX3 by mutation of residues required for this interaction, David a Dalrymple    Chapter 7: Conclusions   
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another method of analysis would be to knockout DDX3 protein expression using siRNA 
technology. Two recent publications have reported the effect knockdown of endogenous 
DDX3 has on HCV replication. In a study of 62 host genes shown to physically interact 
with HCV RNA or HCV-encoded proteins, knockdown of endogenous DDX3 by siRNA 
resulted in a significant reduction in both HCV RNA levels and viral titer (Randall et al., 
2007).  Furthermore,  shRNA  mediated  knockdown  of  cellular  DDX3  also  resulted  in 
reduced accumulation of HCV RNA and reduced viral titers (Ariumi et al., 2007). The 
same  publication  also  reports  a  reduction  in  HCV  RNA  replication  by  a  subgenomic 
replicon lacking core protein. However, no association between DDX3 and viral RNA or 
other HCV proteins has ever been reported. Although these reports suggest knockdown of 
DDX3 suppresses HCV RNA replication, no indication of the viability of the cells is given. 
As DDX3 is a multifunctional protein involved in splicing (Deckert et al., 2006, Zhou et 
al., 2002), cell cycle regulation (Chang et al., 2006, Chao et al., 2006), nucleo-cytoplasmic 
RNA shuttling (Yedavalli et al., 2004) and RNA transport (Kanai et al., 2004), knockdown 
of  this  protein  may  have  serious  consequences  for  essential  processes  within  the  cell 
which, in turn, may have a secondary effect on HCV replication. These effects may include 
inhibition of protein synthesis (thus limiting any cellular factors required for HCV RNA 
translation) or cell cycle regulation, which may result in the host entering into a stage of 
the  cell  cycle  that  is  not  optimum  for  HCV  replication.  Such  an  effect  on  cell  cycle 
regulation was reported to occur in NIH-3T3 cells in which knockdown of mouse DDX3 
led to premature entry into S-phase (Chang et al., 2006). Detailed analysis of  cellular 
functions  such  as  cell  cycle  regulation,  splicing  and  protein  synthesis  under  DDX3 
knockdown conditions will be required before direct effects of DDX3 knockdown on HCV 
replication can be determined. As DDX3 is constitutively expressed in all tissues and has 
many  homologues  in  different  species,  it  is  also  possible  that  it  is  an  essential  gene, 
without which the cell cannot survive. In this case, complete knockdown of DDX3 may not 
be possible without cell death. An inducible RNAi system in which the expression levels 
of shRNA (and thus DDX3) can be sensitively controlled may therefore be an option. 
Regarding non-infectious mutant G33A, further analysis is required in order to understand 
if infectious particles are produced that cannot exit the host cell, or, if particles are released 
that are non-infectious. For this, culture medium can be fractionated by sucrose density 
gradient centrifugation and fractions analysed by RT-PCR for the presence of G33A RNA 
and compared to fractions corresponding to wild type virus particles. Detection of mutant 
G33A RNA in the same fraction as wild type particles would indicate that non-infectious 
particles are being released. Mutant G33A culture medium may also be pelleted in order to 
detect  HCV  RNA  and  core  protein,  also  indicative  of  non-infectious  HCV  particle David a Dalrymple    Chapter 7: Conclusions   
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secretion. If HCV RNA and core protein cannot be detected in the culture medium, it is 
possible that infectious particles are being produced but cannot be secreted. To investigate 
this possibility, electroporated cells should be lysed and intracellular material used to infect 
naïve cells. Resultant infection would indicate residue 33 of core is required for secretion 
of infectious particles. However, if no infection occurs then it would indicate a role for 
residue  33  in  particle  assembly.  If  mutant  G33A  core  protein  does  prevent  particle 
assembly it would be of interest to see if this molecule could have a dominant negative 
effect on assembly of wild-type particles. Mutant G33A RNA should be co-transfected 
with wild-type core protein  in order to  see if the  wild-type core can rescue infectious 
particles. More importantly however, wild-type HCV RNA should be co-transfected with 
mutant G33A core  to see if production  of infectious  particles  can  be reduced  or even 
completely abolished due to incorporation of G33A mutant core. If mutant G33A core did 
prove  to  have  a  dominant  negative  effect,  this  may  have  interesting  applications  as  a 
therapeutic agent. However, core has been shown to have many adverse effects on the host 
cell therefore further modifications would be required. Ultimately, the aim of this research 
is to discover both the cellular role of DDX3 and its functional relevance in terms of the 
life cycle of HCV. The reagents and data produced during this project, in conjunction with 
the new HCVcc system will surely prove to be important in the progress of this project in 
the future.      
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Appendix - Oligonucleotides  
Primer  Sequence  Function 
AP233  5'AAACTGCAGCACGATAATAC
CATGGGC 3' 
Used to amplify residues 1-59 of 
core (HCV strain H77c)  
AP234  5'CCCAAGCTTCTATTAGGGGA
TAGGCTGACGTCTACC 3' 
 
Used to amplify residues 1-59 of 
core (HCV strain H77c) 
Quickchange 1  5'GATGAACTATACAAACTGTA
GCACGATAATACCATG 3' 
Site-directed mutagenesis of 
pGFP-Core1-59 to introduce stop 
codon at end of GFP sequence 
Quickchange 2  5'CATGGTATTATCGTGCTACA
GTTTGTATAGTTCATC 3' 
Site-directed mutagenesis of 
pGFP-Core1-59 to introduce stop 
codon at end of GFP sequence 
Mut 99F  5'CGTCGCCCACAGGACGTCAA
GTTCCCGGGT 3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 99 to revert 
residue 22 back to wild type 
Mut 99R  5'ACCCGGGAACTTGACGTCCT
GTGGGCGACG 3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 99 to revert 
residue 22 back to wild type 
Mut 110F  5'CGCAGGGGCCCTAGATTGGG
TGTGCGCGCG 3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 110 to revert 
residue 43 back to wild type 
Mut 110R  5'CGCGCGCACACCCAATCTAG
GGCCCCTGCG 3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 110 to revert 
residue 43 back to wild type 
Mut 111F  5'ATGGGCACGAATCCTAAACC
TCAAAGAAAAACCAAACGTAA
C 3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 111 to revert 
residue 6 back to wild type 
Mut 111R  5'GTTACGTTTGGTTTTTCTTTG
AGGTTTAGGATTCGTGCCCAT 
3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 111 to revert 
residue 6 back to wild type 
Mut 115F  5'CCTAAACCTCAAAGAAAAAC
CAAACGTAACACCAACCGTCG
CCCACAG 3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 115 to revert 
residues 10 and 12 back to wild 
type 
Mut 115R  5'CTGTGGGCGACGGTTGGTGT
TACGTTTGGTTTTTCTTTGAGG
TTTAGG 3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 115 to revert 
residues 10 and 12 back to wild 
type 
Mut 125AF  5'ACCAAACGTAACACCAACCG
TCGCCCACAGGAC 3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 125 to revert 
residue 16 back to wild type 
Mut 125AR  5'GTCCTGTTGGCGACGGTTGG
TGTTACGTTTGGT 3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 125 to revert 
residue 16 back to wild type 
Mut 125BF  5'ACTTCCGAGCGGTCGCAACC
TCGAGGTAGACGT 3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 125 to revert 
residue 57 back to wild type 
Mut 125BR  5'ACGTCTACCTCGAGGTTGCG
ACCGCTCGGAAGT 3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 125 to revert 
residue 57 back to wild type      
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Mut 126F  5'GGCACGAATCCTAAACCTCA
AAGAAAAACCAAACGTAACAC
C 3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 126 to revert 
residue 8 back to wild type 
Mut 126R  5'GGTGTTACGTTTGGTTTTTCT
TTGAGGTTTAGGATTCGTGCC3' 
Site-directed mutagenesis of pC-
E1-E2 mutant 126 to revert 
residue 8 back to wild type 
Alanine 24F  5'CCACAGGACGTCAAGGCCCC
GGGTGGCGGTCAG 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 24 to 
alanine 
Alanine 24R  5'CTGACCGCCACCCGGGGCCT
TGACGTCCTGTGG 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 24 to 
alanine 
Alanine 25F  5'CAGGACGTCAAGTTCGCGGG
TGGCGGTCAGATC 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 25 to 
alanine 
Alanine 25R  5'GATCTGACCGCCACCCGCGA
ACTTGACGTCCTG 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 25 to 
alanine 
Alanine 26F  5'GACGTCAAGTTCCCGGCTGG
CGGTCAGATCGTT 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 26 to 
alanine 
Alanine 26R  5'AACGATCTGACCGCCAGCCG
GGAACTTGACGTC 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 26 to 
alanine 
Alanine 27F  5'GTCAAGTTCCCGGGTGCCGG
TCAGATCGTTGGT 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 27 to 
alanine 
Alanine 27R  5'ACCAACGATCTGACCGGCAC
CCGGGAACTTGAC 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 27 to 
alanine 
Alanine 28F  5'AAGTTCCCGGGTGGCGCTCA
GATCGTTGGTGGA 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 28 to 
alanine 
Alanine 28R  5'TCCACCAACGATCTGAGCGC
CACCCGGGAACTT 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 28 to 
alanine 
Alanine 29F  5'TTCCCGGGTGGCGGTGCGAT
CGTTGGTGGAGTT 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 29 to 
alanine 
Alanine 29R  5'AACTCCACCAACGATCGCAC
CGCCACCCGGGAA 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 29 to 
alanine 
Alanine 30F  5'CCGGGTGGCGGTCAGGCCGT
TGGTGGAGTTTAC 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 30 to 
alanine 
Alanine 30R  5'GTAAACTCCACCAACGGCCT
GACCGCCACCCGG 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 30 to 
alanine 
Alanine 31F  5'GGTGGCGGTCAGATCGCTGG
TGGAGTTTACTTG 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 31 to 
alanine 
Alanine 31R  5'CAAGTAAACTCCACCAGCGA
TCTGACCGCCACC 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 31 to 
alanine      
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Alanine 32F  5'GGCGGTCAGATCGTTGCTGG
AGTTTACTTGTTG 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 32 to 
alanine 
Alanine 32R  5'CAACAAGTAAACTCCAGCAA
CGATCTGACCGCC 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 32 to 
alanine 
Alanine 33F  5'GGTCAGATCGTTGGTGCAGT
TTACTTGTTGCCG 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 33 to 
alanine 
Alanine 33R  5'CGGCAACAAGTAAACTGCAC
CAACGATCTGACC 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 33 to 
alanine 
Alanine 34F  5'CAGATCGTTGGTGGAGCTTA
CTTGTTGCCGCGC 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 34 to 
alanine 
Alanine 34R  5'GCGCGGCAACAAGTAAGCTC
CACCAACGATCTG 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 34 to 
alanine 
Alanine 35F  5'ATCGTTGGTGGAGTTGCCTTG
TTGCCGCGCAGG 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 35 to 
alanine 
Alanine 35R  5'CCTGCGCGGCAACAAGGCAA
CTCCACCAACGAT 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 35 to 
alanine 
Alanine 36F  5'GTTGGTGGAGTTTACGCGTT
GCCGCGCAGGGGC 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 36 to 
alanine 
Alanine 36R  5'GCCCCTGCGCGGCAACGCGT
AAACTCCACCAAC 3' 
Site-directed mutagenesis of pC-
E1-E2 to mutate residue 36 to 
alanine 
Alanine J24F  5'CCAGAAGACGTTAAGGCCCC
GGGCGGCGGCCAG 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue 24 to alanine 
Alanine J24R  5'CTGGCCGCCGCCCGGGGCCT
TAACGTCTTCTGG 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue 24 to alanine 
Alanine J27F  5'GTTAAGTTCCCGGGCGCCGG
CCAGATCGTTGGC 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue 27 to alanine 
Alanine J27R  5'GCCAACGATCTGGCCGGCGC
CCGGGAACTTAAC 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue 27 to alanine 
Alanine J30F  5'CCGGGCGGCGGCCAGGCCGT
TGGCGGAGTATAC 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue 30 to alanine 
Alanine J30R  5'GTATACTCCGCCAACGGCCT
GGCCGCCGCCCGG 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue 30 to alanine 
Alanine J33F  5'GGCCAGATCGTTGGCGCAGT
ATACTTGTTGCCG 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue 33 to alanine 
Alanine J33R  5'CGGCAACAAGTATACTGCGC
CAACGATCTGGCC 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue 33 to alanine      
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Alanine J34F  5'CAGATCGTTGGCGGAGCATA
CTTGTTGCCGCGC 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue 34 to alanine 
Alanine J34R  5'GCGCGGCAACAAGTATGCTC
CGCCAACGATCTG 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue 34 to alanine 
Alanine J35F  5'ATCGTTGGCGGAGTAGCCTT
GTTGCCGCGCAGG 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue 35 to alanine 
Alanine J35R  5'CCTGCGCGGCAACAAGGCTA
CTCCGCCAACGAT 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue 35 to alanine 
Alanine 
J33/34F 
5'CAGATCGTTGGCGCAGCATA
CTTGTTGCCGCGC 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue3 33 and 34 to alanine 
Alanine 
J33/34R 
5'GCGCGGCAACAAGTATGCTG
CGCCAACGATCTG 3' 
Site-directed mutagenesis of 
pGEMT JFH1 1-2614 to mutate 
residue3 33 and 34 to alanine 
JFH 12  5'GCCAGTGAATTCTAATACGA
C 3' 
Used to amplify residues 1-2614 
of HCV JFH1 
AP 357  5'CATATGCATGAATTCTCTAG
ATTATGCTTCGGCCTGGCCCA
A 3' 
Used to amplify residues 1-2614 
of HCV JFH1 
JFH-1 NegRT  5'TTGCGAGTGCCCCGGGA 3'  Used to reverse transcribe 
negative strand HCV JFH1 core 
sequence 
JFH-1 
RTPCR1 
5'GGTCTCGTAGACCGTGCACC 
3' 
Used to amplify HCV JFH1 core 
sequence 
JFH-1 
RTPCR2 
5'GTATTCTTCACCTGGGCAGC 
3' 
Used to amplify HCV JFH1 core 
sequence 
RA16  5'TCTGCGGAACCGGTGAGTAC 
3' 
Used to amplify HCV JFH1 
5'NCR 
RA17  5'GCACTCGCAAGCACCCTATC 
3' 
Used to amplify HCV JFH1 
5'NCR 
 